HCV
MCID: HPT073
MIFTS: 70

Hepatitis C Virus (HCV)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Nephrological diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hepatitis C Virus

MalaCards integrated aliases for Hepatitis C Virus:

Name: Hepatitis C Virus 57 75
Hepatitis C Virus Infection, Response to Therapy of 57 28 5
Hepatitis C Virus, Susceptibility to 57 28 5
Hepatitis C Virus, Response to Therapy of 57
Hepatitis C Virus, Resistance to 57
Resistance to Hepatitis C Virus 5
Hcv, Susceptibility to 57
Hcv 57

Classifications:



External Ids:

OMIM® 57 609532

Summaries for Hepatitis C Virus

OMIM®: 57 HCV, which is principally transmitted by blood, infects about 3% of the world's population. HCV infection causes acute hepatitis, which is self-resolving in 20 to 50% of cases but does not confer permanent immunity. In 50 to 80% of cases, HCV infection becomes chronic and results in chronic hepatitis, cirrhosis, and hepatocellular carcinoma. As a result, HCV infection is a leading killer worldwide and the most common cause of liver failure in the U.S. HCV is opportunistic in individuals infected with human immunodeficiency virus (HIV; see 609423), approximately 25% of whom are coinfected with HCV. HCV infection is also associated with cryoglobulinemia (see 123550), a B-lymphocyte proliferative disorder (Pawlotsky, 2004; Chisari (2005); Pileri et al., 1998). (609532) (Updated 24-Oct-2022)

MalaCards based summary: Hepatitis C Virus, also known as hepatitis c virus infection, response to therapy of, is related to hepatitis c and viral infectious disease. An important gene associated with Hepatitis C Virus is IFNG (Interferon Gamma), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Overview of interferons-mediated signaling pathway. The drugs Ezetimibe and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and bone marrow, and related phenotypes are no effect and no effect

Wikipedia: 75 The hepatitis C virus (HCV) is a small (55-65 nm in size), enveloped, positive-sense single-stranded RNA... more...

Related Diseases for Hepatitis C Virus

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis C Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1338)
# Related Disease Score Top Affiliating Genes
1 hepatitis c 33.1 SCARB1 PSMA7 PI4KA IFNL4 IFNG IFITM3
2 viral infectious disease 32.9 IFNG EIF2AK2 CLEC4M CCR5
3 hepatitis 32.7 SLC3A2 SCARB1 PSMA7 PI4KA IFNL4 IFITM3
4 hepatitis b 32.5 PSMA7 IFNG EIF2AK2 DDX3X
5 stomatitis 31.5 IFNG IFITM3 EIF2AK2
6 acquired immunodeficiency syndrome 31.4 IFNG CCR5 APOE
7 human immunodeficiency virus infectious disease 31.0 IFNG CLEC4M CCR5
8 influenza 30.9 IFNG IFITM3 EIF2AK2 CLEC4M
9 west nile virus 30.8 SPCS1 IFITM3 CLEC4M CCR5
10 ebola hemorrhagic fever 30.8 IFITM3 CLEC4M CCR5
11 herpes zoster 30.8 IFNG CCR5 APOE
12 encephalitis 30.7 SPCS1 DDX3X CLEC4M CCR5
13 neuritis 30.1 IFNG CCR5 APOE
14 west nile fever 30.1 CLEC4M CCR5
15 hepatocellular carcinoma 11.6
16 recurrent hepatitis c virus induced liver disease in liver transplant recipients 11.6
17 cryoglobulinemia, familial mixed 11.5
18 liver cirrhosis 11.5
19 polyarteritis nodosa 11.3
20 immune deficiency disease 11.3
21 liver disease 11.3
22 splenic marginal zone lymphoma 11.3
23 cryoglobulinemia 11.3
24 nodal marginal zone b-cell lymphoma 11.3
25 immunotactoid glomerulopathy 11.2
26 fibrillary glomerulonephritis 11.2
27 non-alcoholic fatty liver disease 11.2
28 gianotti crosti syndrome 11.2
29 immunotactoid or fibrillary glomerulopathy 11.2
30 viral hepatitis 11.2
31 vasculitis 11.1
32 glomerulonephritis 11.1
33 lymphoma, hodgkin, classic 11.1
34 lymphoma 11.1
35 fibrosis of extraocular muscles, congenital, 1 11.0
36 human immunodeficiency virus type 1 11.0
37 type 2 diabetes mellitus 11.0
38 lichen planus 11.0
39 end stage renal disease 11.0
40 hemophilia 11.0
41 lymphoproliferative syndrome 11.0
42 fatty liver disease, nonalcoholic 1 11.0
43 membranoproliferative glomerulonephritis 11.0
44 b-cell lymphoma 11.0
45 primary agammaglobulinemia 11.0
46 hepatitis a 11.0
47 chronic kidney disease 11.0
48 alcohol use disorder 10.9
49 sjogren syndrome 10.9
50 autoimmune hepatitis 10.9

Graphical network of the top 20 diseases related to Hepatitis C Virus:



Diseases related to Hepatitis C Virus

Symptoms & Phenotypes for Hepatitis C Virus

Clinical features from OMIM®:

609532 (Updated 24-Oct-2022)

GenomeRNAi Phenotypes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.13 ACY3 APOE CCR5 CLDN6 CLDN9 CLEC4M
2 no effect GR00402-S-2 10.13 ACY3 APOE CCR5 CLDN6 CLEC4M DDX3X
3 Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection GR00233-A-1 8.85 HM13
4 Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after viral supernatant infection GR00233-A-3 8.65 IFITM3

MGI Mouse Phenotypes related to Hepatitis C Virus:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.5 APOE CCR5 CLEC4M HM13 IFNG PI4KA
2 mortality/aging MP:0010768 9.44 APOE CCR5 CLDN6 CLEC4M DDX3X EIF2AK2

Drugs & Therapeutics for Hepatitis C Virus

Drugs for Hepatitis C Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ezetimibe Approved Phase 4 163222-33-1 150311
2
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
3
Amantadine Approved Phase 4 768-94-5 2130
4
Diamorphine Approved, Illicit, Investigational Phase 4 561-27-3 5462328
5
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
6
Ledipasvir Approved Phase 4 1256388-51-8 67505836
7
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
8
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
9
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
10
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
11
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
12
Chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
13
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
14
Colchicine Approved Phase 4 64-86-8 2833 6167
15
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
16
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
17
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
18
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
19
Zidovudine Approved Phase 4 30516-87-1 35370
20
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
21
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
22
Maraviroc Approved, Investigational Phase 4 376348-65-1 3002977
23
Fosamprenavir Approved Phase 4 226700-79-4 131536
24
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
25
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
26
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
27
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
28
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
29
Nelfinavir Approved Phase 4 159989-64-7 64143
30
Cobicistat Approved Phase 4 1004316-88-4 24950485 25151504
31
Elvitegravir Approved Phase 4 697761-98-1 23083982 5277135
32
Iron Approved Phase 4 7439-89-6 29936
33
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
34
Didanosine Approved Phase 4 69655-05-6 50599
35
Tenofovir Experimental, Investigational Phase 4 147127-20-6, 202138-50-9 464205 6398764
36
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
37 Analgesics, Non-Narcotic Phase 4
38 Analgesics Phase 4
39 Antiparkinson Agents Phase 4
40 Neurotransmitter Agents Phase 4
41 Antioxidants Phase 4
42 Platelet Aggregation Inhibitors Phase 4
43 Dopamine Agents Phase 4
44 Detox adjuvant Phase 4
45 Radiation-Protective Agents Phase 4
46 Phosphodiesterase Inhibitors Phase 4
47 Vasodilator Agents Phase 4
48 Ledipasvir, sofosbuvir drug combination Phase 4
49 Cytochrome P-450 Enzyme Inhibitors Phase 4
50 Cytochrome P-450 CYP3A Inhibitors Phase 4

Interventional clinical trials:

(showing 652, show less)
# Name Status NCT ID Phase Drugs
1 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
2 An Open-Label Study to Evaluate Long-Term Outcomes With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Fertile Women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection Unknown status NCT02950870 Phase 4 Ombitasvir-Paritaprevir-Ritonavir;Dasabuvir;Ribavirin
3 A Phase IV, Single Arm, Open-Label Study to Determine the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Naive Alcoholic Subjects With Chronic Genotype 1 Hepatitis C Infection Unknown status NCT02759861 Phase 4 harvoni
4 Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment: A Pilot Project Unknown status NCT02460133 Phase 4 Paritaprevir;Ritonavir;Dasabuvir;Ombitasvir;Ribavirin
5 the Prevalence of Acute Kidney Injury in Patients With Chronic Hepatitis c Virus Receiving Sofuspovir Containing Direct Acting Antiviral Therapy Unknown status NCT04267458 Phase 4
6 Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney Unknown status NCT03296930 Phase 4 Sofosbuvir 400 MG Oral Tablet,;Ombitasvir/paritaprevir/ritonavir
7 Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant Unknown status NCT03359746 Phase 4 Grazoprevir/Elbasvir
8 Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
9 Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection Unknown status NCT00127777 Phase 4 Amantadine sulphate (in addition to standard treatment)
10 Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care Unknown status NCT03364725 Phase 4 Glecaprevir-pibrentasvir
11 Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860 Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
12 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
13 Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial Unknown status NCT01649245 Phase 4 Reiferon retard
14 Generic Velpatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Completed NCT03250910 Phase 4 Sofosbuvir and Velpatasvir;Ribavirin
15 A Study of the Antiviral Activity of Metformin as an Anti-Hepatitis C Virus Agent in Patients With Chronic Hepatitis C Virus Infection Completed NCT02972723 Phase 4 Metformin
16 "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study" Completed NCT02058173 Phase 4 150 mg/daily chloroquine compare to placebo for 12 week;Chloroquine;placebo
17 Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4 Completed NCT01686789 Phase 4 Pegylated interferon alpha-2a
18 A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV Completed NCT02128542 Phase 4 Sofosbuvir;RBV
19 Improvement of the Surveillance and Control of Liver Disease and Complication Due to Chronic Hepatitis C: Project A) Antiviral Drugs Use, Efficacy, Safety and Costs; Project B) Kinetics of Virological Response. Completed NCT01195181 Phase 4 peginterferon plus ribavirin
20 Phase IV Study of Long Term Peg-Intron for Patients Who Have Failed to Respond to Rebetron/Interferon With Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C- The Copilot Trial Completed NCT00179413 Phase 4 PEG -Intron;Colchicine
21 Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection Completed NCT01097395 Phase 4 ribavirin
22 A Multicenter Study Evaluating the Efficacy and Safety of 12 Weeks Versus 24 Weeks Peginterferon Alfa-2a 40KD Combination Therapy With Ribavirin in Interferon Naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Completed NCT00143000 Phase 4 Peginterferon alfa-2a 40KD and Ribavirin
23 A Multi-Site, Open-Label, Partially-Randomized Trial of the Efficacy and Safety of Fixed Dose Elbasvir/Grazoprevir (EBR/GZR) Based Regimens in French Subjects With Chronic Hepatitis C Virus (HCV) Genotype 4 Infection Completed NCT03111108 Phase 4 EBR/GZR (50 mg/100 mg) FDC
24 A Prospective, Single-center, Open-label, Pilot Study to Investigate the Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients. Completed NCT01469884 Phase 4 Everolimus;Cyclosporine;Tacrolimus
25 Treatment of Acute Hepatitis C Virus in HIV Co-Infection Completed NCT00845676 Phase 4 Pegylated interferon alfa-2a + Ribavirin
26 Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis Completed NCT02874066 Phase 4 PTV/r/OBV/DSV
27 Pegylated Interferon Alfa-2a Plus Ribavirin for Patients With Chronic Hepatitis c Virus on Opioid Pharmacotherapy: Virological and Psychological Outcomes Completed NCT01120795 Phase 4 Pegylated interferon and ribavirin
28 An Open-Label, Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus (HCV) Infection Genotype 2K/1B- NINJA Study Completed NCT03050905 Phase 4 VEKIRAX;EXVIERA
29 Randomized Clinical Trial to Assess the Effectiveness of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 1 (TNT-1 Study) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
30 A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus (HIV) and Hepatitis C Completed NCT02881762 Phase 4 Maraviroc
31 A Pilot Study to Assess the Feasibility of Hepatitis C Virus (HCV) Treatment as Prevention With Interferon-free Direct Acting Antivirals (DAAs) in the Prison Setting Completed NCT02064049 Phase 4 Sofosbuvir/velpatasvir
32 Management of Hepatitis C Virus (HCV) Infection in Pregnant Women With Opioid Use Disorder (OUD): the Potential of an Integrated Medical Home Model: Phase IV Trial of Sofosbuvir/Velpatasvir (SOF/VEL) in Postpartum Women With Chronic HCV Completed NCT03057847 Phase 4 Sofosbuvir/Velpatasvir
33 Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir Completed NCT01222611 Phase 4 Fosamprenavir
34 Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Genotype 1-infected Patients in Taiwan Completed NCT00495131 Phase 4 Pegylated interferon alfa-2a plus ribavirin
35 Randomized Study on the Efficacy and Safety of Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation Completed NCT00383864 Phase 4 Pegylated interferon and ribavirin
36 Evaluation of the Benefit of Antithymocyte Induction Therapy on Hepatic Fibrosis in de Novo Hepatitis C Virus Liver Transplant Patients. Completed NCT00538265 Phase 4 tacrolimus;tacrolimus, ATG;ATG+mycophénolate mofétil+tacrolimus
37 A Phase Iv Single-Arm Open-Label Non-Randomized Study To Evaluate The Safety And Pharmacokinetics Of Nelfinavir (Viracept, A430) 1250mg Twice Daily (250mg Or 625mg Forms) With Lamivudine/Zidovudine (Combivir) Background Therapy In Hiv/Hepatitis C Virus (Hcv) Co-Infected Subjects With Hepatic Dysfunction. Completed NCT00141284 Phase 4 nelfinavir 1,250 mg twice daily;Zidovudine 300 mg twice daily;Lamivudine 150 mg twice daily
38 Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study Completed NCT02220868 Phase 4 Sofosbuvir, Ribavirin, and Stribild
39 A Multi-Center, Open-Label Study of Glecaprevir/Pibrentasvir to Treat Recipients of Transplanted Kidneys From Deceased Donors With Hepatitis C Virus Completed NCT03781726 Phase 4 glecaprevir/pibrentasvir treatment
40 Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks Completed NCT00194480 Phase 4 Pegylated Interferon
41 Analysis of Gene Expression of PBMC in the Hepatitis C Virus Genotype 1b-infected Patients During Peg-interferon-α Plus Ribavirin Combination Therapy Completed NCT00680173 Phase 4 pegylated interferon alpha 2a and plus ribavirin
42 A Randomized Trial Comparing a Short Course Versus Standard Treatment in Patients With Chronic Hepatitis C Virus Infection Completed NCT00502970 Phase 4 16 weeks Interferon Tiw with Ribavirin;24 weeks Interferon
43 Evaluation of Liver Fibrosis by Serum Hyalornic Acid Measurement in β-Thalassemic Children Infected With Hepatitis C Virus Before and After Direct-Acting Antiviral Therapy Completed NCT03961828 Phase 4 Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]
44 Treatment of Recently Acquired Hepatitis C Virus Infection Completed NCT01336010 Phase 4 Peginterferon alfa-2a;Ribavirin
45 TEN Switch - An Observational Phase IV Study to Evaluate the Safety and Efficacy of Substituting Tenofovir for Didanosine in Virologically Controlled HIV-infected Patients Co-infected With Hepatitis C Virus. Completed NCT00358696 Phase 4 tenofovir
46 A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes Completed NCT02461745 Phase 4 ombitasvir, paritaprevir/r, dasabuvir + ribavirin;ombitasvir, paritaprevir/r, dasabuvir
47 A Phase IV Open-label, Multicentre, International Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir ±Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection and Recent Injection Drug Use or Receiving Opioid Substitution Therapy Completed NCT02498015 Phase 4 "3D" regimen;"3D" regimen with ribavirin
48 Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection Completed NCT02482077 Phase 4 SOF+RBV;SOF+DCV;LDV/SOF
49 Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis Completed NCT03420300 Phase 4 EBR/GZR
50 Pharmacist-led Hepatitis C Diagnosis and Rapid Management - in Community Recruiting NCT04322981 Phase 4
51 Safety, Tolerability, and Outcomes of Velpatasvir/SofosbuviR in Treatment of Chronic Hepatitis C Virus During Pregnancy (STORC) Recruiting NCT05140941 Phase 4 Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
52 A Randomized Clinical Trial Comparing Two Management Strategies for Treatment of Neutropenia and Anemia Associated With Pegylated Interferon Plus Ribavirin Treatment of Compensated Chronic Hepatitis C in Adult Subjects Infected With HIV. Terminated NCT00194857 Phase 4 erythropoietin, GCSF
53 A Phase IV, Open-label, Single Arm, Multicentre Trial of Grazoprevir/Elbasvir for Genotype 1 or 4 in People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use or Receiving Opioid Substitution Therapy Terminated NCT02940691 Phase 4 Grazoprevir/elbasvir
54 Phase 4 Study Using Infergen and Ribavirin in Patients With Chronic Hepatitis C Virus Who Achieved Partial Response to Peginterferon-alfa and Ribavirin Therapy Terminated NCT00456248 Phase 4 Infergen and ribavirin
55 A Pilot Study on the Efficicay and Safety of Pegylated Interferon, Ribavirin and Telaprevir in Recurrent Hepatitis C Virus (HCV) Infection in Orthotopic Liver Transplant (OLT) Recipients. Terminated NCT01592006 Phase 4 Peginterferon alfa-2a;Ribavirin;telaprevir
56 A Single-site, Open-label, Non-comparator Clinical Trial to eLiminate HCV-infection in Treatment-naïve, EgyptiAn Patients With End-stage Renal Disease on Renal Dialysis, With Chronic Hepatitis C Genotype 4 Infection Using a 12-week Course of Once-daily Single Oral Tablet of Elbasvir (50mg)/Grazoprevir (100 mg) Withdrawn NCT03381859 Phase 4 Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
57 Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers Withdrawn NCT03313414 Phase 4 Sofosbuvir/Velpatasvir Treatment for 14 days
58 A Randomized Trial of Telaprevir, Peginterferon, and Ribavirin Versus Peginterferon and Ribavirin for Treatment of Genotype 1 Hepatitis C Virus With Host Interleukin 28B CC Polymorphism Withdrawn NCT01415141 Phase 4 Peginterferon alfa-2a;Ribavirin;telaprevir
59 Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers Withdrawn NCT01766115 Phase 4 Telaprevir
60 A Multi-Site, Open-Label, Trial of the Efficacy and Safety of Fixed-dose Elbasvir/Grazoprevir (EBR/GZR) in Brazilian Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4) Withdrawn NCT03143998 Phase 4 MK-5172A
61 Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents Unknown status NCT03343444 Phase 3 12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg);8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)
62 A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Seraprevir in Combination With Sofosbuvir in Patients With Chronic Genotype 1 Hepatitis C Virus Infection. Unknown status NCT04001608 Phase 3 Seraprevir;Sofosbuvir
63 Clinical Pharmacokinetics, Safety and Efficacy Study of Daclatasvir/Sofosbuvir in Adolescents Aged 12 to 18 Years Old With Hepatitis C Virus: A Preliminary Study Unknown status NCT03540212 Phase 2, Phase 3 Daclatasvir and sofosbuvir
64 An Open-label, Multi-center Study to Evaluate Sustained Virologic Response With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Genotype 1 Chronic Hepatitis C Virus Infected Patients With Past PI Failure Unknown status NCT02646111 Phase 3 12 weeks without Ribavirin;12 weeks with Ribavirin;24 weeks with Ribavirin
65 Open-label Study of Efficacy and Safety of Generic Sofosbuvir/Ledipasvir±Ribavirin in Iranian Patients With Hepatitis C Virus Genotype 1 Infection Unknown status NCT03061032 Phase 3 Sofosbuvir/Ledipasvir 12W;Sofosbuvir/Ledipasvir plus Ribavirin 12W;Sofosbuvir/Ledipasvir 24W;Sofosbuvir/Ledipasvir plus Ribavirin 24W
66 Pharmacokinetics of Sofosbuvir and Ledipasvir in Hepatitis C Virus - Infected Adolescent Patients With Haematological Disorders Unknown status NCT04353986 Phase 3 Sofosbuvir and Ledipasvir
67 Assessment of Haematological and Biochemical Effect After New Direct Acting Antiviral Drugs in Chronic Hepatitis c Virus Egyptian Patients in Assiut Province Unknown status NCT03163849 Phase 3 Sofosbuvir , daclatasvir;Placebos
68 Efficacy of a Fixed-Dose Combination Pill of Sofosbuvir and Daclatasvir in Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus Completed NCT03369327 Phase 3 sofosbuvir and daclatasvir
69 A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3) Completed NCT02640157 Phase 3 ABT-493/ABT-530;Sofosbuvir;Daclatasvir
70 A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (CERTAIN-1) Completed NCT02707952 Phase 3 ABT-493/ABT-530;OBV/PTV/r
71 A Randomized, Open-Label, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2) Completed NCT02723084 Phase 3 ABT-493/ABT-530;sofosbuvir (SOF);ribavirin (RBV)
72 A Phase 3, Open-Label Study With Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b Plus Ribavirin With Chronic Hepatitis C Genotypes 1 or 4 Infection Completed NCT01573351 Phase 3 Asunaprevir;Daclatasvir;Peg-interferon Alfa-2a;Ribavirin
73 Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects Completed NCT01571583 Phase 3 Telaprevir;Pegylated interferon alfa-2a;Ribavirin
74 A Phase III Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of TMC435 Plus PegIFNα-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Subjects Who Are Co-infected With Human Immunodeficiency Virus Type 1 (HIV-1) Completed NCT01479868 Phase 3 TMC435;Pegylated interferon alpha-2a;Ribavirin
75 A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II) Completed NCT02243293 Phase 2, Phase 3 ABT-493;ABT-530;ribavirin (RBV);ABT-493/ABT-530
76 A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of a 12- or 8-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve and -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection Without Cirrhosis Completed NCT02114177 Phase 3 Simeprevir;Sofosbuvir
77 A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Naïve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin Completed NCT01741545 Phase 3 Ribavirin;Daclatasvir
78 A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2) Completed NCT02640482 Phase 3 ABT-493/ABT-530;Placebo for ABT-493/ABT-530
79 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II) Completed NCT02609659 Phase 3 ombitasvir/paritaprevir/ritonavir and dasabuvir;ribavirin
80 A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1) Completed NCT02604017 Phase 3 ABT-493/ABT-530
81 A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Treatment-Naive and IFN Experienced Subjects With Genotype 1 Chronic Hepatitis C Completed NCT02123654 Phase 3 Daclatasvir;Asunaprevir;DCV 3DAA
82 A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis Completed NCT03089944 Phase 3 Glecaprevir/Pibrentasvir
83 A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection and Chronic Kidney Disease Completed NCT02092350 Phase 2, Phase 3 Grazoprevir;Elbasvir;Placebo to Grazoprevir;Placebo to Elbasvir
84 An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) Co-administered With Ribavirin (RBV) for 12 or 16 Weeks in Treatment-Naïve and Treatment-Experienced Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT-II) Completed NCT02023112 Phase 3 ABT-450/r/ABT-267;Ribavirin
85 A Phase 3, Comparative Study of Asunaprevir and Daclatasvir (DUAL) Combination Therapy Versus Telaprevir Therapy in Japanese Genotype 1b Chronic Hepatitis C IFN Eligible-naive Subjects With a Single Arm Assessment of DUAL Therapy in IFN-therapy Relapsers Completed NCT01718145 Phase 3 Daclatasvir;Asunaprevir;Ribavirin;Telaprevir
86 A Multicenter, Randomized, Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection and Decompensated Cirrhosis Completed NCT02996682 Phase 3 SOF/VEL;RBV
87 An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cirrhosis (GARNET) Completed NCT02582632 Phase 3 ombitasvir/paritaprevir/ritonavir;dasabuvir
88 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1) Completed NCT02265237 Phase 3 ombitasvir/paritaprevir/ritonavir;ribavirin
89 A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis Completed NCT02114151 Phase 3 Simeprevir;Sofosbuvir
90 A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT1, GT4, and GT6 Infection. Completed NCT02105467 Phase 3 Grazoprevir 100mg / Elbasvir 50 mg FDC;Placebo to Grazoprevir / Elbasvir 50 mg FDC
91 A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-5) Completed NCT03069365 Phase 3 Glecaprevir/pibrentasvir
92 A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection Completed NCT02613871 Phase 3 LDV/SOF
93 A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV Completed NCT02671500 Phase 3 SOF/VEL
94 A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor Completed NCT02639247 Phase 3 SOF/VEL/VOX;SOF/VEL
95 A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) Completed NCT02636595 Phase 3 ABT-493/ABT-530
96 A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis Completed NCT02639338 Phase 3 SOF/VEL/VOX;SOF/VEL
97 A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1) Completed NCT02642432 Phase 3 ABT-493/ABT-530
98 Efficacy and Safety of Sofosbuvir Plus Daclatasvir With or Without Ribavirin: Large Real-life Results of Patients With Chronic Hepatitis C Genotype 4 Completed NCT04387526 Phase 2, Phase 3 (SOF and DCV);(SOF, DCV, and RBV)
99 An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis (TURQUOISE-CPB) Completed NCT02219477 Phase 3 ombitasvir/paritaprevir/ritonavir;dasabuvir;ribavirin
100 A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 Completed NCT02170727 Phase 3 DCV/ASV/BMS-791325
101 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response Completed NCT00308048 Phase 3 Pegylated Interferon alfa 2b and ribavirin
102 A Phase 3b, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection Completed NCT02738333 Phase 3 LDV/SOF;SOF;RBV
103 A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection (EXPEDITION-2) Completed NCT02738138 Phase 3 ABT-493 coformulated with ABT-530
104 Efficacy of High Doses of Both Pegylated Interferon Alfa-2a and Ribavirin for Retreatment of HIV-coinfected Patients With Liver Cirrhosis Due to HCV Genotype 1 or 4 Nonresponders to Previous Standard Therapy. Completed NCT01006031 Phase 2, Phase 3 Pegylated interferon alfa-2a and Ribavirin
105 HRN 003PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy Completed NCT00215865 Phase 3 PEGIntron plus ribavirin
106 A Phase 3 Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic HCV Infection and Compensated Cirrhosis Completed NCT04112303 Phase 3 SOF/VEL
107 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Subjects With Chronic Genotype 3 HCV Infection Completed NCT02201953 Phase 3 SOF/VEL;SOF;RBV
108 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV Completed NCT02201940 Phase 3 SOF/VEL;Placebo
109 Adjuvant α-Interferon Treatment After Resection of Hepatocellular Carcinoma in HCV-Related Cirrhosis: a Randomized Trial on Prevention of Cancer Recurrence Completed NCT00273247 Phase 3 Interferon alpha-2b
110 An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I) Completed NCT02207088 Phase 3 ombitasvir/paritaprevir/ritonavir;dasabuvir;Ribavirin
111 A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Subjects With Chronic Genotype 1 or 2 HCV Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen Completed NCT02822794 Phase 3 SOF/VEL;RBV
112 A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection Completed NCT02722837 Phase 3 SOF/VEL
113 An Open-label, Randomized, Active Control Study to Demonstrate Non-Inferiority in Efficacy, and to Compare Safety and Tolerability of P1101 + Ribavirin to PEG-Intron + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic HCV Genotype 2 Infection Completed NCT04382937 Phase 3 P1101 + Ribavirin;PEG-Intron + Ribavirin
114 A Phase 3 Study With Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects With Chronic Hepatitis C Genotype 1b Infection Completed NCT01581203 Phase 3 Asunaprevir (ASV);Daclatasvir (DCV);Pegylated-interferon alfa 2a (PegIFN);Ribavirin (RBV)
115 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3) Completed NCT02939989 Phase 3 Sofosbuvir;Glecaprevir/Pibrentasvir;Ribavirin
116 A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection Completed NCT02073656 Phase 3 LDV/SOF;RBV
117 A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/- Ribavirin for 12 and 24 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection. Completed NCT01701401 Phase 3 LDV/SOF;RBV
118 A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection Completed NCT03074331 Phase 3 SOF/VEL
119 An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection Completed NCT03067129 Phase 2, Phase 3 Glecaprevir/pibrentasvir adult formulation;Glecaprevir/pibrentasvir pediatric formulation
120 A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection Completed NCT02966795 Phase 3 Glecaprevir/Pibrentasvir
121 A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (MAGELLAN-2) Completed NCT02692703 Phase 3 glecaprevir/pibrentasvir
122 A Single-Arm, Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4) Completed NCT02651194 Phase 3 ABT-493/ABT-530
123 A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I) Completed NCT01939197 Phase 2, Phase 3 ABT-450/r/ABT-267;ABT-333;ribavirin
124 A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naïve and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection. Completed NCT01838590 Phase 3 SOF;RBV
125 A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection Completed NCT01851330 Phase 3 LDV/SOF;RBV
126 An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I) Completed NCT02219490 Phase 3 ABT-333;ABT-450/r/ABT-267;Ribavirin (RBV)
127 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection Completed NCT02220998 Phase 3 SOF/VEL;SOF;RBV
128 An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (Turquoise-IV) Completed NCT02216422 Phase 3 Ombitasvir/Paritaprevir/Ritonavir;Dasabuvir;Ribavirin (RBV)
129 A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis Completed NCT02201901 Phase 3 SOF/VEL;RBV
130 An Open-Label, Multicenter Study to Evaluate Long-term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II) Completed NCT02167945 Phase 3 ABT-450/r/ABT-267;ABT-333;Ribavirin (RBV)
131 A Phase 3b Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic HCV Infection Completed NCT04211909 Phase 3 SOF/VEL;SOF/VEL/VOX
132 A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, With and Without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naïve Genotype 2 and 3 Chronic Hepatitis C Subjects Completed NCT01616524 Phase 3 Ribavirin;Daclatasvir;Placebo matching Daclatasvir
133 An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Treatment-Naïve and Treatment-Experienced Asian Adults With GT1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis Completed NCT02517528 Phase 3 ABT-450/r/ABT-267;ABT-333;ribavirin
134 A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection Completed NCT02487030 Phase 3 LDV/SOF;RBV
135 A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Failed a Prior Direct-Acting Antiviral Agent (DAA)-Containing Therapy Completed NCT02446717 Phase 2, Phase 3 ABT-493, ABT-530;ribavirin (RBV);ABT-493/ABT-530
136 A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection Completed NCT01768286 Phase 3 LDV/SOF;RBV
137 A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 Chronic Hepatitis C Subjects Completed NCT01754974 Phase 3 Ribavirin
138 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection Completed NCT03222583 Phase 3 Placebo;Glecaprevir/Pibrentasvir
139 An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects Who Participated in a Prior Gilead-Sponsored HCV Treatment Study Completed NCT03118843 Phase 3 SOF/VEL/VOX
140 A Phase 3b, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection Completed NCT02472886 Phase 3 LDV/SOF;RBV
141 A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin Completed NCT01598090 Phase 3 Ribavirin;Telaprevir
142 An Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naïve and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection Completed NCT03235349 Phase 3 Glecaprevir/Pibrentasvir
143 An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA) Completed NCT02442284 Phase 3 ombitasvir/paritaprevir/ritonavir and dasabuvir;Ribavirin
144 A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1 - 6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1 Completed NCT03212521 Phase 3 Glecaprevir/Pibrentasvir
145 An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-II) Completed NCT02487199 Phase 3 ombitasvir/paritaprevir/ritonavir and dasabuvir;ombitasvir/paritaprevir/ritonavir
146 An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection Completed NCT02346721 Phase 3 SOF/VEL
147 A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naïve Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection Completed NCT03219216 Phase 3 Glecaprevir/Pibrentasvir
148 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection Completed NCT02517515 Phase 3 ombitasvir/paritaprevir/ritonavir and dasabuvir;Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
149 A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection Completed NCT02480712 Phase 3 SOF/VEL
150 An Open-Label, Treatment Duration-Ranging Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/ Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Naive Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Completed NCT02399345 Phase 3 ombitasvir/paritaprevir/ritonavir, dasabuvir;sofosbuvir (SOF);ribavirin (RBV)
151 A Randomized, Open-Label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection Completed NCT01241760 Phase 3 Ribavirin;Telaprevir;Pegylated interferon alfa-2a
152 Multicenter Study on Efficacy of New Therapeutic Schedules With Peg-Interferon alpha2b and Ribavirin in Patients With Genotype 3 Chronic HCV( Hepatitis C Virus) Infection Completed NCT01121705 Phase 3 Peg Interferon alpha2b + Ribavirin
153 A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive or -Experienced Subjects With Chronic Genotype 4 Hepatitis C Virus Infection Completed NCT02250807 Phase 3 Simeprevir;Sofosbuvir
154 A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Treatment-Naïve and Treatment-Experienced Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT I) Completed NCT02023099 Phase 3 ABT-450/r/ABT-267;Placebo
155 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II) Completed NCT01715415 Phase 3 ABT-450/r/ABT-267, ABT-333;Ribavirin;Placebo for ABT-450/r/ABT-267;Placebo for ABT-333;Placebo for ribavirin
156 An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin or Glecaprevir/Pibrentasvir for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection. Completed NCT02634008 Phase 3 Paritaprevir/ritonavir/ombitasvir;Dasabuvir;Ribavirin;Glecaprevir/pibrentasvir
157 Safety, Efficacy and Pharmacokinetics of BI 201335 NA in Patient With Genotype 1 Chronic Hepatitis C Virus Infection in Combination With Pegylated Interferon Alfa-2b and Ribavirin - Cohort 1 for Treatment-naive Patients: Randomised, Double-blind Part of BI 201335 NA for 12 or 24 Weeks - Cohort 2 for Treatment-experienced Patients: Open-label Part of BI 201335 NA for 24 Weeks Completed NCT01579474 Phase 3 BI 201335 high dose;BI 201335 low dose
158 A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection With Advanced Cirrhosis and Child-Pugh (CP)-B Hepatic Insufficiency Completed NCT02115321 Phase 2, Phase 3 Grazoprevir;Elbasvir;MK-5172A
159 A Phase 3b, Multi-Center, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naïve Adults With Chronic Genotype 1 or 3 Hepatitis C Virus Infection Completed NCT02074514 Phase 3 Sofosbuvir;RBV
160 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I) Completed NCT01716585 Phase 3 ABT-450/r/ABT-267, ABT-333;Ribavirin;Placebo for ABT-450/r/ABT-267;Placebo for ABT-333;Placebo for ribavirin
161 Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects With Genotype 1 Chronic Hepatitis C and Human Immunodeficiency Virus Type 1 (HCV-1/HIV-1) Coinfection Completed NCT01513941 Phase 3 Telaprevir;Ribavirin;Pegylated-Interferon-alfa-2a
162 Pharmacokinetics of Low-dose Sofosbuvir in Dialysis-dependent Patients With Hepatitis C Virus Infection Completed NCT03883698 Phase 3 Sofosbuvir;Daclatasvir 60 mg
163 An Open-Label, Single-Arm Phase III Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Subjects Completed NCT01567735 Phase 3 TMC435
164 A Phase 3, Open Label Study of Safety and Efficacy With BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected With Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Completed NCT01471574 Phase 3 Daclatasvir;Ribavirin;PEG-Interferon alfa 2a
165 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II) Completed NCT01704755 Phase 3 ABT-450/r/ABT-267, ABT-333;Ribavirin (RBV)
166 Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a Plus Ribavirin Completed NCT00516321 Phase 3 eltrombopag;placebo
167 Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection. A Randomized, Controlled and Double Blind Study. Completed NCT00502086 Phase 3
168 An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III) Completed NCT02219503 Phase 3 Ombitasvir/Paritaprevir/Ritonavir;Dasabuvir
169 Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia Completed NCT02825212 Phase 2, Phase 3 Harvoni;Epclusa
170 Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2b Plus Ribavirin) Completed NCT00529568 Phase 3 eltrombopag;placebo
171 Outcome of Decompensated Hepatitis C Virus-Related Cirrhotic Patients Treated With Peginterferon Alfa-2b and Ribavirin: Results of a Controlled Study Completed NCT00301509 Phase 2, Phase 3 peginterferon and ribavirin
172 An Open-label, Randomized Pilot Study to Compare the Effectiveness of Peginterferon-alfa-2b Plus Ribavirin to Peginterferon-alfa-2b Plus Epoetin-alfa and Two Doses of Ribavirin in the Treatment of Chronic Hepatitis C Virus Infection Completed NCT00248339 Phase 3 Peginterferon-alpha-2b (PEG-Intron);Ribavirin;Epoetin-alpha (Procrit)
173 An Open-Label Study to Evaluate the Safety and Efficacy of the Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Chronic Hepatitis C Virus Genotype 4 Infection in Egypt Completed NCT02247401 Phase 3 2 DAA;RBV
174 Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 3 Infection Completed NCT02576314 Phase 3 sofosbuvir and daclatasvir;ledipasvir/sofosbuvir
175 A Prospective 3-Year Follow-up Study in Subjects Previously Treated in a Phase IIb or Phase III Study With a TMC435-Containing Regimen for the Treatment of Hepatitis C Virus (HCV) Infection Completed NCT01349465 Phase 3 No treatment
176 An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin) Completed NCT00996216 Phase 3 Eltrombopag;Antiviral therapy
177 A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV) Completed NCT01833533 Phase 3 ABT-450/r/ABT-267, ABT-333;Ribavirin;Placebo for Ribavirin
178 A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects Completed NCT01783678 Phase 3 Sofosbuvir;RBV
179 An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON) Completed NCT02486406 Phase 2, Phase 3 Ombitasvir/paritaprevir/ritonavir;Dasabuvir;Ribavirin;Ombitasvir mini tablet;Paritaprevir mini tablet;Ritonavir mini tablet;Dasabuvir mini tablet;Ribavirin solution
180 A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection Completed NCT01773070 Phase 3 ABT-450/ritonavir;ABT-333;ABT-267
181 A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III) Completed NCT01767116 Phase 3 ABT-450/r/ABT-267, ABT-333;Ribavirin;Placebo for ribavirin
182 A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects Completed NCT01667731 Phase 3 SOF;RBV
183 A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection Completed NCT02441283 Phase 2, Phase 3 ABT-493;ABT-530
184 An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Treatment-Naïve or Treatment-Experienced Adults in Brazil With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ III) Completed NCT02442271 Phase 3 ombitasvir/paritaprevir/ritonavir and dasabuvir;ribavirin
185 NIK-333(Peretinoin) PhaseⅢ Study Investigation of the Efficacy and Safety to Suppress Recurrence of Hepatitis C Virus(HCV)-Positive Hepatocellular Carcinoma(HCC), Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group Study Completed NCT01640808 Phase 3 NIK-333(peretinoin);Placebo
186 A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin in Treatment-Experienced Subjects With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-II) Completed NCT01674725 Phase 3 ABT-450/r/ABT-267, ABT-333;Ribavirin
187 An Exploratory Study to Evaluate Immune Restoration Following Removal of Viral Antigen in Treatment-Naïve and Treatment-Experienced Adults With Genotype (GT) 1a Chronic Hepatitis C Virus (HCV) Infection Administered Ombitasvir/ ABT-450/Ritonavir With Dasabuvir and Ribavirin (RBV) for 12 Weeks Completed NCT02476617 Phase 3 ombitasvir/paritaprevir/ritonavir;dasabuvir;ribavirin
188 A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents With Acute Hepatitis C Virus (HCV) Infection Recruiting NCT04903626 Phase 3 Glecaprevir/Pibrentasvir (GLE/PIB)
189 Micro-elimination of Hepatitis C Virus Infection With Pan-genotypic DAA Regimen in Hepatitis C Highly Endemic and Contagious Community (ERASE-C) Active, not recruiting NCT03891550 Phase 3 Epclusa
190 A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Subjects Who Have Failed Prior Treatment With Sofosbuvir-based Therapies Terminated NCT02600351 Phase 3 LDV/SOF;RBV
191 Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects With Chronic Liver Disease Undergoing Elective Invasive Procedures Terminated NCT00678587 Phase 3 Eltrombopag;Placebo
192 An Open Label,Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1) Terminated NCT01467479 Phase 3 Telaprevir;Ribavirin;Highly Active Antiretroviral Therapy (HAART)
193 A Prospective 3-Year Follow-up Study in Subjects Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection Terminated NCT03099135 Phase 3 No Treatment
194 High-dose Versus Standard-dose Weight-based Ribavirin in Combination With Peginterferon Alfa-2a for Patients Infected With Hepatitis C Virus Genotype 1 or 4 Terminated NCT00662220 Phase 3 ribavirin
195 Effect of Long-term Vitamin D Therapy on IL-6, Visfatin and Hyaluronic Acid in Hepatitis C Virus Patients' Assessment Terminated NCT01997203 Phase 3 Vitamin D
196 Reversal of Hepatic Impairment by Achieving Sustained Virologic Response (SVR) With 12 Weeks of Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection and Early Decompensation of Cirrhosis (MELD 10 or Less) Terminated NCT02455167 Phase 3 Simeprivir (SMV);Sofosbuvir (SOF);Ribavirin (RBV)
197 A Double-Blinded Randomized Control Study Evaluating the Efficacy and Safety of Pegylated Lambda Interferon Compared to Pegylated Alfa-2a Interferon, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 or 4 Chronic Hepatitis C Subjects Withdrawn NCT01447394 Phase 3 Ribavirin
198 An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease on Hemodialysis (GIFT-R) Withdrawn NCT02806362 Phase 3 Ombitasvir/paritaprevir/ritonavir
199 A Pilot Trial of the Safety and Efficacy of Telaprevir +Peginterferon +Ribavirin +Vitamin D3 Among Treatment-naive Veterans Infected With Genotype 1 Hepatitis C Virus Withdrawn NCT01890772 Phase 2, Phase 3 Telaprevir;Peginterferon alfa-2a;Ribavirin
200 A Phase III, Randomised, Open Label, Active-controlled Study of an Interferon-free Regimen of BI 207127 in Combination With Faldaprevir and Ribavirin Compared to Telaprevir in Combination With Pegylated interferon-a and Ribavirin in Treatment-naive Patients With Chronic Genotype 1b Hepatitis C Virus Infection Withdrawn NCT01858961 Phase 3 BI 201335;ribavirin;BI 207127;Telaprevir;Pegylated Interferon
201 Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A) Unknown status NCT02057887 Phase 1, Phase 2 HM10660A;Pegasys
202 A Phase IIa, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Seraprevir in Combination With Sofosbuvir in Patients With Chronic Genotype 2,3,6 Hepatitis C Virus Infection Unknown status NCT04111367 Phase 2 Seraprevir;Sofosbuvir
203 A Phase I/IIa Open-Label, Dose Ranging, Parallel, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C® in Combination With Electroporation in Chronic HCV Genotype 1 Infected and Treatment Naïve Patients With Low Viral Load Unknown status NCT00563173 Phase 1, Phase 2 CHRONVAC-C®
204 Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination With Ribavirin to Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection Unknown status NCT01001754 Phase 2 PEG-rIL-29;Peginterferon alfa-2a;Ribavirin
205 Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection Unknown status NCT01872936 Phase 2 Miravirsen;Telaprevir;Ribavirin
206 Dose Finding and Early Efficacy Study of Erlotinib in Treatment of Chronic Hepatitis C Virus infection_proof of Concept Study Unknown status NCT01835938 Phase 1, Phase 2 1- Erlotinib;placebo
207 A Phase II Open-Label, Randomized, Parallel Group, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination With Electroporation Followed by Standard of Care in Chronic Hepatitis C Virus Genotype 1 Infected and Treatment Naïve Subjects Unknown status NCT01335711 Phase 2 ChronVac-C + SOC;SOC
208 Prospective Randomized Double Blind Placebo Controlled Trial of Rifaximin 550mg PO Twice Daily for Three Months to Prevent Recurrent Fibrosis in Liver Transplant Recipients With Chronic Hepatitis C Virus Infection Unknown status NCT01603108 Phase 2 Rifaximin;Placebo
209 Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor to HCVNegative Organ Transplant Recipient - Pilot Trial Completed NCT04596475 Phase 1, Phase 2 glecaprevir/pibrentasvir (GLE/PIB)
210 A Phase 2A Study of BMS-791325 in Combination With Peg Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve Subjects With Chronic Hepatitis C Virus Genotype 1 Infection Completed NCT01193361 Phase 2 BMS-791325;Placebo;Peg-interferon alfa-2a;Ribavirin
211 An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 1, 4, 5, and 6 Infection (SURVEYOR-I) Completed NCT02243280 Phase 2 ABT-493;ABT-530
212 Pilot Study to Assess Efficacy and Safety of a Quadruple Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Non-responders to Pegylated Interferon-Ribavirin Regimen Completed NCT02107365 Phase 2 Asunaprevir;Daclatasvir;Ribavirin;Pegylated Interferon alpha-2a
213 A Phase 2, Randomized, Open-Label Study of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin in Subjects With Chronic Genotype 1 HCV Infection Completed NCT01726517 Phase 2 LDV/SOF;RBV
214 A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant Completed NCT01687270 Phase 2 Sofosbuvir;RBV
215 Phase I/II, Multicenter, Randomized, Open,Active-Controlled, ClinicalTrial to Evaluate PK, PD, Safety and Tolerability Of Interferon Alfa 5, S.C. 3 Times Per Week, For 29 Days, To Treat-Experienced Pat. With Genotype-1 Chronic Hepatitis C Completed NCT01121731 Phase 1, Phase 2 Interferon α-5;Interferon-α5 plus Interferon-α 2b;Interferon α-2b (INTRON® A)
216 A Phase 2B Study of BMS-790052 in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who Are Null or Partial Responders to Prior Treatment With Peginterferon Alfa Plus Ribavirin Therapy Completed NCT01170962 Phase 2 BMS-790052;Placebo;peginterferon alfa-2a;ribavirin
217 A Multicenter, Randomized, Open-label, Phase 2b Study to Evaluate the Efficacy and Safety of Two Regimens of All-oral Triple Therapy (VX-222 in Combination With Telaprevir [Incivek™] and Ribavirin [Copegus®]) in Treatment-Naïve Subjects With Genotype 1a Chronic Hepatitis C Completed NCT01581138 Phase 2 VX-222;telaprevir;ribavirin
218 A Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Completed NCT00851890 Phase 2 ABT-333;Pegylated interferon;Ribavirin
219 A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 2 or 3 Infection Completed NCT01257204 Phase 2 Placebo;Daclatasvir;Pegylated interferon alfa-2a;Ribavirin
220 A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection Completed NCT02249182 Phase 2 LDV/SOF;RBV
221 A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects With Genotype 1, 4, 5 and 6 Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease Completed NCT03036839 Phase 2 LDV/SOF
222 An Open-Label Re-Treatment Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C Completed NCT01428063 Phase 2 Daclatasvir;Asunaprevir;Pegylated interferon alfa-2a;Ribavirin
223 A Multicenter, Open-Label Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, and Ribavirin) in Subjects With Genotype 1 Chronic Hepatitis C With Compensated Cirrhosis Completed NCT01516918 Phase 2 VX-222;telaprevir;ribavirin
224 A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection Completed NCT01125189 Phase 2 Daclatasvir;Placebo;peg-interferon alfa-2a;ribavirin
225 A Phase II Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects With Chronic Hepatitis C Virus Infection Who Failed Prior Direct Acting Antiviral Therapy Completed NCT02105454 Phase 2 Grazoprevir (GZR);Elbasvir (EBR);Ribavirin (RBV)
226 A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Completed NCT01995071 Phase 2 ABT-493;ABT-530;ABT-450/r/ABT-267, ABT-333;Ribavirin (RBV)
227 A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection Completed NCT01713283 Phase 2 SOF;RBV
228 A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection Completed NCT03022981 Phase 2 SOF/VEL
229 A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis Completed NCT02994056 Phase 2 SOF/VEL;RBV
230 A Multi-center, Placebo-Controlled, Dose Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Oral Administration of PSI-7977 in Combination With Pegylated Interferon and Ribavirin in Treatment-Naïve Patients With Chronic HCV Infection Genotype 1, and an Open Label Assessment of PSI-7977 in Patients With HCV Genotypes 2 or 3 Completed NCT01188772 Phase 2 Sofosbuvir;Placebo to match sofosbuvir;PEG;RBV
231 A Dose Response Study of CTS-1027 in Hepatitis C Patients Completed NCT00570336 Phase 2 CTS-1027
232 A Phase 2, Randomized, Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection and Cirrhosis Completed NCT02226549 Phase 2 LDV/SOF;VDV;RBV
233 A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Randomized Study to Investigate the Effect of Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection Completed NCT02219685 Phase 2 LDV/SOF;Placebo
234 A Phase 2, Open-label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Subjects Undergoing Cancer Chemotherapy Completed NCT02868242 Phase 2 LDV/SOF
235 Effectiveness of Sofosbuvir/Pegylated-interferon Plus Ribavirin in Treatment of Hepatitis C Virus Genotype 4 Patients Completed NCT04382339 Phase 1, Phase 2 SOF/RBV/PegINFα-2
236 Effect of Immunosuppression Drug Weaning on Hepatitis C Virus Induced Liver Damage After Liver Transplantation. Completed NCT00668369 Phase 2
237 A Phase 2a/2b Study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotypes 1 and 4 Chronic Hepatitis C Infection Completed NCT01030432 Phase 2 BMS-650032;Placebo;Peginterferon Alfa-2a;Ribavirin
238 A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection Completed NCT02175758 Phase 2 SOF;RBV
239 A Sofosbuvir-based Quadruple Regimen is Highly Effective in HCV Type 4-infected Egyptian Patients With DAA Treatment Failure Completed NCT04387539 Phase 1, Phase 2 SOF/SMV/DCV/RBV
240 A Multiple-Center, Observer-Blinded, Randomized, Placebo-Controlled, Single & Multiple Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, & Food Effect of RO5024048 in Healthy Volunteers & in Patients With Chronic HCV Infection Completed NCT00382798 Phase 1, Phase 2 RO5024048
241 A Phase 2 Study Assessing the Safety and Efficacy of AT-527 in Combination With Daclatasvir in Subjects With Chronic HCV Infection Completed NCT04019717 Phase 2 AT-527;Daclatasvir
242 A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis Completed NCT02781558 Phase 2 SOF/VEL;RBV
243 Sofosbuvir in Combination With Ribavirin or Simeprevir: Real-life Study of Patients With Hepatitis C Genotype 4 Completed NCT04385407 Phase 2 Sofosbuvir + Simeprevir + Ribavirin
244 A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir Fixed Dose Combination Administered for Four Weeks in Patients Infected With Chronic HCV in the Peri-Operative Liver Transplantation Setting Completed NCT02728206 Phase 2 SOF/VEL
245 Phase II Trial of Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma Completed NCT01008358 Phase 2
246 A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-072 After Discontinuation of ABT-072 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-072 Clinical Studies Completed NCT00872196 Phase 2 ABT-072
247 Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients Completed NCT04391985 Phase 1, Phase 2 SOF plus (OBV/PTV/r) plus RBV
248 An Open-Label, Sequential Arm, Multicenter Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-267 With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) Infection Completed NCT01458535 Phase 2 ABT-450;ABT-267;ribavirin;ritonavir
249 A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection Completed NCT02251717 Phase 2 LDV/SOF
250 An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-530, With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 3 Chronic Hepatitis C Virus (HCV) Infection Completed NCT02068222 Phase 2 ABT-450/ritonavir (r);ABT-530;Ribavirin (RBV)
251 A Randomized Study to Evaluate the Safety and Efficacy of IDX719 in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Subjects With Chronic Hepatitis C Infection Completed NCT01852604 Phase 2 Samatasvir;Simeprevir;Ribavirin (RBV);TMC647055;Ritonavir (RTV)
252 A Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of ABT-267 in Combination With Peginterferon Alpha-2a and Ribavirin (pegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Completed NCT01314261 Phase 2 ABT-267;Pegylated interferon (pegIFN);Ribavirin (RBV)
253 An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-333 and Ribavirin (RBV) in Treatment-Naive and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Completed NCT01306617 Phase 2 ABT-450;ABT-333;ribavirin;ritonavir
254 Efficacy of Ombitasvir With Paritaprevir/Ritonavir Plus Ribavirin on the Treatment naïve Patients With Chronic Hepatitis C Virus Genotype 4 Completed NCT04378608 Phase 1, Phase 2 OBV/PTV/r) ± ribavirin (RBV)
255 A Randomized, Open-label Phase II Trial of the Anti-HCV Activity and Safety of VGX-410 (Mifepristone) at 3 Dose Levels in HCV Infected Patients Completed NCT00255177 Phase 2 VGX-410 (Mifepristone);Placebo
256 A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects With Chronic HCV Infection Who Have Received a Liver Transplant Completed NCT02781571 Phase 2 SOF/VEL
257 A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/GS-5816/GS-9857 Fixed-Dose Combination With or Without Ribavirin in Subjects With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen Completed NCT02536313 Phase 2 SOF/VEL/VOX;RBV
258 A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy With Genotype 1 Chronic Hepatitis C Completed NCT01628692 Phase 2 Daclatasvir;Simeprevir;Ribavirin
259 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection or Genotype 3 HCV Infection With or Without Cirrhosis Completed NCT02292719 Phase 2 OBV/PTV/r;Sofosbuvir;Ribavirin (RBV)
260 Phase I Clinical Trial of PEG-IFN-SA in HCV Disease: Evidence for Drug Safety, Tolerance, and Antiviral Activity Completed NCT01605513 Phase 1, Phase 2 interferon
261 An Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Subjects With Sickle Cell Disease Completed NCT02301936 Phase 2 LDV/SOF
262 A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Non-Genotype 1 HCV Infection Completed NCT02378961 Phase 2 VOX;SOF/VEL
263 A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Genotype 1 HCV Infection Completed NCT02378935 Phase 2 VOX;SOF/VEL;RBV
264 A Phase 2, Randomized, Open-label Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of 6 or 8 Weeks of Treatment With Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Subjects With Chronic Hepatitis C Virus Genotype 1 Infection Completed NCT02349048 Phase 2 Simeprevir 150 mg;Daclatasvir 60 mg;Sofosbuvir 400 mg
265 An Open Label Study to Evaluate The Efficacy And Safety Of Sofosbuvir/GS-5816 Fixed Dose Combination With Ribavirin For 24 Weeks In Chronic HCV Infected Subjects Who Participated In A Prior Gilead Sponsored HCV Treatment Study Completed NCT02300103 Phase 2 SOF/VEL;RBV
266 A Phase 2 Open- Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naïve Patients With Chronic HCV Genotype 3 Infection Completed NCT02413593 Phase 2 LDV/SOF;RBV
267 A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic HCV for Use in the Peri-Operative Liver Transplantation Setting Completed NCT02350569 Phase 2 LDV/SOF
268 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared With GS-5885, GS-9451 With Tegobuvir or RBV in Treatment-Experienced Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection Completed NCT01435226 Phase 2 GS-5885;GS-9451;tegobuvir;placebo to match tegobuvir;placebo to match RBV;Ribavirin
269 QUANTUM: An International, Multi-center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Administration of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients With Chronic Hepatitis C Virus (HCV) Infection Completed NCT01435044 Phase 2 Sofosbuvir;GS-0938;RBV;Placebo to match sofosbuvir;Placebo to match GS-0938
270 A Phase 2, Randomized, Placebo Controlled, Dose Ranging Study To Evaluate Peginterferon Alfa 2a (Pegasys®) And Ribavirin (Copegus®) With And Without PF-00868554 In Subjects Chronically Infected With Hepatitis C Virus Completed NCT00720434 Phase 2 PF-00868554;Placebo
271 A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection Completed NCT01220947 Phase 2 Copegus;Danoprevir;Pegasys;Ritonavir
272 A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders Completed NCT02120300 Phase 2 LDV/SOF;SOF;RBV
273 The Safety and Efficacy of Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C Virus Infection in Naïve Children Completed NCT05091008 Phase 2 Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet
274 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®) in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0123) Completed NCT01225380 Phase 2 GS-9190;GS-9256;Copegus®;GS-9190 placebo;GS-9256 placebo
275 Part A: Drug Interaction Study Between GS-7977 and Antiretroviral Therapy (ARV) Combinations of Efavirenz, Tenofovir and Emtricitabine; Efavirenz, Zidovudine and Lamivudine; Atazanavir/Ritonavir, Tenofovir and Emtricitabine; Darunavir/Ritonavir, Tenofovir and Emtricitabine; Raltegravir, Tenofovir and Emtricitabine in Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-infected Patients. Part B: A Phase 2, Open-Label Study to Investigate the Efficacy and Safety of GS-7977 With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naïve HIV/HCV Co-infected Patients. Completed NCT01565889 Phase 1, Phase 2 SOF;EFV/FTC/TDF;EFV;ZDV/3TC;ATV;Ritonavir;FTC/TDF;DRV;RAL;PEG;RBV
276 Double-Blind, Randomized, Placebo-Controlled Study to Assess Safety, Efficacy, and Pharmacokinetics (PK) of GSK2336805 in Combination With Peginterferon and Ribavirin in Treatment-naive Chronic Hepatitis C Subjects With Hepatitis C Virus Genotypes 1 or 4 Completed NCT01439373 Phase 2 GSK2336805;Pegylated interferon alfa-2a;Ribavirin;GSK2336805 Matching Placebo
277 A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ± Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection Completed NCT01717326 Phase 2 Grazoprevir;Elbasvir;Placebo to Elbasvir;Ribavirin
278 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy Using Combinations of Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol GS US 256 0124) Completed NCT01371578 Phase 2 GS-5885 tablet;GS-9451 tablet;ribavirin tablet
279 A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 With Ritonavir (ABT-450/r) in Combination With ABT-267 and/or ABT-333 With and Without Ribavirin (RBV) for 8, 12 or 24 Weeks in Treatment-Naïve and Null Responder Subjects With Genotype 1 Chronic Hepatitis C Virus Infection Completed NCT01464827 Phase 2 ABT-450;ABT-333;ABT-267;Ribavirin;Ritonavir
280 Antiviral Effect, Safety and Pharmacokinetics of BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naïve and Treatment-experienced Patients for 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Double-blinded, Randomised, Placebo-controlled, Phase II) Completed NCT00774397 Phase 2 BI 201335 NA 240 mg QD / LI;PegIFN/RBV;BI 201335 NA 120mg QD / LI;BI 201335 NA 240 mg QD;BI 201335 NA 240 mg BID;Placebo
281 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS 9190, in Combination With Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV) Infection (GS-US-196-0103) Completed NCT00743795 Phase 2 placebo;GS-9190;Peginterferon Alfa 2a;Ribavirin
282 A Phase IIa, Randomized, Double-blind (Subject and Investigator Blind, Sponsor Open), Placebo-controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of Oral ACH-0141625 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Two Segments, After 28 Days of Dosing and, Subsequently, After 12 Weeks of Dosing in Subjects With Chronic Hepatitis C Virus Genotype 1 Completed NCT01180790 Phase 2 ACH-0141625 (Sovaprevir);Placebo;Pegylated Interferon alpha-2a;Ribavirin
283 Open-Label Study to Evaluate the Safety and Tolerability of Telaprevir in Combination With Sofosbuvir in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotype 1 Completed NCT01994486 Phase 2 Telaprevir and Sofosbuvir
284 A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection Completed NCT01710501 Phase 2 Grazoprevir;Ribavirin;Placebo
285 An Open-label, Ascending Dose, Phase II Study to Evaluate Tolerability, Safety, Antiviral Activity, and Pharmacokinetics of BI 207127 NA in Combination With BI 201335 NA and Ribavirin for 8 Weeks in Treatment-naïve Japanese Patients With Genotype 1chronic Hepatitis C Virus Infection Completed NCT01528735 Phase 2 BI 207127 NA;peginterferon;Ribavirin;BI 201335 NA
286 Open-Label, Multiple-Dose, Dose Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Coadministration of BMS-650032, BMS-790052, and BMS-791325 When Administered for 24 or 12 Weeks in Treatment-Naïve Subjects Infected With Hepatitis C Virus Genotype 1 Completed NCT01455090 Phase 2 BMS-650032;BMS-790052;BMS-791325;Ribavirin
287 Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity and Safety, Tolerability, and Pharmacokinetics of BMS-650032 in Subjects Infected With Hepatitis C Virus Genotype 1 Completed NCT00722358 Phase 2 BMS-650032;Placebo
288 An Open-Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Completed NCT01221298 Phase 2 ABT-450;ABT-072;Ribavirin;Ritonavir
289 Phase 2a, Randomized, Double-Blind Study to Investigate the Safety and Efficacy of Faldaprevir in Combination With Ribavirin and TD-6450 for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 4 Hepatitis C Virus Completed NCT02593162 Phase 2 Faldaprevir;TD-6450;Ribavirin
290 Pirfenidone, an Antifibrotic and Antiinflammatory Drug for Treatment of Patients With Cirrhosis Due to Hepatitis C Virus. Phase II/III Study Completed NCT02161952 Phase 2 Pirfenidone;Matched equivalent placebo
291 A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Experienced Patients With Chronic Genotype 1 Hepatitis C Virus Infection Completed NCT00704405 Phase 2 Vaniprevir;Pegylated Interferon (Peg-IFN);Ribavirin (RBV);Placebo (PBO)
292 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Low-Dose Human Interferon-alpha by the Oral Mucosal Route During the 6-Month Follow-up Period of Standard Combination Therapy for Hepatitis C Virus Infection Completed NCT00695019 Phase 2 interferon-alpha lozenges;placebo lozenges
293 A Phase 2a Study of Daclatasvir in Combination With Peginterferon Alfa-2a(Pegasys®) and Ribavirin (Copegus®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Completed NCT01017575 Phase 2 Daclatasvir;Placebo;Peginterferon alfa-2a;Ribavirin
294 A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2b (PegIntron®) and Ribavirin (Rebetol®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Completed NCT01016912 Phase 2 BMS-790052;Placebo;Peginterferon alfa-2b;Ribavirin
295 Parallel, Open-Label, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-790052 and BMS-650032 in Combination in Null Responders to Standard of Care Infected With Chronic Hepatitis C Virus Genotype 1 Completed NCT01012895 Phase 2 BMS-790052;BMS-650032;Pegylated-interferon alfa-2a;Ribavirin
296 Antiviral Effect and Safety of Once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naive Patients for 12 or 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Randomised, Open Label, Phase II) Completed NCT00984620 Phase 2 BI 201335;Pegylated Interferon-alpha (IFN);Ribavirin (RBV)
297 #0810010040: Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus Infection: A Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C Completed NCT00892697 Phase 2 Telaprevir;Peginterferon alfa-2a;Ribavirin
298 A Phase 2, Randomized, Open-Label Trial of GS-9256 Plus GS-9190 Alone and in Combination With Ribavirin for 28 Days in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0112) Completed NCT01072695 Phase 2 GS-9256;GS-9190;Ribavirin;Peginterferon alfa-2a
299 Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-650032 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1 Completed NCT00559247 Phase 1, Phase 2 BMS-650032 or Placebo
300 Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-790052 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1 Completed NCT00546715 Phase 1, Phase 2 Daclatasvir;Placebo
301 Phase 2 Comparison of Weight-based Doses of Taribavirin Combined With Peginterferon Alfa-2b Versus Ribavirin Combined With Peginterferon Alfa-2b in Therapy-naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection Completed NCT00446134 Phase 2 Taribavirin;Ribavirin
302 A Pilot Study of Treatment With Pegylated Interferon-Alpha2a, Ribavirin and Insulin Sensitizer Pioglitazone of Insulin Resistance (With the Exception of Diabetes) in Hepatitis C Virus Infection (The INSPIRED HCV Study) Completed NCT00433069 Phase 2 Pioglitazone;Interferon Alfa-2a;Ribavirin
303 A Prospective Multicenter, Phase II, Open Label, Controlled Trial Evaluating the Response of Hepatitis C Virus (HCV) to Pegylated Interferon Alpha-2A and Ribavirin in Hemophilic Patients With and Without Coinfection With the Human Immunodeficiency Virus (HIV) Completed NCT00055341 Phase 2 Peginterferon alfa-2a;Ribavirin
304 Double Blind, Randomized, Multicenter, Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine Together With Polyarginine, HCV Peptide Vaccine Alone, or Polyarginine Alone, in Patients With Chronic HCV Having Not Responded to or Relapsed From Primary Standard HCV Therapy Completed NCT00602784 Phase 2
305 ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections Completed NCT00035945 Phase 2 ISIS 14803
306 A Prospective, Multicenter, Phase II/III, Open-Label, Controlled, Randomized Trial Evaluating the Efficacy, Safety, and Tolerability of Interferon-alfa-2a Plus Ribavirin Versus PEG-interferon-alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus (HCV) Infection in Individuals Co-Infected With Human Immunodeficiency Virus-1 (HIV-1) Completed NCT00008463 Phase 2 Ribavirin;Interferon alfa-2a;Peginterferon alfa-2a
307 Randomized, Multicentric, Partially Double-Blinded Placebo-Controlled Phase II Study for Examining the Influence of Ribavirin on the Initial Virological Response With Treatment of Peginterferon Alfa-2a (40KD) and Ribavirin With a Six Week Pretreatment-Phase of Ribavirin/Placebo or PEG-Interferon Monotherapy in Treatment Naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection Completed NCT02716779 Phase 2 Pegylated Interferon (PEG-IFN) alfa-2a;Placebo;Ribavirin
308 A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1 Completed NCT00874770 Phase 2 Daclatasvir;Placebo;Peginterferon alpha-2a;ribavirin
309 A Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone, and GI-5005 Salvage of Standard of Care Failures, in Patients With Genotype 1 Chronic Hepatitis C Infection Completed NCT00606086 Phase 2 GI-5005;Pegylated Interferon and Ribavirin
310 A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN Completed NCT00328549 Phase 2 Pegylated Interferon and Ribavirin
311 The Adult-to-adult Living Donor Liver Transplantation Cohort Study (A2ALL) Low Accelerated Dosing Regimen (LADR) Protocol: Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C Virus (HCV) After Liver Transplantation Completed NCT00135798 Phase 2 LADR Treatment
312 Suppressive Long-Term Antiviral Management of Hepatitis C Virus (HCV) and HIV-1 Coinfected Subjects (SLAM-C) Completed NCT00078403 Phase 2 Peginterferon alfa-2a;Ribavirin
313 A Blinded, Randomized, Placebo-controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-450 With Ritonavir (ABT-450/r), ABT-333 or ABT-072 Each Administered Alone and in Combination With Peginterferon α-2a and Ribavirin (PegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Completed NCT01074008 Phase 2 ABT-450;ABT-072;ABT-333;Ritonavir;Peginterferon alpha-2a;Ribavirin
314 Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus Completed NCT00403533 Phase 2 20 mg of atorvastatin daily
315 Anticoagulation for Liver Fibrosis in Patients With Hepatitis C Virus Infection: Pilot Study Completed NCT00180674 Phase 2 Warfarin
316 A Phase 2b, Multicenter, Randomized, Open-label Study to Investigate the Efficacy, Safety and Pharmacokinetics of Different Treatment Regimens of AL-335, Odalasvir, and Simeprevir in Treatment-naive and Treatment-experienced Subjects With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5, and 6 Infection Without Cirrhosis Completed NCT02765490 Phase 2 AL-335;Odalasvir;Simeprevir
317 An Open-Label Study to Explore the Clinical Efficacy of GS-7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant Completed NCT01559844 Phase 2 Sofosbuvir;Ribavirin
318 A Phase 2 Open-label Study to Investigate the Efficacy, Safety and Pharmacokinetics of 12 Weeks of Treatment With Simeprevir, Daclatasvir and Sofosbuvir, Followed by a 5-Year Post-treatment Long-term Follow-up, in Treatment-naïve and Treatment-experienced Subjects With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease Completed NCT02262728 Phase 2 Simeprevir;Daclatasvir;Sofosbuvir
319 A Phase 2, Open-Label Study to Investigate the Efficacy and Safety of an 8-Week and 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 4 Hepatitis C Virus Infection With and Without Cirrhosis Completed NCT02253550 Phase 2 Simeprevir;Sofosbuvir
320 A Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects Who Had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis Following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following Anti-HCV Therapy Completed NCT02138253 Phase 2 IDN-6556;Placebo
321 A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection Completed NCT01716156 Phase 2 Grazoprevir;Ribavirin
322 A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I) Completed NCT01685203 Phase 2 ABT-450/r;ABT-267;Ribavirin (RBV)
323 A Randomized, Active-Control Phase II Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic Hepatitis C Virus Genotype 1 Infection Completed NCT01273948 Phase 1, Phase 2 Bavituximab;Pegylated interferon (PEG-IFN)
324 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of 3 Days of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus (HCV) Infected Patients Completed NCT01825980 Phase 1, Phase 2 BZF961;Ritonavir;Placebo
325 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir (GS-9190) Followed by Response Guided PEG and RBV in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS US 196 0140 Completed NCT01271790 Phase 2 Tegobuvir (GS-9190);GS-9451;Copegus®;Tegobuvir placebo;GS-9451 placebo
326 A Phase II, Multi-center, Open-label, Interventional Study to Evaluate the Safety of Intravenous Silibinin (iSIL) and Its Effect on the Hepatitis C Virus Load in Treatment-experienced HCV-HIV Co-infected Individuals With Advanced Liver Fibrosis in the Swiss HIV Cohort Study (SHCS) Completed NCT01816490 Phase 2 Intravenous Silibinin (iSIL)
327 Parallel, Open-Label, Randomized Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of PSI-7977 in Combination With BMS-790052 With or Without Ribavirin in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotypes 1, 2, or 3 Completed NCT01359644 Phase 2 PSI-7977;Daclatasvir;Ribavirin
328 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy With GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection Completed NCT01356160 Phase 2 GS-5885;GS-9451;ribavirin tablet;GS-9451 Placebo
329 A Phase II, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study, With an Open-Label Extension, to Evaluate the Efficacy, Safety, and Pharmacokinetics of E5501 in Subjects With Chronic Hepatitis C Virus Related Thrombocytopenia Who Are Potential Candidates for Antiviral Treatment Completed NCT01355289 Phase 2 Avatrombopag;Placebo;Pegylated interferon (PEG-IFN);Telaprevir;Ribavirin
330 A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Genotype 1 Hepatitis C Virus Infection Completed NCT01353911 Phase 2 Grazoprevir;Boceprevir;Placebo for Grazoprevir;Placebo for Boceprevir;Peg-interferon alfa-2b;Ribavirin
331 A Randomised, Double-blind, Placebo Controlled Trial With 25 mg, 200 mg and 500 mg BILN 2061 ZW Given p.o. at Two Consecutive Days Bid to Investigate the Antiviral Efficacy, Pharmacokinetics, Safety in Patients With Chronic Hepatitis C Virus Infection Completed NCT02226952 Phase 1, Phase 2 BILN 2061 W, low dose;BILN 2061 W, medium dose;BILN 2061 W, high dose;Placebo
332 Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity and Safety, Tolerability, and Pharmacokinetics of Daclatasvir in Subjects Infected With Hepatitis C Virus Genotype 1 Completed NCT00663208 Phase 2 Daclatasvir;Placebo
333 Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-791325 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1 Completed NCT00664625 Phase 1, Phase 2 BMS-791325;Placebo
334 Infliximab (Remicade®) as an Adjunct to Pegylated- Interferon α-2b and Ribavirin in the Treatment of Hepatitis C Virus Infection Completed NCT00512278 Phase 2 Infliximab;Placebo
335 A Phase 2, Randomized, Open-Label Study Of The Safety, Antiviral Activity, And Pharmacokinetics Of HCV-796 Administered In Combination With Peginterferon Alfa 2B (Peg-Intron) Plus Ribavirin (Rebetol) Versus Peg-Intron Plus Rebetol In Subjects With Hepatitis C Virus Genotype 1 Infection Completed NCT00367887 Phase 2 Peg-Intron;REBETOL;HCV 796
336 PEG-Intron/REBETOL vs PEG-Intron/ SCH 503034 With and Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 (HCV-1) Peginterferon Alfa/Ribavirin Nonresponders: A SCH 503034 Dose-Finding Phase 2 Study Completed NCT00160251 Phase 2 Boceprevir (BOC);Ribavirin (RBV)
337 A Multiple Rising-Dose Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection Completed NCT00047814 Phase 2 FK788
338 A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and TD 6450 Alone and in Combination With Other Antivirals for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1 Hepatitis C Virus Completed NCT02716428 Phase 2 Faldaprevir;TD-6450;Ribavirin
339 An Open-label, Single-Arm, Phase 2 Study to Evaluate the Combination of ABT-450/r/ABT-267 and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Hepatitis C Virus (HCV) Infection Taking Methadone or Buprenorphine Completed NCT01911845 Phase 2 ABT-450/r/ABT-267;ABT-333;Ribavirin (RBV)
340 Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I) Completed NCT01782495 Phase 2 ombitasvir/paritaprevir/ritonavir and dasabuvir;ombitasvir/paritaprevir/ritonavir;ribavirin
341 Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection With Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study Completed NCT02309918 Phase 2 LDV/SOF FDC
342 A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Treatment naïve East Asian Subjects With Chronic Hepatitis C Virus Genotype 1b Infection. Completed NCT02340962 Phase 2 TG-2349;Ribavirin;Interferon Alfa-2a
343 An Exploratory Study to Evaluate the Kinetics of Viral Load Decline With Ombitasvir/ABT 450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) Infection Completed NCT02493855 Phase 2 Ombitasvir/ABT-450/Ritonavir;Dasabuvir;Ribavirin (RBV)
344 Investigation of Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816 Completed NCT02468648 Phase 2 Sofosbuvir;GS-5816
345 A Phase 2, 2-panel, Open-label Randomized Study in Hepatitis C Virus Infected Subjects to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir and Ledipasvir in Treatment-naive Participants. Completed NCT02421211 Phase 2 Simeprevir (SMV);Ledipasvir (LDV);Sofosbuvir (SOF)
346 An Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With or Without Sofosbuvir (SOF) and Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection Completed NCT02356562 Phase 2 ombitasvir/paritaprevir/ritonavir and dasabuvir;Sofosbuvir;Ribavirin
347 A Phase 2 Study to Evaluate the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection Completed NCT01672983 Phase 2 ABT-450/ritonavir, ABT-267
348 A Phase 2, Single-Center, Open-Label Pilot Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection Completed NCT02480387 Phase 2 Ledipasvir/Sofosbuvir FDC
349 TAC (Treatment Africa Hepatitis C) : Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa Completed NCT02405013 Phase 2 Sofosbuvir;Ribavirin;Ledipasvir
350 A Phase II, Open-label, Single Arm, Multicentre, International Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use Completed NCT02336139 Phase 2 Sofosbuvir (SOF)/GS-5816
351 Evaluation of Efficacy and Safety of KW-136 Plus Sofosbuvir for Treatment-naive Adults Chronically Infected With Hepatitis C Virus: a Randomized, Open-label, Multicenter Phase 2 Trial Completed NCT03416491 Phase 2 KW-136;Sofosbuvir
352 An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination With Peginterferon Alpha-2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects Who Have Experienced Virologic Failure in a Previous AbbVie or Abbott DAA Combination Study Completed NCT01609933 Phase 2 ABT-450/r;ABT-267;pegylated interferon alpha-2a (pegIFN);Ribavirin (RBV)
353 Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Subjects With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection Completed NCT02457611 Phase 2 LDV/SOF
354 An Open Label, Randomised Phase 2 Study to Evaluate the Safety and Efficacy of MTL-CEBPA Administered in Combination With Sorafenib or Sorafenib Alone in TKI naïve Participants With Previously Treated Advanced Hepatocellular Carcinoma (HCC) and Hepatitis B or Hepatitis C Virus (OUTREACH2) Recruiting NCT04710641 Phase 2 MTL-CEBPA;Sorafenib
355 Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy Recruiting NCT03903185 Phase 1, Phase 2 Ledipasvir / Sofosbuvir Oral Product
356 Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C) Recruiting NCT04042740 Phase 2 Glecaprevir/Pibrentasvir (G/P);Ribavirin (RBV)
357 A Phase II Study of Pembrolizumab (MK-3475) in Hepatitis C Virus Positive and Negative Subjects With Advanced Hepatocellular Carcinoma Who Progressed on or Were Intolerant to First-Line Systemic Therapy Active, not recruiting NCT02940496 Phase 2 Elbasvir/Grazoprevir;Ribavirin
358 A Multicenter Study to Evaluate the Anti-viral Activity of an Interferon-free Treatment With Ledipasvir/Sofosbuvir (G1 and G4) and Sofosbuvir/Velpatasvir (G2 and G3) for Patients With Hepatitis C Virus-associated Indolent B-cell Lymphomas Active, not recruiting NCT02836925 Phase 2 Ledipasvir+Sofosbuvir;Sofosbuvir+Velpatasvir
359 A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed Dose Combination in Adolescents and Children With Chronic HCV Infection Terminated NCT03820258 Phase 2 SOF/VEL/VOX
360 A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Terminated NCT01080222 Phase 2 telaprevir;VX-222;ribavirin
361 Safety and Efficacy Study in Non-Responder Hepatitis C Genotype 1 Patients With PHN121 Terminated NCT01052090 Phase 1, Phase 2 PHN121
362 A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of LEGALON SIL for the Treatment of HCV Recurrence in Stable Liver Transplanted Patients Terminated NCT01518933 Phase 2 Silibinin (Legalon-SIL);Saline
363 A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected With Genotype 1 Hepatitis C Virus Following Liver Transplantation Terminated NCT01467505 Phase 2 Telaprevir;Ribavirin;Pegylated Interferon Alfa-2a;Immunosuppressant Regimen
364 A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 Weeks of the Combination Regimen of MK-3682 + Ruzasvir in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5 or 6 Infection Terminated NCT02956629 Phase 2 Uprifosbuvir;Ruzasvir;Ribavirin
365 Phase II Trial of Retreatment Strategies for Difficult-to-Treat Hepatitis C Virus (HCV)-Infected Individuals Who Have Failed Prior Direct Acting Antiviral (DAA)-Based Regimens Terminated NCT02605304 Phase 2 Ledipasvir/sofosbuvir;Ribavirin
366 A Phase 2 Randomized, Open-Label, Exploratory Trial of GS-5885, GS-9451 With Peginterferon Alfa 2a and Ribavirin (RBV) in Treatment-Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and IL28B CC Genotype Terminated NCT01384383 Phase 2 GS-5885;GS-9451;RBV;PEG
367 A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Pegylated-Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 2 or 3 Hepatitis C Virus Infection Terminated NCT01440595 Phase 2 Grazoprevir;Placebo to Grazoprevir;Peginterferon alfa-2b (Peg-IFN);Ribavirin (RBV)
368 A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 Infected With Genotype 1 Hepatitis C Virus Terminated NCT01701063 Phase 1, Phase 2 Telaprevir;Peginterferon alfa-2b;Ribavirin
369 Liver Transplantation in Patients With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Coinfection ANRS HC08 Thevic Terminated NCT00158535 Phase 2
370 A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS 9450 in Adults With Chronic Hepatitis C Virus Infection (GS-US-227-0106) Terminated NCT00874796 Phase 2 GS-9450;Placebo
371 A Phase II Open-Label Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) Combined With Oral Direct-Acting Antivirals in Hepatitis C Infected Patients Undergoing Liver Transplantation Terminated NCT01532908 Phase 2 Telaprevir (Part 1);Sofosbuvir (Part 2)
372 A Phase II Randomized, Double-Blind, Placebo Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody Against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) in Hepatitis C Infected Patients Undergoing Liver Transplantation Terminated NCT01121185 Phase 2
373 Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT) Terminated NCT02194998 Phase 2 Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT);Dasabuvir (DSV);Ribavirin (RBV)
374 A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C Withdrawn NCT00814606 Phase 2 Fluvastatin;Peginterferon alfa2a;ribavirin
375 A Randomized, Placebo-controlled, Phase 2a Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I Withdrawn NCT01142700 Phase 2 BMS-824393;Placebo;Peginterferon Alpha-2a;Ribavirin
376 A Phase I/IIa Study Assessing AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects Withdrawn NCT04309734 Phase 1, Phase 2 AT-777;Placebo;AT-527
377 A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 Hepatitis C Virus Infection Withdrawn NCT00895882 Phase 2 vaniprevir (MK7009);Comparator: vaniprevir (MK7009);Comparator: Pegylated Interferon (peg-IFN) alfa-2a;Comparator: Ribavirin;Comparator: Placebo to vaniprevir
378 Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen Withdrawn NCT02309450 Phase 2 .Asunaprevir, Daclatasvir and BMS - 791325
379 Phase 2b Evaluation of PegIFNα Free Combinations of BMS-986094 (INX-08189) and Daclatasvir, With or Without Ribavirin, in Treatment Naive and Treatment Experienced Patients With Chronic Hepatitis C Withdrawn NCT01629732 Phase 2 Daclatasvir;BMS-986094;Ribavirin;Placebo for BMS-986094
380 A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1) Withdrawn NCT02556086 Phase 2 Daclatasvir;Sofosbuvir
381 A Phase 2, Open-label, Single-arm Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of 12 Weeks Treatment With Simeprevir and Daclatasvir in Subjects With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis. Withdrawn NCT02397395 Phase 2 Simeprevir (SMV) 150 mg;Daclatasvir (DCV) 60 mg
382 The Interaction of HSV-2 Co-infection in Veterans With Chronic Hepatitis C: the Effect of Valacyclovir on HCV Viral Load Unknown status NCT01037621 Phase 1 Valacyclovir
383 A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending and Multiple Oral Doses of MB-110 and to Evaluate the Antiviral Activity in Hepatitis C Virus Infected Patients Unknown status NCT02617615 Phase 1 MB-110;Placebo
384 A Phase I, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study of the Safety and Virologic Effects of Ascending Single (and Multiple) Doses of XTL6865 in Patients With Chronic Hepatitis C Virus Infection Unknown status NCT00300807 Phase 1 XTL 6865
385 Phase 1 Study of Autologous Bone Marrow Mononuclear Cells Infusion in Peripheral Vein in Liver Cirrhosis Due to Hepatitis C Virus Unknown status NCT00832247 Phase 1
386 Phase I,Randomized,Double-blind,Placebo-controlled,Multiple Dose Study Evaluating Safety,Tolerability,Pharmacokinetics and Antiviral Activity of JTK-853 in HCV Genotype 1 Infected Subjects,Followed by a Genotypic Resistance Monitoring Study Completed NCT01473056 Phase 1 JTK-853;Dose 2 JTK-853;Dose 3 JTK-853;Dose 4 JTK-853;Placebo
387 A Phase I, 2-panel, Open-label, Randomized, Cross-over Trial in Healthy Subjects to Investigate the Effect of TMC435 at Steady-state on the Pharmacokinetics of the Immunosuppressants Cyclosporine and Tacrolimus Completed NCT01479881 Phase 1 tacrolimus;TMC435;cyclosporine
388 A Phase 1b Study to Assess the Safety, Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection Completed NCT01247194 Phase 1 PPI-461;Placebo
389 A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Antiretroviral Agents, Efavirenz and Raltegravir, at Steady State Completed NCT01241773 Phase 1 raltegravir;TMC435 + raltegravir;TMC435;TMC435 + efavirenz;efavirenz
390 An Open-Label, One-Period Study in Patients Receiving Methadone or Buprenorphine/Naloxone Maintenance Therapy to Evaluate the Effect of SCH 503034 (Boceprevir) on Either Methadone or Buprenorphine/Naloxone Plasma Concentrations (Protocol No. P08123) Completed NCT01396005 Phase 1 boceprevir;methadone;buprenorphine/naloxone
391 Phase I, First-in-human, Double-blind, Randomized, Placebo-controlled Trial to Examine the Safety, Tolerability and Plasma Pharmacokinetics of Increasing Single Oral Doses of JNJ-47910382 in Healthy Caucasian and Japanese Volunteers Completed NCT01482611 Phase 1 JNJ-47910382;Placebo
392 Study of the Absolute Oral Bioavailability of BMS-791325 in Healthy Subjects Completed NCT02112110 Phase 1 BMS-791325;[13C]-BMS-791325
393 Photosensitivity Trial. A Randomized, Double-blind, Double Dummy, Placebo- and Positive Controlled Phase I Trial to Evaluate the Photosensitizing Potential of TMC435 in Healthy Subjects. Completed NCT01124799 Phase 1 TMC435;Placebo;Ciprofloxacin
394 A Phase I, 2-panel, Open-label, Randomized, Cross-over Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Antiretroviral Agents, TMC278 and Tenofovir Disoproxil Fumarate (TDF), at Steady State Completed NCT01205139 Phase 1 TMC435;TDF;TMC435 + TDF;TMC435 + TMC278;TMC278
395 An Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-914143 in Subject With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction Completed NCT01708889 Phase 1
396 Phase I, Open-label Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435 Completed NCT01381835 Phase 1 TMC435
397 A Phase 1, Open-Label, Randomized, 3-Way Crossover Study In Healthy Subjects To Estimate The Pharmacokinetics Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State Completed NCT00861458 Phase 1 Pharmacokinetics
398 Pilot BA Study With Phase III/Commercial Versus Phase IIB Formulation. A Phase I, Open Label, Randomized, Single Dose, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of TMC435 Following Administration of Potential Phase III Formulations Compared to the Phase IIb Capsule Completed NCT01134718 Phase 1 TMC435 (G006);TMC435 (F021);TMC435 (G007)
399 A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment Completed NCT02002767 Phase 1 Velpatasvir
400 Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic Hepatitis C Virus Infection Completed NCT01740791 Phase 1 Velpatasvir;Placebo
401 A Phase-I, Open-label Trial in Healthy Female Subjects to Investigate the Effect of TMC435 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone Completed NCT01486004 Phase 1 TMC435;Ovysmen
402 A Phase 1, Randomized, Placebo Controlled, Blinded (3rd Party Open), Sequential, Multiple-Dose Escalation Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691 In Healthy Volunteers Completed NCT00810758 Phase 1 PF-04878691 3mg;PF-04878691 6mg;PF-04878691 9mg
403 A Phase I Study in Healthy Subjects to Assess the Relative Bioavailability of TMC435 Following Administration of Potential Phase III Formulations Compared to the Phase IIb Capsule and to Assess the Effect of Food on the Bioavailability of TMC435 Following Intake of the Phase IIb Capsule Completed NCT01022125 Phase 1 TMC435
404 Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection Completed NCT02185794 Phase 1 Voxilaprevir;Placebo to match voxilaprevir;SOF/VEL
405 A Phase Ib Open-Label, Escalating Repeat-Dose Trial of Bavituximab (Chimeric Anti-Phosphatidylserine Monoclonal Antibody) in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus Completed NCT00503347 Phase 1 bavituximab
406 A Pilot Study of the Grapefruit Flavonoid Naringenin for the Treatment of HCV Infection Completed NCT01091077 Phase 1
407 A Phase I, Open-label, Sequential Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of TMC435 in Subjects With Moderately or Severely Impaired Hepatic Function Completed NCT01046058 Phase 1 TMC435
408 An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis Completed NCT02195440 Phase 1 PRI-724
409 Test-Retest Repeatability Study of Magnetic Resonance Elastography (MRE) for Liver Fibrosis Assessment in Healthy Volunteers and Hepatitis C Virus-Infected Patients Completed NCT00896233 Phase 1
410 A Phase I, Open-label, Randomized, 3-way Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Escitalopram at Steady-state Completed NCT01090700 Phase 1 TMC435;Escitalopram;TMC435 + Escitalopram
411 Effect of BMS-650032 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri- Cyclen (R)) in Healthy Female Subjects Completed NCT01063023 Phase 1 Ortho Tri-Cyclen®;BMS-650032
412 An Open-label, Two Part Investigation of the Pharmacokinetics, Safety, and Tolerability of Alisporivir and EDP239 When Co-administered to Healthy Adult Subjects Completed NCT02173574 Phase 1 DEB025;EDP239
413 A Phase 1, Non- Randomized, Open Label, Sequential Group, Multicenter Study To Evaluate The Antiviral Activity Of Multiple Doses Of A Small Molecule Direct Antiviral Agent In Chronically Infected Hepatitis C Subjects. Completed NCT00671671 Phase 1 Small Molecule Agent (PF-868554)
414 A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and CYP3A Inhibitors, Erythromycin and Darunavir/Ritonavir (DRV/r) Completed NCT01323257 Phase 1 erythromycin;Ritonavir;TMC435;Darunavir
415 A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Transporter Substrates, Digoxin and Rosuvastatin Completed NCT01288742 Phase 1 Rosuvastatin;TMC435;Digoxin
416 A Multiple-Dose Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of MK-1075 in GT3 and GT1 HCV Infected Patients Completed NCT02461563 Phase 1 200 mg MK-1075;400 mg MK-1075;800 mg MK-1075
417 A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Escalating, Multiple, Oral Doses of GS 5885 in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection Completed NCT01193478 Phase 1 GS-5885;Placebo
418 A Phase 1b, Open-label, Pilot Study to Evaluate the Safety, Tolerability and Antiviral Activity of Oral ACH-0143102 Administered in Combination With Ribavirin for 12 Weeks in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection Genotype 1b. Completed NCT01700179 Phase 1 ACH-0143102;Ribavirin
419 A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Dynamics Following Administration of MK-5172 in Hepatitis C Infected Patients Completed NCT01537900 Phase 1 Grazoprevir
420 A Randomized, Double-blind, Placebo-controlled Phase I Study to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of SH229 in Patients With Hepatitis C Virus (HCV) Infection Completed NCT03588923 Phase 1 SH229;Placebos
421 A Phase 1b, Randomized, Single-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection Completed NCT01431898 Phase 1 GS-9669 tablets;Placebo to Match GS-9669 tablet
422 A Phase I Study to Assess the Safety and Immunogenicity of Ad6NSmut and AdCh3NSmut in Patients With Hepatitis C Virus Infection Completed NCT01094873 Phase 1
423 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With Hepatitis C Virus Genotype 1 (Protocol No. P04695) Completed NCT01081158 Phase 1 Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron);Drug: SCH 900518 Biologic: Peginterferon alfa-2b;Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron);Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
424 A Phase I Study to Assess the Safety and Immunogenicity of New Hepatitis C Virus Vaccine Candidates AdCh3NSmut and Ad6NSmut Completed NCT01070407 Phase 1
425 A Phase 1 Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients Chronically Infected With Hepatitis C Virus (HCV) Who Are Non-Responders or Relapsers After Treatment With Pegylated Interferon Plus Ribavirin Completed NCT00128271 Phase 1 Bavituximab
426 A Single-center, Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Consecutive Dose Study to Assess the Tolerability, Pharmacokinetics and Pharmacodynamics of HEC74647 in Subjects With Chronic Hepatitis C Virus Infection Completed NCT04201275 Phase 1 HEC74647PA capsule;placebo
427 Open Label, Multiple-Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of BMS-824393 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1 Completed NCT00971308 Phase 1 BMS-824393
428 A Phase 1 Study to Assess the Safety and Antiviral Activity of PEG-rIL-29 Administered as a Single Agent and in Combination With Ribavirin in Treatment-Relapsed and Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection Completed NCT00565539 Phase 1 PEGylated recombinant interleukin 29 (PEG-rIL-29)
429 A Multi-center, Open-label, Dose-ranging, Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-6150, Administered ID and Followed by Cellectra® 2000 Healthy Adults and in Persons Previously Treated for Hepatitis C Virus Infection. Completed NCT03674125 Phase 1
430 Antiretroviral Therapy and the Hepatitis C Virus Completed NCT00545558 Phase 1 Efavirenz;Emtricitabine/Tenofovir disoproxil fumarate
431 A Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation, Multi-center Therapeutic Trial of the Safety, Immunogenicity, and Efficacy of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, in Patients With Chronic Hepatitis C Infection Completed NCT00124215 Phase 1
432 A Pilot Study to Explore a Potential Role of Nitazoxanide (NTZ) in the Prevention of Recurrent Hepatitis C Virus (HCV) Infection After Orthotopic Liver Transplantation Completed NCT01074203 Phase 1 Nitazoxanide
433 Open-label, Dose-escalating, Phase I Study of TG4040 (MVA-HCV) in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus (HCV Genotype 1) Completed NCT00529321 Phase 1
434 A Phase I Single-blind Randomised Placebo Controlled Dose Escalating Study of One Virosome Formulated CD4 and Two Virosomes Formulated CD8 Hepatitis C Virus (HCV) Vaccine Components (PEV2A and PEV2B) Administered to Healthy Adult Volunteers Completed NCT00445419 Phase 1
435 A Phase 1, Randomized, Double Blind (3rd Party Open), Placebo-controlled, Sequential Group, Multicentre Study To Evaluate The Multiple Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics, of PF-00868554 in Hepatitis C Virus (HCV) Positive Otherwise Healthy Patient Volunteers Completed NCT00445315 Phase 1 PF-00868554;Placebo
436 A Phase Ia/Ib Study Assessing Single and Multiple Doses of CDI-31244: A Non-Nucleoside Inhibitor in Healthy and Hepatitis C Virus-Infected Subjects Completed NCT02760758 Phase 1 CDI-31244;Placebo
437 A Multicenter, Double-Blind, Randomized, Placebo-Controlled Probe Study With an Additional Open-Label Control Arm to Evaluate the Safety and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine in Subjects With Chronic Hepatitis C Virus Infection Completed NCT00857311 Phase 1
438 A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults Completed NCT00752687 Phase 1 ABT-072;placebo
439 A Double-Blinded, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Antiviral Activity of TD-6450, a NS5A Inhibitor, in Treatment Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) Completed NCT02116543 Phase 1 TD-6450;Placebo
440 Phase I Pharmacokinetic and Safety Trial of Ledipasvir/Sofosbuvir Fixed Dose Combination in Pregnant Women With Chronic Hepatitis C Virus Infection Completed NCT02683005 Phase 1 ledipasvir/sofosbuvir
441 A Drug-drug Interaction Study Between the Novel Anti-hepatitis c Virus (HCV) Agent Daclatasvir and The Antidiabetic Agent Metformin in Healthy Volunteers Completed NCT02565862 Phase 1 Daclatasvir;Metformin
442 A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection Completed NCT01316237 Phase 1 GS-6620;GS-6620 tablet, 450 mg BID;GS-6620 tablet
443 A Phase I Study to Assess the Safety and Immunogenicity of AdCh3NSmut and MVA-NSmut in Healthy Volunteers and Patients With Hepatitis C Virus Infection Completed NCT01296451 Phase 1
444 Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection Completed NCT01292824 Phase 1 ITX 5061
445 Phase I, Open Label, Unicentric Study of Multiple-dose Pharmacokinetics of Raltegravir in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus With and Without Advanced (Child-Pugh C) Hepatic Cirrhosis. Completed NCT01289951 Phase 1 Raltegravir 400 mg/12hours
446 Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects Completed NCT00696904 Phase 1 ABT-333;Placebo
447 CPG10101 Combination Therapy For The Treatment Of Hepatitis C: A Phase 1b Open Label Randomized Trial Of CPG10101 Alone, With Interferon, Ribavirin, Or Interferon And Ribavirin In The Treatment Of Relapsed Hepatitis C Virus (HCV) Subjects Completed NCT00142103 Phase 1 CPG10101;Control
448 Phase I, Open-label Trial in Healthy Subjects to Evaluate the Drug-drug Interaction Between Ritonavir at Steady-state and TMC435350, a Viral Protease Inhibitor Against Hepatitis C Virus, After the First and the Last Dose of a Multiple Dosing Regimen Completed NCT01891851 Phase 1 TMC435350 200 mg;Ritonavir 100 mg
449 Double-Blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of Single Doses of EDP239 in Hepatitis C Virus (HCV) Infected Subjects Completed NCT01856426 Phase 1 EDP239;Placebo
450 A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Activity of GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection Completed NCT01591668 Phase 1 Single Ascending Dose Cohorts GS-9620;Multiple Ascending Dose Cohorts GS-9620
451 Phase I Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection Active, not recruiting NCT02772003 Phase 1
452 Phase 1 Pharmacokinetic Trial of Sofosbuvir/Velpatasvir in Pregnant Women With Chronic Hepatitis C Virus Infection Active, not recruiting NCT04382404 Phase 1 Sofosbuvir-Velpatasvir Drug Combination
453 A Phase Ib, Double-Blind, Randomized, Placebo-Controlled Trial in Genotype 1 HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of TMC649128 Given as Monotherapy and Given in Combination With Pegylated Interferon + Ribavirin Terminated NCT01391117 Phase 1 placebo.;TMC649128.;placebo;TMC649128
454 Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection Terminated NCT01560468 Phase 1 ITX 5061
455 A Phase I Study of Low Dose Interleukin 2 (IL-2)Monotherapy, Followed by IL-2 Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I Infection Terminated NCT00277758 Phase 1 Ribavirin;Ribavirin + Pegylated interferon-alpha
456 A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Following Administration of MK-7009 in Hepatitis C Infected Patients Terminated NCT00954993 Phase 1 Vaniprevir
457 A Randomized, Double-blind, Placebo-controlled, First-in-human, 3 Part Study of Orally Administered AL-611 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Part 3) of Single Ascending Doses in Healthy Volunteers (Parts 1-2), and Multiple Ascending Doses in Subjects With Chronic Hepatitis C Virus Infection (Part 3) Terminated NCT03253471 Phase 1 AL-611;Placebo
458 A Multicenter, Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study of the Safety and Efficacy of XTL 2125 in Adult HCV-Infected Patients With Compensated Liver Disease, Who Are Interferon-Alpha Non-Responders or Have Relapsed From Interferon-Alpha Therapy Withdrawn NCT00255359 Phase 1 XTL-2125
459 Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C Withdrawn NCT00633230 Phase 1 standardized herbal formula, Sho-saiko-to (SST)
460 A Randomized, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-791325 in Healthy Japanese Subjects Withdrawn NCT00947245 Phase 1 BMS-791325;Placebo
461 Double-Blinded, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of BMS-929075 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1 Withdrawn NCT01525212 Phase 1 BMS-929075;Placebo matching BMS-929075
462 Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard Therapy Withdrawn NCT00956722 Phase 1 Bovine Colostrum Powder
463 Effects of Personalized Physical Activity and Psycho-Education Program on Patients With Chronic Hepatitis C Infection Unknown status NCT01572233
464 Application of the Stem Cell Therapy in the End Stage Liver Disease and Assessment Its Consequences in the Quality of Live Style as Well as Development of HCC. Unknown status NCT01729221
465 HCV Care Pathway in Ile-de-France Unknown status NCT02893046
466 Trends in Risk of Mother-to-child Transmission of Hepatitis C Through Analysis of Prevalence of Risk Factors for Maternal Infection Among a Southern European Population Unknown status NCT00894257
467 ANRS 12320 IMMHoTHep : Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C Unknown status NCT02826447
468 Genetic Polymorphisms of Interleukin-10 and TNF-α on Outcome of HCV-Related Chronic Liver Disease Unknown status NCT00630006
469 Pegylated Interferon Alpha-2b Plus Ribavirin Combination Treatment for Older Patients With Chronic Hepatitis C Unknown status NCT00956982 Pegylated interferon alpha-2b plus ribavirin
470 Prospective Clinical Study on the Role of the Immune Response, in Relation to Diet, in Patients With Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD). Director Prof. V. Barnaba, Head of Internal Medicine; Principal Investigator, Prof. C. Balsano Unknown status NCT02038387
471 Liver Elastography in Patients Undergoing Treatment for Hepatitis C - a Longitudinal Study Unknown status NCT03434470
472 High Dose Insulin Therapy to Improve Liver Function in Patients With HCV Liver Cirrhosis Unknown status NCT01271140 Insulin
473 Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT Unknown status NCT00294489
474 Prediction of Response to PEGINTERFERON and RIBAVIRIN Treatment in Patients With Chronic HCV Infection by Genetic Profile Unknown status NCT00272389
475 An Assessment of Intrahepatic HCV RNA Levels at the Time of Liver Transplantation in Patients With HCV Receiving Antiviral Therapy While on the Liver Transplant Waiting List Compared to Those Not Currently Receiving Therapy Unknown status NCT01836718
476 Impact of Sustained Virologic Response on Glycemic Control Among Diabetic Patients With Hepatitis C Virus Related Liver Disease Unknown status NCT03591783
477 Safety of Sofosbuvir Plus Daclatasvir in Patients With Chronic Hepatitis c Virus and Assessment of Resistance Associated Variants in Resistant and Relapsed Cases Unknown status NCT03572140
478 Efficacy, Safety and Adherence of Patients Infected With Hepatitis C Virus in Retreat With INFERGEN (Interferon Alfacon1) Unknown status NCT01426204
479 Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) in Patients With Hepatitis C Virus Unknown status NCT01545544
480 Study of Parameters of Early Hepatitis C Virus Dynamics for Predicting the Outcome of Standard Interferon Therapy With Chinese Cohort Unknown status NCT01434212 Interferon Alfa-2b, Ribavirin
481 Correlation Between Values of Serum Cytokines and of Those Dosed by mRNA Expression Through the Use of Real-time PCR and Hepatic Histology in Patients Infected by HIV-1 and the Hepatitis-C Virus Unknown status NCT00499434
482 Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection Unknown status NCT00164073
483 Metabolic Changes in Chronic Hepatitis C Virus Patients Receiving Direct Acting Antivirals Unknown status NCT04211844 sofosbuvir plus daclatasvir;Sofosbuvir plus Ledipasvir
484 Role OF OCT-A TO Detect Possible Retinal Vascular Complications of Sofosbuvir (Sovaldi) in Patients With Hepatitis C Virus Infection Unknown status NCT04159246 Sofosbuvir (Sovaldi)
485 FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of HCV Recurrence and Progression Post Liver Transplantation Unknown status NCT00701272
486 Opportunistic Treatment of Hepatitis C Virus Infection (OPPORTUNI-C): A Pragmatic Clinical Trial of Immediate Versus Outpatient Treatment Initiation Among Hospitalized Patients Unknown status NCT04220645
487 Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis Unknown status NCT02856243 new antiviral therapy
488 Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4 Unknown status NCT02772744 Daclatasvir 60 MG Oral Tablet [Daklinza];Sofosbuvir 400 MG Oral Tablet [Sovaldi];Ribavirin Oral Product
489 The Incidence of Occult Hepatitis C Virus Infection in Hemodialysed Patients With Liver Enzymes Disturbances Unknown status NCT01054664
490 Liver Transplanted Patients for HCV Related End Stage Liver Disease.Functional Role of Blood Circulating Dendritic Cells in the Pathogenesis of Hepatitis C Virus Infection During Liver Transplantation. Unknown status NCT00213707
491 Safety and Efficacy of Directly Acting Antiviral Agents in Genotype 4 Hepatitis C Virus Relapse Among Egyptian Patients Unknown status NCT04662138 directly acting antivirals
492 Mother-To-Child Transmission (MTCT) of Hepatitis C Virus and Spontaneous Viral Clearance in Infected Children: a Retrospective Study. Unknown status NCT02044042
493 Evaluation of the Natural History and Vertical Transmission of Chronic Hepatitis C Virus Infection in Pregnancy With Targeted Elimination by Postpartum Treatment Unknown status NCT03570112 SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg
494 Cohort of Liver Transplanted Patients With Hepatitis C Virus Recurrence and Treated With Direct-acting Antiviral Agents Unknown status NCT01944527
495 Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan Unknown status NCT00543244 Pegylated interferon alfa and ribavirin
496 Study of Parameters of Early Hepatitis C Virus Dynamics for Predicting the Outcome of Standard Interferon Therapy With Chinese Cohort (Second Phase) Unknown status NCT01760148 interferon alpha 2b
497 Impact of Insulin Resistance on Therapeutic Response for Oral Treatment of Chronic Hepatitis C Virus Infection Unknown status NCT03212833
498 Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs: Prospective Controlled Clinical Trial Unknown status NCT03170076
499 Evaluation of Vitamin D and Iron Status in Chronic Hepatitis C Virus Patients Before and After Treatment Unknown status NCT03166280 Sofosbuvir 400 mg;Daclatasvir 60 mg/day
500 An Investigative Study on the Possible Effect of the Antiviral Inhibitors (Sofosbuvir and Daclatasvir) for Treatment of Hepatitis C Virus Infection in Cardiac Function Unknown status NCT03166943
501 Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy Unknown status NCT03226717 Antiviral agents
502 Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia Unknown status NCT02511496
503 Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients: Factors Influencing Treatment Initiation and Seroconversion Unknown status NCT02395198
504 Assessment of Hepatic Fibrosis, Hemodynamics, and Disease Severity of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs. Unknown status NCT03241823
505 The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia Unknown status NCT03169348 sofosbuvir daclatasvir;Ledipasvir/sofosbuvir
506 Expanded Access to Glecaprevir/ Pibrentasvir Approved for marketing NCT03123965 glecaprevir;pibrentasvir
507 Evaluation of Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Adults Chronically Infected With Genotype 2 Hepatitis C Virus: an Open-label, Multicenter Confirmatory Study Completed NCT03453346 Sofosbuvir;Ribavirin
508 CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS Completed NCT02402218
509 An Extension, Observational Protocol to Evaluate the Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C in the Original Study ML17862 Completed NCT00361179
510 Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients: A Trial of Ultra-short Duration Direct Acting Anti-viral Prophylaxis To Prevent Virus Transmission From Hepatitis C Viremic Donors To Hepatitis C Negative Kidney Transplant Recipients (DAPPER) Completed NCT03249194 Early Phase 1 Direct acting Anti-Viral Therapy using Epclusa or Zepatier
511 Drug Use-Results Survey in Patients Infected With Hepatitis C Virus Genotype 2 Completed NCT02945228
512 Quality of Life Measurement Using Wrist Actigraphy in HCV Genotype 1 Infected, Treatment naïve Patients Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir Tablets and Dasabuvir Tablets (Viekirax®/Exviera®; 3D Regimen): The HEMATITE Study Completed NCT03002818
513 Evaluate the Utility of Shear Wave Sonoelastography as a Tool to Measure Liver Fibrosis Grade Completed NCT01747772
514 A Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Harvoni Treatment Regimen in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea Completed NCT02951364 LDV/SOF
515 Mapping Natural Polymorphisms of Hepatitis C Virus NS3/4A Protease and NS5A Region Among Brazilian Chronic Patients (MAPPING) Completed NCT02597270
516 Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1 Completed NCT02629172
517 A Follow-up Study to Assess the Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection Completed NCT02581020
518 Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors Completed NCT00819026
519 Study of IL-6 Transsignaling in Chronic Human Liver Disease Completed NCT00770198
520 A Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Sovaldi in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea Completed NCT02907996 Sofosbuvir
521 Evaluation of Hepatitis C Virus Antibody Detection From Dried Blood Spots With the Fujirebio INNOTEST® HCV Ab IV Completed NCT04317729
522 Observational Multicenter Study to Evaluate Influence of Insulin Resistance on the Safety and Efficacy (as Measured by Sustained Virological Response) of Treatment With Any Pegylated Interferon and Ribavirin (Standard of Care) in Different Populations of HCV Patients in Russia. Completed NCT00705224 Ribavirin
523 Prospective Diagnostic Accuracy Study of Rapid Diagnostic Tests (RDTs) Detecting Antibodies Against Hepatitis C Virus (HCV) in Freshly Collected Whole Blood, Plasma and Serum Completed NCT04139941
524 Demonstration Project on Assessment of Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine Completed NCT04038320 Sofosbuvir/ledipasvir (SOF/LDV)
525 Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort." hEPAtic Study. Completed NCT02196064
526 Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6 Completed NCT03341871
527 Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease Completed NCT00610597
528 Hepatitis C Virus and the Humoral Immune System Completed NCT00219999
529 Real World EviDEnce of the EffecTIveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents 12 to <18 Years of Age With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation (DETI-2) Completed NCT04189627
530 Protocol to Describe the Actual Situation of Hepatitis C Treatment in Brazil Completed NCT02773394
531 Associations of Hematologic Malignancies and Thyroid Cancer With HCV Infection Among US Military Veterans Completed NCT00342641
532 Directly Observed Therapy for the Treatment of Hepatitis C Virus Infection in Injection Drug Users Completed NCT00247884
533 A Follow-up Evaluation Study of the Safety and Efficacy of PRI-724 Administration in Patients With Cirrhosis Due to Hepatitis C Completed NCT02828254 PRI-724
534 Randomized, Open-label Study to Evaluate the Hepatitis C Virus (HCV) Burden in Patients Receiving Cyclosporine (Neoral or CSA) Versus Tacrolimus (Prograf) in de Novo Liver Recipients Receiving Mycophenolate Sodium (Myfortic): Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation Completed NCT00710801
535 Evaluation of the Safety and Effectiveness of Direct-acting Antiviral Drugs in the Treatment of Hepatitis C in Patients With Inflammatory Bowel Disease: National Multicenter Study (MIC Project). Completed NCT05452187 Assess the effectiveness and safety of DAAs in patients with IBD.;Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and/or biologics.
536 A Prospective Observational Study to Examine Patient Characteristics, Health Care Management, and Effectiveness Among HCV Patients Treated With Simeprevir at Various Practice Settings Completed NCT02103699 No intervention
537 A Multicenter, Prospective, Observational, Post Marketing Surveillance Study to Evaluate the Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Patients With Chronic Hepatitis C Virus Infection in India Completed NCT02592057 SOF
538 REAl World Evidence Of The Effectiveness And Clinical Practice Use Of Glecaprevir/Pibrentasvir For 8 Weeks Treatment In Patients With Chronic HepatitiS C GenotYpes 1 to 6 And Liver Cirrhosis In Russian Federation (EASY) Completed NCT04352309
539 FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy Completed NCT00606528
540 Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study) Completed NCT00399672 Interferon injections and ribavirin
541 Clinical Trial to Evaluate the Acceptance and Viability of Three Strategies in Birth Cohort Hepatitis C Screening Completed NCT04037046
542 A Registry for Subjects With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection Completed NCT02292706 Sofosbuvir
543 Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults Completed NCT04513899
544 Post-marketing Surveillance Study of Viekira/ Exviera Tablets for Korean Hepatitis C Patients According to the Standard for "Re-examination of New Drugs" Completed NCT03201718
545 A Prospective Observational Post-Marketing Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection Completed NCT02537379 SOF;COPE
546 Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in DAA Treatment-Experienced Patients With Chronic Hepatitis C Genotype 1 in Russian Federation (CHOICE) Completed NCT04577482
547 Smoking Cessation Intervention for Persons Infected With Hepatitis C Virus Completed NCT05466981
548 Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma. (Retrospective-cohort Study) Completed NCT03109457
549 Collection of Plasma and Serum Samples From Individuals Initiating Therapy With Sofosbuvir for Chronic Hepatitis C Virus Infection for the Clinical Evaluation of the Aptima HCV Quant Dx Assay Completed NCT02068963
550 Treatment of Chronic Hepatitis C Virus Infection With Direct Acting Antivirals in Kidney Transplant Recipients Completed NCT03880682
551 Case Management in Hepatitis C Virus Infected People Who Inject Drugs in Belgium Completed NCT03106194
552 Effectiveness and Safety of Interferon-free Antiviral Regimens for the Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients Completed NCT02969668
553 Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study Completed NCT04873609
554 Screening for Chronic Hepatitis C Virus in Hospitalized Patients at Saint Joseph Hospital in Marseille Completed NCT04437277
555 Evaluation of the Health-Related Quality of Life During Combined Treatment of Chronic Hepatitis Due to Hepatitis C Virus Under Habitual Clinical Practise Conditions. Completed NCT00863109 Ribavirin (RBV)
556 Anti-E1E2 Antibodies for the Prediction of Virological Response to Triple Therapy in Treatment-experienced Hepatitis C Virus-cirrhosis Cases Completed NCT02877199
557 Long-term Outcomes Following Treatment of Recently Acquired Hepatitis C Virus Infection. Completed NCT02000063
558 Prevalence of Hepatitis c Virus Infection Among Rheumatological Patients Completed NCT03587714
559 Clinical Relevance of Serum Non-organ-specific Antibodies in Hepatitis C Virus Patients Receiving Direct-acting Antiviral Therapy Completed NCT03566966
560 Intravenous Interferon During the Anhepatic Phase of Liver Transplantation and Prevention of Recurrence of Hepatitis C Virus Completed NCT01192698 IV interferon
561 Multicentre Clinical Trial to Assess the Performance of Centralized Assays for Hepatitis C Virus RNA Detection From Dried Blood Spot (DBS) Samples Completed NCT03896087
562 A Clinical Study to Evaluate the Biological Effects of Administering Rimantadine in Patients With Hepatitis C Virus (HCV) Infection Alongside Standard Combination Therapy With Pegylated Interferon and Ribavirin Completed NCT01413490 rimantadine
563 Impact of Hepatitis C Virus Infection on Insulin Resistance and Inflammatory Biomarkers in Patients With Maintenance Hemodialysis Completed NCT00527774
564 Immunogenetics of Hepatitis C Virus Infection Completed NCT00005657
565 Dynamics of Hepatitis C Infection in Subjects With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Receiving Highly Active Antiretroviral Therapy (HAART) Completed NCT00001117
566 Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in Community-based Settings: the SHARP-C Study Completed NCT03343925
567 Association of Hepatitis C Virus Seropositivity With Breast Cancer Prognosis and Treatment Outcome Completed NCT04090164
568 An Observational Study of Hepatitis C Virus in Pregnancy Completed NCT01959321
569 Predictive Value of P300 Event-related Potential Component in Early Cognitive Impairment in Patients With Uncomplicated Newly Diagnosed Hepatitis C Virus Completed NCT04389268
570 Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis and Other Potential Extrahepatic Manifestations Completed NCT03693586
571 Benefit of Direct-acting Antiviral Therapy in Hepatitis C Virus (HCV) Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia Completed NCT03342261 DAA treatment
572 Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection - a Prospective Observational Cohort Study Completed NCT04094272
573 Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood Completed NCT02718573
574 Hepatitis C Virus Dynamic and Immune Activation in HIV-1 Coinfected Patients Treated With Pegylated Interferon Alfa-2a and Ribavirin Completed NCT00909129 pegylated interferon-alpha (Pegasys);ribavirin (COPEGUS)
575 STOP-HCC Evidence-Based Hepatocellular Cancer Prevention Through Treatment of Hepatitis C Virus Infection Completed NCT03706742
576 PREDICT - Prospective Observational Study Of A Cohort Of Naïve Patients With Chronic Hepatitis C Infected With Hepatitis C Virus Genotype 1 Low Viral Load (HCV LVL G1) And Treated With Peg-Intron 1.5 ug/Kg/Week Plus Rebetol 800-1200 mg/Day Who Achieved A Negative HCV-RNA At Week 4 and at Week 24 Completed NCT00709228 PegIntron;Rebetol
577 Hepatitis C Virus Particles-bound Human Proteins : Identification in Clinical Samples and Implication in the Viral Life Cycle Completed NCT02795403
578 Biliverdin Reductase A in Chronic Hepatitis C Virus Infection Completed NCT01112033
579 Use of Single Photon Emission Computed Tomography (SPECT) as a Noninvasive Alternative to Liver Biopsies in Assessing Liver Involvement in Subjects Coinfected With HIV and Hepatitis C Virus (HCV) Completed NCT00006643
580 Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus: A Comparative Egyptian Study Completed NCT03276039
581 Evaluation Study of Rapid Diagnostic Tests (RDTs) Detecting Antibodies Against Hepatitis C Virus Completed NCT04033887
582 Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting (The SHARP-P Study) Completed NCT03740906
583 "Factors Associated With Porphyria Cutanea Tarda in Patients Infected With Hepatitis C Virus" Completed NCT00213772
584 Risk of Post Transfusion Hepatitis C Virus Infection Completed NCT00005339
585 Occult Hepatitis C Virus Infection In Hemodialysis Patients Who Achieved A Sustained Virological Response To Directly Acting Antiviral Drugs: Is It A Concern ? Completed NCT04719338
586 Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver Transplantation Completed NCT00794911
587 Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes Completed NCT02650024
588 A Prospective Observational Post-Marketing Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection Completed NCT02562742 SOF;REB
589 A Bioequivalence Study to Evaluate the Potential for Drug-drug Interactions Between Boceprevir 800mg Thrice Daily and the HIV Non-nucleoside Reverse Transcriptase Inhibitor Etravirine 200mg Twice Daily in HIV/(Hepatitis C Virus) (HCV) Negative Volunteers Completed NCT01427504 boceprevir; etravirine
590 Oral Microbiome of Patients With Chronic Hepatitis C Virus Infection: A Case-Control Study Completed NCT03682549
591 The Impact of Peginterferon Alpha-2a Maintenance Therapy on Portal Hypertension in Patients With Chronic Hepatitis C Virus Infection and Advanced Fibrosis and Cirrhosis Enrolled in the HALT-C Trial Completed NCT00252642 Peginterferon Alpha-2a
592 Evaluation of the Immune Response in Humans After Exposure to Hepatitis C Virus Completed NCT00006301
593 A Prospective, Non-Interventional Cohort Study of Approved Sofosbuvir-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice Completed NCT02783976 Sovaldi
594 Hepatitis C Virus Infection Induced Insulin Resistance: Different Contribution From Liver and Extrahepatic Sites as Inferred by Treating Chronic Hepatitis C Patients With an Interferon-free Antiviral Combination Completed NCT02760355 Ledipasvir 90 mg/Sofosbuvir 400 mg;Ribavirin
595 The Pathogenesis of Hepatitis C Virus Vertical Transmission Completed NCT01921400
596 Observational,Post-authorization Prospective Study to Develop and Validate a Prognostic Tool for Optimizing Therapy in Patients With Hepatitis C Virus (HCV) Genotype 1 and 4. Completed NCT01884402 Peginterferon alfa-2a;Ribavirin
597 Assessing Healthcare Outcomes of Hepatitis C Virus (HCV) Positive Patients Counseled for Cardiovascular Disease Risk Factors Completed NCT03402334
598 Reducing Hepatitis C Virus (HCV)/Human Immunodeficient Virus (HIV) Risk Behaviors Among Injection Drug Users in China Completed NCT01647191
599 Treatment of Hepatitis C Virus Infection With Direct-acting Antiviral Drugs in Patients With Hemoglobinopathies Completed NCT03149289 Antiviral drugs
600 Efficacy and Safety in Clinical Practice of Ombitasvir/Paritaprevir/ Ritonavir and Dasabuvir Administered for 8 Weeks (3D8) in Treatment-naïve Genotype 1b Hepatitis C Virus Infected Patients: Analysis of Data From Hepa-C Registry. Completed NCT03122132 ombitasvir/paritaprevir/ritonavir 8 weeks;dasabuvir 8 weeks
601 Efficacy and Safety of Treatment Against Hepatitis C Virus Infection Based on Direct-acting Antivirals in Real-life Conditions: The GEHEP Cohort Completed NCT02333292 Telaprevir;Boceprevir;Sofosbuvir;Simeprevir;Daclatasvir;Ledipasvir;ritonavir-boosted Paritaprevir/ Ombitasvir;Dasabuvir;Velpatasvir;Elbasvir;Grazoprevir
602 Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection Completed NCT02452814
603 Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan Completed NCT02402699
604 Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/Hepatitis C Virus (HCV) Seronegative Volunteers Completed NCT02404805 dolutegravir;simeprevir
605 Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Facilities "Outside the Walls" Using the Dual Screening Method TROD (Rapid Diagnostic Tests) and FibroScan Recruiting NCT05361603
606 Risk of Hepatitis C Virus Reinfection in Human Immunodeficiency Virus and Hepatitis C Virus Coinfected Patients Achieving Sustained Virologic Response by Antiviral Therapy Recruiting NCT04768517
607 Rapid HCV Test and Treat to Increase HCV Treatment Uptake Among People Who Use Drugs Recruiting NCT04677153
608 The Occurrence of HCC and Possible Differences in Its Course Depending on DAA Treatment Recruiting NCT05376943 Direct Acting Antivirals
609 Risk of Hepatitis C Virus Reinfection in Hemodialysis Patients With Chronic Hepatitis C Achieving Sustained Virologic Response Following Antiviral Therapy Recruiting NCT04732832
610 Hepatitis C Reinfection After Successful Directly Acting Antiviral Treatment: A Belgian Interventional Multicenter Study Recruiting NCT04251572
611 Implementation of a Simplified, Low-barrier Primary Care HCV Treatment Model for High Risk, High Prevalence Populations in Austin, Texas Recruiting NCT05460130
612 Pharmacokinetics of Sofosbuvir/Daclatasvir in HCV-infected Lactating Women: a Pilot Study Recruiting NCT04852614
613 Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection: Real-world Effectiveness and Safety in Taiwan Recruiting NCT05092074 Vosevi 400/100/100 Oral Tablet
614 CARES-HCV: Promoting Concurrent Hepatitis C Virus Screening and Colorectal Cancer Screening Uptake Among Diverse Baby Boomers Recruiting NCT04980157
615 Clinical Trial to Evaluate Efficacy and Acceptance of a Telemedicine Based Programme to Treat Hepatitis C Among Patients at Drug Addiction Centers Recruiting NCT04035980
616 Real World Evidence of the Safety and Clinical Practice Use of Maviret in Adolescents Patients Infected With Chronic Hepatitis C Virus (All Case Survey) Recruiting NCT04214028
617 Prevalence of Undiagnosed HCV Infections in HIV-negative MSM Visiting a Sexual Health Clinic. Recruiting NCT04005248
618 New Care Pathways to Achieve HCV Elimination in the Community: Real-world Outcomes From HCV Infected Patients Treated in Addiction Centers in France Recruiting NCT04366973
619 Interventions to Curb Hepatitis C Reinfections Among Men Who Have Sex With Men Recruiting NCT04156945
620 Screening for the Hepatitis C Virus by TROD Paired With Mammography and Management of Chronic Hepatitis C in Women Aged 50 to 74 in the Agglomeration of Montpellier Recruiting NCT05067374
621 A Precision Randomized Trial to Evaluate the Impact of Tailored Hepatitis C Virus (HCV) Treatment Adherence Support on HCV Treatment Outcomes in HIV/HCV Co-infected and HCV Mono-infected People Who Inject Drugs (PWID) in India. Recruiting NCT04652804
622 Management of Hepatitis C Virus Infection Among People Who Inject Drugs in a Low-threshold Setting: Efficacy of Direct-acting Antiviral Treatment and the Risk of Reinfection Recruiting NCT04063839 Elbasvir / Grazoprevir Oral Tablet
623 Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan Recruiting NCT03200379
624 Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan Recruiting NCT05248919 undefined
625 Metabolic Syndrome and Long-term Survival Following Liver Resection for Hepatocellular Carcinoma Among Patients With Chronic Hepatitis C Virus Infection Recruiting NCT05568576
626 The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis in Cirrhotic Patients Infected With Chronic Hepatitis C Virus Recruiting NCT02461979
627 Cross Sectional Survey on the Burden, Impacts and Causes of Hepatitis C Virus (HCV) Outbreak in South West Region in Burkina Faso Active, not recruiting NCT04136405
628 A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials Active, not recruiting NCT02510300 Sofosbuvir (SOF);Ledipasvir/Sofosbuvir (LDV/SOF);Sofosbuvir/Velpatasvir (SOF/VEL);Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
629 Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection in a Blood Donor Population Active, not recruiting NCT00004850
630 A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients Active, not recruiting NCT01946516
631 Cohort Study of Hepatitis C Virus Treatment With Zepatier (Elbasvir/Grazoprevir) in Genotype 1 or 4 HCV Treatment-Naïve or Peginterferon/Ribavirin-Experienced Patients With Substance Use in Urban, Multidisciplinary Specialty Clinics Active, not recruiting NCT04048850 Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
632 Integrated Treatment of Hepatitis C Virus Infection Among Patients With Injecting Drug Abuse:a Randomised Controlled Trial (INTRO-HCV) Active, not recruiting NCT03155906
633 A Communication-Based Study Focused on Assessing and Improving Hepatitis C Screening Rates, As Well As Treatment Rates in Arizona as a Step Towards Disease Eradication Not yet recruiting NCT05071261
634 Implementation of Low Cost Solutions to Help Facilitate Linkage to Care for Persons With Hepatitis C Virus Infection Not yet recruiting NCT05397067
635 Emergency Department Patient's Perceptions and Acceptability Toward a Novel Point-of-Care Hepatitis C Virus Viral Load Testing Not yet recruiting NCT03767231
636 The Prevalence of Insulin Resistance and the Potential Modulation of Insulin Resistance by N-acetylcysteine (NAC) in Patients Chronically Infected by the Hepatitis C Virus Suspended NCT00614757 N-acetylcysteine 20% 4ml;N-acetylcysteine 20% in 4 ml
637 Pilot Study to Assess Gut Mucosal B Cells in Individuals Co-Infected With HCV and HIV Terminated NCT01040039
638 Study of the Role of the Biliary Salts Nuclear Receptor FXR in Hepatitis C Virus Replication Terminated NCT01492998
639 Analysis of the Maternal-fetal Interface During Maternal Hepatitis C Virus Infection and Influenza Virus Vaccination Terminated NCT00810875
640 Re-treatment of Chronic Hepatitis C Virus Infection Among Non-responders or Those Who Relapsed to Treatment With Regimens Based on Direct-acting Antiviral Drugs Terminated NCT03483987 Sof+Ledi+R arm;Sof+Ledi+R+Peg-IFN arm;Sof+Dacla+R arm;Sof+Dacla+R+Peg-IFN arm;Sof+Velpa+R arm;Sof+Velpa+R+Peg-IFN arm
641 Impact of the Hepatitis C Virus Variability on Liver Steatosis Terminated NCT00843076
642 A Randomized Study of the Effectiveness of Patient Registry Directed Patient Navigation in Improving Attainment of Hepatitis C Virus (HCV) Care Among Patients Using Opioid Substitution Therapy and Patients Who Currently Inject Drugs Terminated NCT03441542
643 Associations, Outcomes and Genomics of GB Virus C, Hepatitis C Virus and Human Immunodeficiency Virus Infection Terminated NCT00164060
644 An Open-Label Pilot Study of the Safety, Tolerability and Anti-Viral Activity of High Dose Intravenous Ascorbic Acid in Patients Chronically Infected With Hepatitis C Virus Genotype 1, Who Have Failed Prior Therapy With Interferon-alpha and Ribavirin Terminated NCT01250743
645 Evaluation of the SIMpill Medication Dispensing Device in the Treatment of Chronic Hepatitis C Withdrawn NCT01691235
646 IFNL4 Genotype for Predicting Response to Ledipasvir/Sofosbuvir: Kaiser Permanente Northern California Withdrawn NCT03639207
647 Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors. Withdrawn NCT01813266
648 Characterization of Cellular Immune Responses in the Liver in Patients With Chronic Hepatitis C Virus Infection Withdrawn NCT01062659
649 Observational Prospective Registry of the Efficacy, Safety, and Adherence to Therapy of Infergen® (Interferon Alfacon 1) in Patients Chronically Infected With Hepatitis C Virus Withdrawn NCT00951223 Infergen® (Interferon alfacon-1)
650 Immunologic Determinants of Hepatitis C Virus Infection Resolution or Persistence Withdrawn NCT00165919
651 STOP-HCC Evidence-Based Hepatocellular Cancer Prevention Through Treatment of Hepatitis C Virus Infection Withdrawn NCT04395118
652 Hepatitis C Virus in Neutrophil Granulocyte Progenitor Cells Withdrawn NCT02545387

Search NIH Clinical Center for Hepatitis C Virus

Genetic Tests for Hepatitis C Virus

Genetic tests related to Hepatitis C Virus:

# Genetic test Affiliating Genes
1 Hepatitis C Virus, Susceptibility to 28 CCR5 IFNG IFNL3
2 Hepatitis C Virus Infection, Response to Therapy of 28

Anatomical Context for Hepatitis C Virus

Organs/tissues related to Hepatitis C Virus:

MalaCards : Liver, Kidney, Bone Marrow, T Cells, Whole Blood, B Cells, Thyroid

Publications for Hepatitis C Virus

Articles related to Hepatitis C Virus:

(showing 30043, show less)
# Title Authors PMID Year
1
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. 62 57 5
17215375 2007
2
The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. 57 5
15863470 2005
3
MCPIP1 suppresses hepatitis C virus replication and negatively regulates virus-induced proinflammatory cytokine responses. 62 57
25225661 2014
4
IPS-1 is essential for type III IFN production by hepatocytes and dendritic cells in response to hepatitis C virus infection. 62 57
24532585 2014
5
A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication. 62 57
24055031 2013
6
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. 62 57
23291588 2013
7
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. 62 57
22231557 2012
8
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. 62 57
21516087 2011
9
Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. 62 57
20935628 2010
10
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. 62 57
19965718 2010
11
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. 62 57
19759533 2009
12
A genome-wide genetic screen for host factors required for hepatitis C virus propagation. 62 57
19717417 2009
13
Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. 62 57
17804490 2007
14
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. 62 57
17325668 2007
15
Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. 62 57
16299033 2006
16
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. 62 57
16141076 2005
17
Adaptive immune responses in acute and chronic hepatitis C virus infection. 62 57
16107834 2005
18
Unravelling hepatitis C virus replication from genome to function. 62 57
16107832 2005
19
Evasion of intracellular host defence by hepatitis C virus. 62 57
16107833 2005
20
Unscrambling hepatitis C virus-host interactions. 62 57
16107831 2005
21
Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. 62 57
15893726 2005
22
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. 62 57
15297676 2004
23
Pathophysiology of hepatitis C virus infection and related liver disease. 62 57
15036326 2004
24
Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. 62 57
12702807 2003
25
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. 62 57
12634366 2003
26
L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. 62 57
12676990 2003
27
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. 62 57
12356718 2002
28
Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. 62 57
12186904 2002
29
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. 62 57
11781363 2002
30
Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. 62 57
11781364 2002
31
Identification of eIF2Bgamma and eIF2gamma as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach. 62 57
10900014 2000
32
Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation. 62 57
10675342 2000
33
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. 62 57
10609818 1999
34
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. 62 57
10535997 1999
35
NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. 62 57
10318918 1999
36
Binding of hepatitis C virus to CD81. 62 57
9794763 1998
37
Interferon-inducible protein SCOTIN interferes with HCV replication through the autolysosomal degradation of NS5A. 57
26868272 2016
38
RACK1 controls IRES-mediated translation of viruses. 57
25416947 2014
39
IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. 57
24752298 2014
40
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. 57
23712427 2013
41
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. 57
20547162 2010
42
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. 57
20173735 2010
43
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. 57
19749757 2009
44
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. 57
19749758 2009
45
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. 57
19684573 2009
46
Shared and distinct genetic variants in type 1 diabetes and celiac disease. 5
19073967 2008
47
Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B. 5
19017985 2008
48
Altered CD45 expression in C77G carriers influences immune function and outcome of hepatitis C infection. 57
16505159 2006
49
CCR5 deficiency increases risk of symptomatic West Nile virus infection. 5
16418398 2006
50
The geographic spread of the CCR5 Delta32 HIV-resistance allele. 5
16216086 2005
51
The case for selection at CCR5-Delta32. 5
16248677 2005
52
Reappraisal of the historical selective pressures for the CCR5-Delta32 mutation. 5
15744032 2005
53
A mutated CCR5 gene may have favorable prognostic implications in MS. 5
12874407 2003
54
Specific expression and regulation of the new melanoma inhibitory activity-related gene MIA2 in hepatocytes. 57
12586826 2003
55
Absence of the HIV-1 protective Delta ccr5 allele in most ethnic populations of India. 5
11781692 2001
56
The coreceptor mutation CCR5Delta32 influences the dynamics of HIV epidemics and is selected for by HIV. 5
11517319 2001
57
Chemokine receptor polymorphism in transplantation immunology: no longer just important in AIDS. 5
11403804 2001
58
CC chemokine receptor 5 and renal-transplant survival. 5
11403814 2001
59
Delta 32 deletion of CCR5 gene and association with asthma or atopy. 5
11081537 2000
60
CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. 5
10803840 2000
61
Prevalence of CCR5delta32 in allergic diseases. 5
10615909 2000
62
Association of CCR5 delta32 with reduced risk of asthma. 5
10520641 1999
63
Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. 57
10390359 1999
64
Distribution of the CCR5 gene 32-bp deletion in Europe. 5
9768627 1998
65
Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. 5
9585595 1998
66
Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptors) in resistance to HIV-1 infection and AIDS development among intravenous drug users. 5
9600249 1998
67
The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in Northeastern Europe. 5
9466996 1998
68
First report of a healthy Indian heterozygous for delta 32 mutant of HIV-1 co-receptor-CCR5 gene. 5
9511755 1998
69
The extent of genetic variation in the CCR5 gene. 5
9207783 1997
70
Global distribution of the CCR5 gene 32-basepair deletion. 5
9140404 1997
71
HIV-1 infection in an individual homozygous for the CCR5 deletion allele. 5
9055842 1997
72
Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. 5
9132277 1997
73
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. 5
8751444 1996
74
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. 5
8756719 1996
75
Molecular cloning and functional expression of a new human CC-chemokine receptor gene. 5
8639485 1996
76
Sexually-transmitted hepatitis C virus reinfections among people living with HIV in Taiwan: the emerging role of genotype 6. 62
35412439 2022
77
MIP-based electrochemical sensor for direct detection of hepatitis C virus via E2 envelope protein. 62
35850055 2022
78
Independent evolution of multi-dominant viral genome species observed in a hepatitis C virus carrier. 62
36072891 2022
79
Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis. 62
34969349 2022
80
Utilization of HCV viremic donors in kidney transplantation: a chance or a threat? 62
35260039 2022
81
Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry. 62
36036096 2022
82
Hepatitis C Virus Screening: Factors Associated With Test Completion in a Large Academic Health Care System. 62
34694928 2022
83
Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients. 62
35916643 2022
84
Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland: A quantitative cross-sectional analysis. 62
35994940 2022
85
Association Between Time to First RNA-Negative Test Result Among People With Hepatitis C Virus Infection and Homelessness or Testing at a Correctional or Substance Use Treatment Facility, New York City. 62
34694921 2022
86
Identifying barriers and enablers to opt-out hepatitis C virus screening in provincial prisons in Quebec, Canada: A multilevel, multi-theory informed qualitative study with correctional and healthcare professional stakeholders. 62
36030569 2022
87
Retraction Note to: Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice. 62
36125557 2022
88
Testing for Hepatitis C Virus Infection Among Adults Aged ≥18 in the United States, 2013-2017. 62
34606398 2022
89
Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. 62
35283317 2022
90
Alterations in Hepatocellular Carcinoma-Specific Immune Responses Following Hepatitis C Virus Elimination by Direct-Acting Antivirals. 62
36232928 2022
91
Primary Care Evaluation of a Hepatitis C Virus (HCV) Screening Education Intervention. 62
36257701 2022
92
Hepatitis C virus, insulin resistance, and diabetes: A review. 62
35941761 2022
93
Exosome-associated microRNA-375 induces cell proliferation by regulating IGFBP4 upon hepatitis C virus infection. 62
36203260 2022
94
Risk factors for liver-related mortality of patients with hepatitis C virus after sustained virologic response to direct-acting antiviral agents. 62
36262540 2022
95
B-cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma. 62
35460540 2022
96
Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders. 62
36184751 2022
97
High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus. 62
36062500 2022
98
Long-Term Follow-Up of Thalassemia Major Patients with Hepatitis C Virus Treated with Sofosbuvir and Daclatasvir: A Cohort Study. 62
36216685 2022
99
Hepatitis C Virus Nonstructural Protein 5A Interacts with Immunomodulatory Kinase IKKε to Negatively Regulate Innate Antiviral Immunity. 62
35993162 2022
100
Full-genome next-generation sequencing of hepatitis C virus to assess the accuracy of genotyping by the commercial assay LiPA and the prevalence of resistance-associated substitutions in a Belgian cohort. 62
35981443 2022
101
Improved detection of hepatitis C virus-positive blood donors and determination of infection status. 62
36251615 2022
102
The Lived Experience of Patients Utilizing Second-Generation Direct-Acting Antiviral for Treatment of Chronic Hepatitis C Virus Infection: A Phenomenological Analysis. 62
36231842 2022
103
Berberis lyceum and Fumaria indica: in vitro cytotoxicity, antioxidant activity, and in silico screening of their selected phytochemicals as novel hepatitis C virus nonstructural protein 5A inhibitors. 62
33764266 2022
104
A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice. 62
35313015 2022
105
Barriers to hepatitis C virus infection in mice. 62
36244239 2022
106
Outcomes of Interferon-free Treatment of Hepatitis C Virus Infection Seven Years after Approval and Problems with Drop out during and after Treatment: A Retrospective, Single-center Study. 62
35945005 2022
107
Hepatitis C virus monitoring in inpatient psychiatry: Doctors' practice. 62
36239069 2022
108
Reevaluating Liver Donor Risk in the Era of Improved Hepatitis C Virus Treatment. 62
36197654 2022
109
Structure of the hepatitis C virus E1E2 glycoprotein complex. 62
36264808 2022
110
Hepatocellular Carcinoma Risk Declines but Remains High Enough for Screening in the First 7 Years After Hepatitis C Virus Cure With Direct-Acting Antivirals in Patients With Cirrhosis or High Fibrosis-4 Score. 62
35777481 2022
111
Tumour suppressor p53 inhibits hepatitis C virus replication by inducing E6AP-mediated proteasomal degradation of the viral core protein. 62
35918185 2022
112
Targeted Electronic Patient Portal Messaging Increases Hepatitis C Virus Screening in Primary Care: a Randomized Study. 62
35230622 2022
113
Construction of novel lncRNA-miRNA-mRNA ceRNA networks associated with prognosis of hepatitis C virus related hepatocellular carcinoma. 62
36217480 2022
114
Flow cytometry assessment of monocyte subsets alteration in hepatocellular carcinoma post hepatitis C virus infection. 62
36197152 2022
115
Partial nonstructural 3 region analysis of hepatitis C virus genotype 3a. 62
36002650 2022
116
Sofosbuvir-velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan. 62
35802063 2022
117
Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis. 62
35749289 2022
118
Non-targeted hepatitis C virus screening in acute care healthcare settings in the Southern Appalachian region. 62
36172306 2022
119
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5. 62
35876967 2022
120
Soluble Immune Checkpoint Protein CD27 Is a Novel Prognostic Biomarker of Hepatocellular Carcinoma Development in Hepatitis C Virus-Sustained Virological Response Patients. 62
35963463 2022
121
More intensive hepatitis C virus care models promote adherence among people who inject drugs with active drug use: The PREVAIL study. 62
36197920 2022
122
The Impact of Supportive Housing on Liver-Related Outcomes Among Persons With Hepatitis C Virus Infection. 62
36208165 2022
123
Outcomes and Risk Factors for Complications in Cataract Patients with Hepatitis C Virus Infection. 62
36196031 2022
124
Prevalence of hepatitis C virus infection in patients with end-stage renal disease in Latin America and the Caribbean: a systematic review and meta-analysis. 62
36195804 2022
125
Identification of a novel variant of hepatitis B virus isolated from patient co-infected with hepatitis C virus. 62
35809696 2022
126
A simple and sensitive HPLC-FL method for bioanalysis of velpatasvir, a novel hepatitis C virus NS5A inhibitor, in rat plasma: Investigation of factors determining its oral bioavailability. 62
35921698 2022
127
Immunogenicity against hepatitis C virus with mesenchymal stem cells of inbreed BALB/c mice sub cloned with HCVcp protein gene. 62
35764239 2022
128
Risk factors for hepatitis C virus infection at a large urban emergency department. 62
35789152 2022
129
Factors linked to hepatocellular carcinoma development beyond 10 years after viral eradication in patients with hepatitis C virus. 62
35790055 2022
130
Defer no more: advances in the treatment and prevention of chronic hepatitis C virus infection in children. 62
35852787 2022
131
Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective. 62
36125059 2022
132
The Indian Health Service can meet its goals for hepatitis C virus treatment through telehealth expansion. 62
36210510 2022
133
Clinical study on the efficacy of hepatitis B vaccination in hepatitis C virus related chronic liver diseases in Egypt. 62
36209916 2022
134
Expression of cyclo-oxygenase-2 and yap/taz in hepatocellular carcinoma in untreated and treated hepatitis C virus patients. 62
35979755 2022
135
Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication. 62
35652276 2022
136
Certification program of Addiction Centres for hepatitis C virus elimination in Spain. HepCelentes Project. 62
36200230 2022
137
Hepatitis C Virus Coinfection in People With Human Immunodeficiency Virus in Iran: A Systematic Review and Meta-Analysis. 62
36267256 2022
138
Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study. 62
36240657 2022
139
Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs. 62
36257884 2022
140
Insights into Hepatitis C Virus E2core Interactions with Human Cellular Receptor CD81 at Different pHs from Molecular Simulations. 62
36255318 2022
141
Evaluating the Cardiovascular Risk in an Aging Population of People With HIV: The Impact of Hepatitis C Virus Coinfection. 62
36129038 2022
142
Utilization of hepatitis C virus-positive donors in kidney transplantation. 62
36227758 2022
143
Immunity of two novel hepatitis C virus polyepitope vaccines. 62
36150975 2022
144
Total Joint Arthroplasty Should Not Be Delayed in Hepatitis C Patients After Successful Treatment Achieving a Sustained Viral Load. 62
36082283 2022
145
Changes in Hepatitis C Awareness in Different Disciplines During COVID-19. 62
35946888 2022
146
Healthcare-Related HCV Genotype 4d Infections in Kayseri, Turkey. 62
36098364 2022
147
Treatment for hepatitis C virus with direct acting antiviral agents: Perspectives and treatment experiences of people who inject drugs. 62
35729038 2022
148
Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study. 62
36168675 2022
149
High prevalence of antinuclear antibodies in patients with chronic hepatitis C virus infection. 62
36114565 2022
150
Five-Year Allograft Survival for Recipients of Kidney Transplants From Hepatitis C Virus Infected vs Uninfected Deceased Donors in the Direct-Acting Antiviral Therapy Era. 62
35994263 2022
151
Hepatitis C Virus Treatment Delivered via Telemedicine to Persons With Opioid Use Disorder. 62
35816336 2022
152
The Effectiveness of Low Dead Space Syringes for Reducing the Risk of Hepatitis C Virus Acquisition Among People Who Inject Drugs: Findings From a National Survey in England, Wales, and Northern Ireland. 62
35184173 2022
153
Genetic diversity of hepatitis C virus and resistance associated substitutions to direct-acting antiviral treatment in Colombia. 62
35697300 2022
154
Updated U.S. Public Health Service Guideline for testing of transplant candidates aged <12 years for infection with HIV, hepatitis B virus, and hepatitis C virus - United States, 2022. 62
36039545 2022
155
Interleukin 28B Polymorphism as a Predictor of Sustained Virological Response to Sofosbuvir-Based Therapy for Hepatitis C Virus Patients. 62
36136642 2022
156
Integrated analysis to study the interplay between post-translational modifications (PTM) in hepatitis C virus proteins and hepatocellular carcinoma (HCC) development. 62
36123370 2022
157
Nanoparticle-Based Visual Detection of Amplified DNA for Diagnosis of Hepatitis C Virus. 62
36140129 2022
158
Genetic Polymorphism in Toll-Like Receptor 3 and Interferon Regulatory Factor 3 in Hepatitis C Virus-Infected Patients: Correlation with Liver Cirrhosis. 62
36048530 2022
159
Using Public Health Surveillance Data to Determine Hepatitis C Virus Exposure Among Live-Born Infants in Tennessee, 2013-2017. 62
34404285 2022
160
Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study. 62
36103593 2022
161
Serologic versus molecular testing for screening for hepatitis C virus infection in patients with hematologic malignancies. 62
36123927 2022
162
Identification of novel neutralizing determinants for protection against hepatitis C virus. 62
36056620 2022
163
Viral eradication by direct-acting antivirals does not decrease the serum myostatin level in patients infected with hepatitis C virus. 62
35700590 2022
164
A Simple and Effective Method to Concentrate Hepatitis C Virus: Aqueous Two-Phase System Allows Highly Efficient Enrichment of Enveloped Viruses. 62
36146792 2022
165
Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents. 62
36172658 2022
166
Analysis of hepatitis C virus-positive organs in liver transplantation. 62
36185718 2022
167
Prevalence and Molecular Evaluation of Hepatitis C Virus Infection among Multi-transfused Thalassemia Patients in South of Iran. 62
36188879 2022
168
Clinical characteristics and antiviral therapy in patients infected with hepatitis C virus in the interferon‑free era. 62
35938950 2022
169
Spontaneous Hepatitis C Virus Clearance in a Liver Transplant Recipient After Conversion From Tacrolimus to Everolimus. 62
36169108 2022
170
Economic evaluation of the Hepatitis C virus elimination program in the country of Georgia, 2015 to 2017. 62
36129625 2022
171
Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy. 62
35534339 2022
172
Stem cells as an ideal carrier for gene therapy: A new approach to the treatment of hepatitis C virus. 62
36150664 2022
173
Safety and Efficacy of Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C Virus Infection in Treatment-Naïve Children without and with Comorbidities. 62
35838919 2022
174
Hepatitis C virus nonstructural protein NS3 unfolds viral G-quadruplex RNA structures. 62
36108740 2022
175
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study. 62
35939812 2022
176
A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosis. 62
36066400 2022
177
The Impact of a Sustained Virologic Response to Hepatitis C Virus Treatment on Liver Stiffness in the Puerto Rico Veterans Attending Liver Clinics in the Veterans Affairs Caribbean Healthcare System. 62
36018739 2022
178
Trends in use and three-year outcomes of hepatitis C virus-viremic donor lung transplants for hepatitis C virus-seronegative recipients. 62
36207160 2022
179
Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct-acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort. 62
36000082 2022
180
Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case-control study. 62
36115934 2022
181
Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis. 62
35722709 2022
182
Contribution of DNA methylation to the risk of hepatitis C virus-associated hepatocellular carcinoma: A meta-analysis. 62
36155324 2022
183
Medicaid Hepatitis C Virus Treatment Policies: Impact on Testing and Treatment in the Commercially Insured. 62
35725599 2022
184
Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa. 62
33668068 2022
185
Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review. 62
35150578 2022
186
Molecular architecture of 40S translation initiation complexes on the hepatitis C virus IRES. 62
35822879 2022
187
Meta-analysis: risk of hepatitis C virus infection associated with hospital-based invasive procedures. 62
35758763 2022
188
The clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus: a cohort study. 62
35477818 2022
189
Genetically Engineered Hepatitis C Virus-like Particles (HCV-LPs) Tagged with SP94 Peptide to Acquire Selectivity to Liver Cancer Cells via Grp78. 62
36005152 2022
190
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. 62
35576953 2022
191
Effect of Direct-Acting Antiviral Agents on Gastroesophageal Varices in Patients with Hepatitis C Virus-Related Cirrhosis. 62
36013545 2022
192
Comparison of thrombocytopenia between patients with non-alcoholic fatty liver disease and those with hepatitis C virus-related chronic liver disease. 62
35543116 2022
193
Serum angiopoietin-2 levels predict regression of Mac-2 binding protein glycosylation isomer-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents. 62
35938598 2022
194
Impact of sustained viral response for hepatitis C virus on the outcomes of liver transplantation in hemophilic patients with human immunodeficiency virus/hepatitis C virus co-infection: A nationwide survey in Japan. 62
36002995 2022
195
Comparative Effectiveness of Direct-Acting Antivirals for Posttraumatic Stress Disorder in Veterans Affairs Patients With Hepatitis C Virus Infection. 62
35689641 2022
196
Hepatitis C Virus Reactivation in Anti-HCV Antibody-Positive Patients with Chronic Hepatitis B Following Anti-HBV Therapies. 62
36146665 2022
197
QuickStats: Percentage* of Adults† Aged ≥18 Years with Current Hepatitis C Virus Infection,§ by Health Insurance Coverage¶ - National Health and Nutrition Examination Survey, United States, January 2017-March 2020. 62
35951492 2022
198
Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States. 62
35234860 2022
199
Reply to: 'Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan'. 62
35526785 2022
200
Hepatitis C virus (HCV) seroprevalence, RNA detection, and genotype distribution across Florida, 2015-2018. 62
35803347 2022
201
Development of a Patient Activation Toolkit for Hepatitis C Virus Testing. 62
35971055 2022
202
Outcomes of an automated alert system from microbiology to link diagnosis to treatment in patients with hepatitis C virus. 62
36043540 2022
203
Hepatitis C virus infection reduces the lifespan of chimpanzees used in biomedical research. 62
35946233 2022
204
Effectiveness and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir as a Hepatitis C Virus Infection Salvage Therapy in the Real World: A Systematic Review and Meta-analysis. 62
35749010 2022
205
Hepatitis C virus screening in the 1969-1989 birth cohort: Is not enough! 62
35596923 2022
206
A close view of the Hepatitis C virus vaccines with further perspective. 62
35859760 2022
207
17β-Oestradiol Protects from Hepatitis C Virus Infection through Induction of Type I Interferon. 62
36016428 2022
208
Performance of rapid test for antibodies to hepatitis C virus (anti-HCV) in hemodialysis patients and kidney transplant recipients. 62
35751365 2022
209
Roles of microRNAs in Hepatitis C Virus Replication and Pathogenesis. 62
36016398 2022
210
Taking cues from convalescence to improve vaccines against hepatitis C virus. 62
35912856 2022
211
Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan. 62
36047126 2022
212
[Hepatitis C virus chronic infection: Exhausted T cells remain dysfunctional after cure]. 62
36094230 2022
213
Global dynamics of an age-dependent multiscale hepatitis C virus model. 62
35972543 2022
214
Letter to the Editor in response to the recently published article "Roncero C, Buch B, Martin-Sanchez AM, et al. Prevalence of hepatitis C virus infection in patients with chronic mental disorders: the relevance of dual diagnosis. Gastroenterol Hepatol. 2022". 62
35964813 2022
215
Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis. 62
36079006 2022
216
The Emergence of Hepatitis C Virus Genotype 4d Among Human Immunodeficiency Virus-Infected Patients in Mexico City: A Molecular Epidemiological Study. 62
35001015 2022
217
Cannabis Use as a Protective Factor Against Overweight in HIV-Hepatitis C Virus Co-Infected People (ANRS CO13 HEPAVIH Cohort). 62
35994579 2022
218
Improvement of patient-reported outcomes in patients achieving sustained virologic response with direct-acting antivirals for hepatitis C virus infection. 62
35637143 2022
219
Electrochemical immunoassay for detection of hepatitis C virus core antigen using electrode modified with Pt-decorated single-walled carbon nanotubes. 62
35982360 2022
220
Changes in Liver Stiffness and Markers of Liver Synthesis and Portal Hypertension following Hepatitis C Virus Eradication in Cirrhotic Individuals. 62
36009789 2022
221
Leveraging genomic surveillance to enhance elimination strategies for hepatitis C virus. 62
35985349 2022
222
Low spontaneous clearance rates of recently acquired hepatitis C virus in HIV-positive MSM (The PROBE-C Study). 62
36004410 2022
223
Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan. 62
35288188 2022
224
Integrating Hepatitis C Virus Treatment Programs Within Community Mental Health. 62
34991342 2022
225
No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy. 62
36119787 2022
226
Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment. 62
35951669 2022
227
Dual versus triple therapy in treatment of hepatitis C virus (HCV). 62
36040651 2022
228
Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection. 62
35920743 2022
229
Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment. 62
35957546 2022
230
Treatment of Hepatitis C Virus Prior to Posterior Lumbar Fusion: No Difference in Medical Outcomes or Reoperation. 62
36006411 2022
231
Development and Use of a Kinetical and Real-Time Monitoring System to Analyze the Replication of Hepatitis C Virus. 62
35955844 2022
232
Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR Study. 62
35928504 2022
233
Decision-making Among Hepatitis C Virus-negative Transplant Candidates Offered Organs from Donors with HCV Infection. 62
35923812 2022
234
[The prevalence of HIV, hepatitis C virus and syphilis and related factors among cross-border couples in Mangshi county, Dehong Dai and Jingpo Autonomous Prefecture of Yunnan province from 2017 to 2019]. 62
35922238 2022
235
Improving Liver Transplant Outcomes for Hepatitis C Virus Hepatocellular Carcinoma in the Direct-Acting Antiviral Therapy Era. 62
35933231 2022
236
High Satisfaction with Patient-Centered Telemedicine for Hepatitis C Virus Delivered to Substance Users: A Mixed-Methods Study. 62
35925809 2022
237
Donors with human immunodeficiency virus and hepatitis C virus for solid organ transplantation: what's new. 62
35849522 2022
238
[The diagnostic potential of Golgi protein 73 for cirrhosis in patients with chronic hepatitis C]. 62
36207945 2022
239
Letter to the editor: County-level variation in hepatitis C virus mortality and trends in the United States, 2005-2017. 62
35881668 2022
240
[The analysis of immunoreactivity of individual B-cell epitopes of hepatitis C virus (Flaviviridae: Hepacivirus: Hepatitis С virus) NS4a antigen]. 62
35831966 2022
241
Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Naïve Patients without History of Cardiovascular Disease. 62
35887813 2022
242
Molecular Epidemiology and Baseline Resistance of Hepatitis C Virus to Direct Acting Antivirals in Croatia. 62
35890052 2022
243
Diagnostic Performance of Circulating Tumor Cells for Predicting of Hepatocellular Carcinoma in Hepatitis C Virus-High Risk Patients: Role of Liquid Biopsy. 62
35901363 2022
244
Combined ultrasound and magnetic resonance elastography predict hepatocellular carcinoma after hepatitis C virus eradication. 62
35841314 2022
245
Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings. 62
36158908 2022
246
Retraction Note: Screening and identification of bioactive compounds from citrus against non-structural protein 3 protease of hepatitis C virus genotype 3a by fluorescence resonance energy transfer assay and mass spectrometry. 62
36158915 2022
247
Hepatitis C Virus Core Protein Promotes the Metastasis of Human Hepatocytes by Activating the MAPK/ERK/PEA3-SRF/c-Fos/MMPs Axis. 62
35817647 2022
248
Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment Program in an Urban Safety-Net Health System, Chicago, 2017-2019. 62
34043923 2022
249
Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta-analysis. 62
35357774 2022
250
Systematic Review of Hepatitis C Virus Prevalence in the WHO Western Pacific Region. 62
35891529 2022
251
Hepatitis C Virus Testing During Pregnancy After Universal Screening Recommendations. 62
35849464 2022
252
Heparanase-1 is upregulated by hepatitis C virus and favors its replication. 62
35085593 2022
253
Hepatitis C Virus Infection and Intrinsic Disorder in the Signaling Pathways Induced by Toll-Like Receptors. 62
36101469 2022
254
Updated U.S. Public Health Service Guideline for Testing of Transplant Candidates Aged <12 Years for Infection with HIV, Hepatitis B Virus, and Hepatitis C Virus - United States, 2022. 62
35771714 2022
255
Acute Liver Injury due to Glecaprevir/Pibrentasvir in a Patient with Chronic Hepatitis C Virus Infection without Cirrhosis. 62
36092381 2022
256
Elbasvir/grazoprevir for the treatment of hepatitis C virus infection in people with opioid use disorder. 62
35838498 2022
257
A Human and Rhesus Macaque Interferon-Stimulated Gene Screen Shows That Over-Expression of ARHGEF3/XPLN Inhibits Replication of Hepatitis C Virus and Other Flavivirids. 62
36016278 2022
258
Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment. 62
36016300 2022
259
The impact of direct-acting antivirals on quality of life in patients with hepatitis C virus infection: a meta-analysis. 62
35398571 2022
260
[A survey of the current status of research on the diagnosis and treatment of hepatitis C virus antibody-positive pregnant women]. 62
36038344 2022
261
Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population. 62
35077656 2022
262
Distribution of hepatitis C virus genotype and subtype between Mongolian and Han in Inner Mongolia. 62
35839017 2022
263
Hepatitis C virus infection preceding an outbreak of HIV among persons who inject drugs- Kanawha County, West Virginia, 2019-2021. 62
35903004 2022
264
Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R). 62
35891520 2022
265
PPP2R5D promotes hepatitis C virus infection by binding to viral NS5B and enhancing viral RNA replication. 62
35836293 2022
266
Corrigendum to Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein. 62
35550221 2022
267
A Proteomic Approach to Study the Biological Role of Hepatitis C Virus Protein Core+1/ARFP. 62
36016316 2022
268
General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapy. 62
35822118 2022
269
Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance. 62
35822120 2022
270
Analysis of the albumin-bilirubin score as an indicator of improved liver function among hepatitis C virus patients with sustained viral response after direct-acting antiviral therapy. 62
35822123 2022
271
Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir. 62
35647321 2022
272
Production and immunogenicity of different prophylactic vaccines for hepatitis C virus (Review). 62
35761816 2022
273
A cross-sectional study comparing men who have sex with men and inject drugs and people who inject drugs who are men and have sex with men in San Francisco: Implications for HIV and hepatitis C virus prevention. 62
35844825 2022
274
Impact of CD4+ T-cell count on sustained virologic response to direct-acting antivirals in hepatitis C virus monoinfected cancer patients: a prospective observational study. 62
35605562 2022
275
Hepatitis B virus X protein and hepatitis C virus core protein cooperate to repress E-cadherin expression via DNA methylation. 62
35832344 2022
276
Hepatitis C Virus positivity prediction from serum samples using NIRS and L1-penalized classification. 62
36085978 2022
277
Apelin Association with Hepatic Fibrosis and Esophageal Varices in Patients with Chronic Hepatitis C Virus. 62
35895373 2022
278
Transmission networks of hepatitis C virus among HIV/HCV-coinfected patients in Guangdong, China. 62
35836270 2022
279
Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. 62
35357770 2022
280
An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution. 62
35384259 2022
281
Hepatitis C virus burden: Treating and educating people without prejudice. 62
36158919 2022
282
Efficacy of hepatitis C virus eradication after curative treatment for hepatocellular carcinoma in patients with advanced hepatocellular carcinoma and decreased hepatic functional reserve: A nationwide, multicentre study by the Japanese Red Cross Liver Study Group. 62
35548866 2022
283
Association between the Genetic Polymorphisms of CCL2, CCL5, CCL8, CCR2, and CCR5 with Chronic Hepatitis C Virus Infection in the Chinese Han Population. 62
33902378 2022
284
Hepatitis C virus eradication ameliorates the prognosis of advanced hepatocellular carcinoma treated with sorafenib. 62
35499194 2022
285
Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1. 62
35229326 2022
286
Analysis of direct-acting antiviral-resistant hepatitis C virus haplotype diversity by single-molecule and long-read sequencing. 62
35357088 2022
287
Galectin-9 and Interferon-Gamma Are Released by Natural Killer Cells upon Activation with Interferon-Alpha and Orchestrate the Suppression of Hepatitis C Virus Infection. 62
35891518 2022
288
Hepatitis C virus NS3/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease. 62
35842458 2022
289
The Payer License Agreement, or "Netflix model," for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition. 62
35289467 2022
290
An entropic safety catch controls hepatitis C virus entry and antibody resistance. 62
35796426 2022
291
Nationwide hepatitis C virus screening and treatment of adolescents in Egyptian schools. 62
35489364 2022
292
Prevalence trends and risk factors associated with HIV, syphilis, and hepatitis C virus among pregnant women in Southwest China, 2009-2018. 62
35761327 2022
293
Direct-Acting Antiviral Agents for Hepatitis C Virus Infection-From Drug Discovery to Successful Implementation in Clinical Practice. 62
35746796 2022
294
When Coadministration Cannot Be Avoided: Real World Experience of Direct Acting Antivirals for the Treatment of Hepatitis C Virus Infection in Patients on First Generation Anticonvulsants. 62
33317381 2022
295
Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response. 62
35612312 2022
296
Highly Specific and Rapid Detection of Hepatitis C Virus Using RT-LAMP-Coupled CRISPR-Cas12 Assay. 62
35885430 2022
297
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. 62
35248212 2022
298
Peer support in small towns: A decentralized mobile Hepatitis C virus clinic for people who inject drugs. 62
35362660 2022
299
Three-Stage Pooled Plasma Hepatitis C Virus RNA Testing for the Identification of Acute HCV Infections in At-Risk Populations. 62
35499354 2022
300
A Flare of Hepatitis C Virus-Associated Cryoglobulinemic Vasculitis After COVID-19. 62
35898375 2022
301
Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. 62
35978668 2022
302
Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review. 62
35718017 2022
303
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. 62
35714311 2022
304
microRNA-27b regulates hepatic lipase enzyme LIPC and reduces triglyceride degradation during hepatitis C virus infection. 62
35483451 2022
305
Approaches and strategies to manage the hepatitis C virus-positive heart donor. 62
35649114 2022
306
Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open-label, phase 2 study. 62
35080256 2022
307
Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial. 62
35248213 2022
308
Phylogenetic signature and prevalence of natural resistance-associated substitutions for hepatitis C virus genotypes 3a and 3b in southwestern China. 62
35757658 2022
309
Sustained Virologic Response Rates Before and After Removal of Sobriety Restriction for Hepatitis C Virus Treatment Access. 62
35674245 2022
310
WTAP targets the METTL3 m 6 A-methyltransferase complex to cytoplasmic hepatitis C virus RNA to regulate infection. 62
35794896 2022
311
Association of Referral Source and Substance Use with Hepatitis C Virus Outcomes at a Southern Academic Medical Center. 62
35649518 2022
312
Situational and motivational factors associated with unhealthy alcohol use among Russian women with HIV and hepatitis C Virus co-infection. 62
35783993 2022
313
Potential impact of gut Lactobacillus acidophilus and Bifidobacterium bifidum on hepatic histopathological changes in non-cirrhotic hepatitis C virus patients with different viral load. 62
35706051 2022
314
Surveillance for hepatocellular carcinoma after hepatitis C virus eradication. 62
32166937 2022
315
Seroprevalence and burden of hepatitis C virus infection in WHO South-East Asia Region: A systematic review. 62
35263807 2022
316
Identification of phytochemicals from Eclipta alba and assess their potentiality against Hepatitis C virus envelope glycoprotein: virtual screening, docking, and molecular dynamics simulation study. 62
35694813 2022
317
Seroprevalence of hepatitis C virus infection in children: A systematic review and meta-analysis. 62
35220648 2022
318
Quantification of hepatitis C virus in viremic blood donors in Iran: Need to reinforce post-donation follow up. 62
35123894 2022
319
Prevalence and characteristics of hepatitis C virus-related hepatocellular carcinoma in a Spanish university hospital. 62
35316642 2022
320
Enhancing Surveillance Protocols for Acute Hepatitis C Virus Infection, Utah, 2014-2019. 62
35686292 2022
321
A complex increase in hepatitis C virus in a correctional facility: bumps in the road. 62
35435996 2022
322
Association study of TAP and HLA-I gene combination with chronic hepatitis C virus infection in a Han population in China. 62
35485366 2022
323
Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response. 62
35170532 2022
324
Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial. 62
35538396 2022
325
Decentralisation of hepatitis C virus care into community settings: A key approach on the path to elimination. 62
35678037 2022
326
Current status of hepatitis C virus among people living with human immunodeficiency virus in Egypt. 62
34850231 2022
327
Prevalence of hepatitis C virus infection in patients with chronic mental disorders: The relevance of dual disorders. 62
35780956 2022
328
A surveillance for hepatitis C virus infection in northeastern, Thailand: a 10-year cohort. 62
35968074 2022
329
Egocentric network characteristics of people who inject drugs in the Chicago metro area and associations with hepatitis C virus and injection risk behavior. 62
35655222 2022
330
A Hepatitis C virus genotype 1b post-transplant isolate with high replication efficiency in cell culture and its adaptation to infectious virus production in vitro and in vivo. 62
35763545 2022
331
Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations. 62
35579445 2022
332
Hepatocellular carcinoma, hepatitis C virus infection and miRNA involvement: Perspectives for new therapeutic approaches. 62
35979260 2022
333
Relationship between phase angle, steatosis, and liver fibrosis in patients coinfected with human immunodeficiency virus/hepatitis C virus. 62
35978664 2022
334
Metabolic aspects of hepatitis C virus. 62
35979265 2022
335
Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma. 62
35978673 2022
336
Comparison of Simple RNA Extraction Methods for Molecular Diagnosis of Hepatitis C Virus in Plasma. 62
35885505 2022
337
The Neutralizing Antibody Responses of Individuals That Spontaneously Resolve Hepatitis C Virus Infection. 62
35891372 2022
338
Chronic Infection with Hepatitis C Virus Subtype 1g in a Japanese Patient Successfully Treated with Glecaprevir/Pibrentasvir. 62
34897154 2022
339
Prevalence of hepatitis C virus estimates of undiagnosed individuals in different Italian regions: a mathematical modelling approach by route of transmission and fibrosis progression with results up to January 2021. 62
36066213 2022
340
Impact of proton pump inhibitors on sustained virologic response in veterans treated with sofosbuvir/velpatasvir for chronic hepatitis C virus: A retrospective cohort study. 62
35396730 2022
341
RT-LAMP-Based Molecular Diagnostic Set-Up for Rapid Hepatitis C Virus Testing. 62
35624599 2022
342
Perceived Stress in Hepatitis C Virus Infected Patients under the DAA-Based Therapy. 62
35626332 2022
343
Strategies for hepatitis C virus treatment failure. 62
34538553 2022
344
Glycomics-based serum markers as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection. 62
35505274 2022
345
ASO Visual Abstract: Mac-2 Binding Protein Glycosylation Isomer as a Novel Predictor of Hepatocellular Carcinoma Recurrence in Patients with Hepatitis C Virus Eradication. 62
35595941 2022
346
[Seroprevalence of Hepatitis B virus (HBV), Hepatitis C virus (HCV) and Human Immunodeficiency Virus (HIV) in a sample of patients diagnosed with Alcohol User Disorder in Albacete (Spain).] 62
35642274 2022
347
Real-world long-term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection. 62
35601120 2022
348
Untargeted Plasma Metabolomics Reveals Extensive Metabolic Alterations Among Treatment-Naive Human Immunodeficiency Virus/Hepatitis C Virus Co-Infected Patients with Liver Disease Progression. 62
35383478 2022
349
Sofosbuvir-based direct-acting antivirals for patients with decompensated hepatitis C virus-related cirrhosis. 62
35324552 2022
350
Hepatitis C virus infection and diabetes: A complex bidirectional relationship. 62
35398458 2022
351
Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project. 62
35461078 2022
352
Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice. 62
34990750 2022
353
Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer. 62
35565424 2022
354
Global prevalence of occult hepatitis C virus: A systematic review and meta-analysis. 62
35721241 2022
355
Innovations in education: A prospective study of storytelling narratives to enhance hepatitis C virus knowledge among substance users. 62
35721284 2022
356
Challenges of Treating an Acute Hepatitis C Virus Infection With Concurrent Seizure Treatment in a Free Clinic. 62
35800783 2022
357
Calprotectin in viral systemic infections-COVID-19 versus hepatitis C virus. 62
34254197 2022
358
Distribution and changes in hepatitis C virus genotype in China from 2010 to 2020. 62
35663077 2022
359
Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS). 62
34913180 2022
360
Feasibility of hepatitis C virus testing and linkage in community supervision offices: Great potential but persistent challenges. 62
35367903 2022
361
Possible Alterations in Appetite-related Molecules After the Elimination of Hepatitis C Virus. 62
35478158 2022
362
Assessing in vivo mutation frequencies and creating a high-resolution genome-wide map of fitness costs of Hepatitis C virus. 62
35500034 2022
363
Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment. 62
35552472 2022
364
Seroprevalence of Hepatitis B Virus and Hepatitis C Virus in Patients Undergoing Maintenance Hemodialysis. 62
35686251 2022
365
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. 62
35434589 2022
366
An Unexpected Cause of a Cardiac Murmur in a Patient with a History of Hepatitis C Virus. 62
34986365 2022
367
Drug delivery of sofosbuvir drug capsulated with the β-cyclodextrin basket loaded on chitosan nanoparticle surface for anti-hepatitis C virus (HCV). 62
35278509 2022
368
A Tale of 3 Pandemics: Severe Acute Respiratory Syndrome Coronavirus 2, Hepatitis C Virus, and Human Immunodeficiency Virus in an Urban Emergency Department in Baltimore, Maryland. 62
35392453 2022
369
Predictors of linkage to hepatitis C virus care among people living with HIV with hepatitis C infection and the impact of loss to HIV follow-up. 62
35620551 2022
370
Accessible Hepatitis C Care for People Who Inject Drugs: A Randomized Clinical Trial. 62
35285851 2022
371
The Use of Hepatitis C Virus-Positive Organs in Hepatitis C Virus-Negative Recipients. 62
35487612 2022
372
Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada. 62
35218989 2022
373
Autologous hematopoietic cell transplantation for myeloma patients with hepatitis B virus or hepatitis C virus in the era of novel agents. 62
35332303 2022
374
The role of active metabolites isolated from Jasminum multiflorum flowers against hepatitis C virus infection and related hepatocellular carcinoma. 62
33957828 2022
375
Multimodal Treatment of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antivirals. 62
35800821 2022
376
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. 62
35180382 2022
377
Occult hepatitis B virus infection in hepatitis C virus negative chronic liver diseases. 62
35246933 2022
378
Changes in Health-related Quality of Life for Hepatitis C Virus-Infected People Who Inject Drugs While on Opioid Agonist Treatment Following Sustained Virologic Response. 62
34331539 2022
379
Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus. 62
35064576 2022
380
Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis. 62
35303490 2022
381
Retreatment for hepatitis C virus direct acting antiviral therapy virological failure in primary and tertiary settings: the REACH-C cohort. 62
35583922 2022
382
Low hepatitis C virus-viremia prevalence yet continued barriers to direct-acting antiviral treatment in people living with HIV in the Netherlands. 62
34999607 2022
383
Hepatitis C Virus Treatment Response to Direct-acting Antivirals Among Adolescents With HIV/HCV Coinfection: Real-world Data From Ukraine. 62
35067642 2022
384
Postpartum Follow-up Care for Pregnant Persons With Opioid Use Disorder and Hepatitis C Virus Infection. 62
35576352 2022
385
Using the Electronic Health Record to Characterize the Hepatitis C Virus Care Cascade. 62
33831316 2022
386
Removal of medicaid restrictions were associated with increased hepatitis C virus treatment rates, but disparities persist. 62
35254695 2022
387
FADS2-dependent fatty acid desaturation dictates cellular sensitivity to ferroptosis and permissiveness for hepatitis C virus replication. 62
34520742 2022
388
Toll-like Receptor Response to Hepatitis C Virus Infection: A Recent Overview. 62
35628287 2022
389
Hepatitis C Virus Epidemiology in Lithuania: Situation before Introduction of the National Screening Programme. 62
35746663 2022
390
Phylogenetic Analysis of Spread of Hepatitis C Virus Identified during HIV Outbreak Investigation, Unnao, India. 62
35318918 2022
391
Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO. 62
35122713 2022
392
IL-26 inhibits hepatitis C virus replication in hepatocytes. 62
34952035 2022
393
The In Vivo and In Vitro Architecture of the Hepatitis C Virus RNA Genome Uncovers Functional RNA Secondary and Tertiary Structures. 62
35353000 2022
394
In vitro Selection of High Affinity DNA and RNA Aptamers that Detect Hepatitis C Virus Core Protein of Genotypes 1 to 4 and Inhibit Virus Production in Cell Culture. 62
35183559 2022
395
Serum MicroRNA Transcriptomics and Acute Rejection or Recurrent Hepatitis C Virus in Human Liver Allograft Recipients: A Pilot Study. 62
33979314 2022
396
A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. 62
35026142 2022
397
Clinical and Molecular Basis of Hepatocellular Carcinoma after Hepatitis C Virus Eradication. 62
35456105 2022
398
H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection. 62
35044851 2022
399
Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals. 62
35103020 2022
400
Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients. 62
34464735 2022
401
Sofosbuvir and ledipasvir decreased nephrotic syndrome caused by IgA nephropathy with a membranoproliferative pattern of injury in hepatitis C virus-induced cirrhosis: a case report. 62
35571427 2022
402
Severe chronic atopic dermatitis improvement after hepatitis C virus elimination with sofosbuvir/ledipasvir treatment. 62
35645664 2022
403
Hepatitis C virus (HCV) infection among patients with sickle cell disease at the Korle-Bu teaching hospital. 62
35459145 2022
404
Serological testing on the ADVIA Centaur system for human immunodeficiency virus, hepatitis B virus, and hepatitis C virus in specimens from deceased and living individuals demonstrates equivalent resultsƚ. 62
35176197 2022
405
Hepatitis C Virus Exposure and Infection in the Perinatal Period. 62
35440312 2022
406
Integrating hepatitis C virus screening of baby boomers at a community hospital emergency department. 62
35152523 2022
407
The impact of hepatitis C virus direct acting agents in liver transplant using very old donor grafts: a real-world single-center analysis. 62
34807412 2022
408
Activation of the Ca2+/NFAT Pathway by Assembly of Hepatitis C Virus Core Protein into Nucleocapsid-like Particles. 62
35458491 2022
409
Prevalence of Occult Hepatitis C Virus Infection in Egyptian Patients with Lymphoma: A New Vision. 62
35454063 2022
410
Hepatitis C virus core protein: Not just a nucleocapsid building block, but an immunity and inflammation modulator. 62
35465281 2022
411
Hepatitis C Virus Alters Macrophage Cholesterol Metabolism Through Interaction with Scavenger Receptors. 62
35467430 2022
412
Treatment Response and Drug Resistance Profiling of Genotype 6 of Hepatitis C Virus in HCV/HIV Co-Infected Patients: A Pilot Study from INDIA. 62
35632686 2022
413
Diagnostic accuracy of circulating microRNAs for hepatitis C virus-associated hepatocellular carcinoma: a systematic review and meta-analysis. 62
35365115 2022
414
Brain metabolic and microstructural alterations associated with hepatitis C virus infection, autoimmune hepatitis and primary biliary cholangitis. 62
34719118 2022
415
Mac-2-Binding Protein Glycosylation Isomer as a Novel Predictor of Hepatocellular Carcinoma Recurrence in Patients with Hepatitis C Virus Eradication. 62
34729653 2022
416
Anti-hepatitis C virus drug simeprevir: a promising antimicrobial agent against MRSA. 62
35338386 2022
417
Suppression of hepatitis C virus replication during COVID-19 infection. 62
35049136 2022
418
Monte Carlo Method and GA-MLR-Based QSAR Modeling of NS5A Inhibitors against the Hepatitis C Virus. 62
35566079 2022
419
Genotype Distribution and Demographic Characteristics of Hepatitis C Virus NAT Yield Cases among US Blood Donors. 62
35404410 2022
420
Caregiver exposure to hepatitis C virus following transplantation with hepatitis C viremic donor organs: A case series. 62
34910839 2022
421
High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus. 62
34474121 2022
422
Comment on review article: Chronic hepatitis C virus infection cascade of care in pediatric patients. 62
35582673 2022
423
Nup98 Is Subverted from Annulate Lamellae by Hepatitis C Virus Core Protein to Foster Viral Assembly. 62
35258330 2022
424
Study protocol: a randomised, controlled trial of a nurse navigator program for the management of hepatitis C virus in patients with severe mental disorder. 62
35443727 2022
425
Revolution in the diagnosis and management of hepatitis C virus infection in current era. 62
35646260 2022
426
Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. 62
35362130 2022
427
The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons. 62
35722762 2022
428
Evolution of within-host variants of the hepatitis C virus. 62
35150893 2022
429
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. 62
35499114 2022
430
Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination-authors' reply. 62
35362133 2022
431
Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis. 62
35365728 2022
432
[Detection of serum anti-NS2 antibody and recombinant hepatitis C virus nonstructural protein 2 (NS2): its development and evaluation]. 62
35583066 2022
433
The Impact of Interferon-γ (IFN-γ) and IFN-γ-Inducible Protein 10 (IP-10) Genes' Polymorphism on Risk of Hepatitis C Virus-Related Liver Cirrhosis. 62
33445993 2022
434
Case study of hepatitis C virus control in Egypt: impact of access program. 62
35491550 2022
435
Uptake of hepatitis C virus treatment in a multi-state Medicaid population, 2013-2017. 62
35466398 2022
436
An Easy-to-Implement Risk Score for Targeted Hepatitis C Virus Testing in the General Population. 62
35357241 2022
437
Comparison of Patients Monoinfected with Hepatitis C Virus and Coinfected with Hepatitis B/C in the Amazon Region of Brazil. 62
35632598 2022
438
Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencing. 62
35490163 2022
439
Corrigendum: An interferon lambda 4-associated variant in the hepatitis C virus RNA polymerase affects viral replication in infected cells. 62
35482391 2022
440
Role of liver stiffness measurements in patients who develop hepatocellular carcinoma after clearance of the hepatitis C virus. 62
35129720 2022
441
Sequential Phosphorylation of Hepatitis C Virus NS5A Protein Requires the ATP-Binding Domain of NS3 Helicase. 62
35293767 2022
442
The Human Liver-Expressed Lectin CD302 Restricts Hepatitis C Virus Infection. 62
35297672 2022
443
Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older. 62
35484503 2022
444
Hepatitis C virus infection increases the risk of adverse outcomes following joint arthroplasty: A meta-analysis of observational studies. 62
33930585 2022
445
Hepatitis C virus genotypes and viremia in a tertiary hospital in Istanbul, Turkey. 62
35544629 2022
446
Protein tyrosine kinase Abl promotes hepatitis C virus particle assembly via interaction with viral substrate activator NS5A. 62
35257746 2022
447
A visual method for determination of hepatitis C virus RNAs based on a 3D nanocomposite prepared from graphene quantum dots. 62
35361427 2022
448
Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study. 62
35362522 2022
449
Cost-effectiveness analysis of hepatitis C virus (HCV) point-of-care assay for HCV screening. 62
34847288 2022
450
Conspicuous Response to Direct-Acting Antivirals in Chronic Hepatitis C-related Immune Thrombocytopenia: A Case Report. 62
35592216 2022
451
Prevalence and factors associated with chronic venous insufficiency, leg ulceration and deep-vein thrombosis among people who inject drugs in London, UK. 62
34605086 2022
452
The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment. 62
35354688 2022
453
Incidence of Hepatitis C Virus Infections Among Users of Human Immunodeficiency Virus Pre-exposure Prophylaxis. 62
33737225 2022
454
Liver stiffness-based score at sustained virologic response predicts liver-related complications after eradication of hepatitis C virus. 62
34687140 2022
455
The impact of nucleic acid testing to detect human immunodeficiency virus, hepatitis C virus, and hepatitis B virus yields from a single blood center in China with 10-years review. 62
35321684 2022
456
Laboratory Evaluation of Hepatitis C Virus Infection in Patients Undergoing Hemodialysis from North East India. 62
35535106 2022
457
Reply to: impact of Chronic Hepatitis C virus co-infection on outcomes of infective endocarditis in people who inject drugs. 62
34974351 2022
458
Sero-reactivity to three distinct regions within the hepatitis C virus alternative reading frame protein (ARFP/core+1) in patients with chronic HCV genotype-3 infection. 62
35230930 2022
459
Antiretroviral therapy for HIV and intrahepatic hepatitis C virus replication. 62
34690280 2022
460
Hepatitis C Virus-Induced ROS/JNK Signaling Pathway Activates the E3 Ubiquitin Ligase Itch to Promote the Release of HCV Particles via Polyubiquitylation of VPS4A. 62
35044214 2022
461
Successful Eradication of Hepatitis-C Virus with Sofosbuvir based Antiviral treatment results in improvement in quality of life in cirrhotic patients. 62
35634624 2022
462
Clinical evaluation of a Hepatitis C Virus whole-genome sequencing pipeline for genotyping and resistance testing. 62
34245902 2022
463
Association of Obesity, Diabetes, and Alcohol Use With Liver Fibrosis Among US Adults With Hepatitis C Virus Infection. 62
35302636 2022
464
Long-Lasting Virus-Specific T Cell Response with Divergent Features in Self-Resolved and Chronic Hepatitis C Virus Patients 35 Years Postinfection. 62
35256480 2022
465
Reinforcement learning evaluation of treatment policies for patients with hepatitis C virus. 62
35272662 2022
466
Effect of a Default Order vs an Alert in the Electronic Health Record on Hepatitis C Virus Screening Among Hospitalized Patients: A Stepped-Wedge Randomized Clinical Trial. 62
35297973 2022
467
Induction of neutralizing antibodies against hepatitis C virus by a subviral particle-based DNA vaccine. 62
35196560 2022
468
Reduced fitness of the mosquito Culex pipiens (Diptera: Culicidae) after feeding on a blood meal with hepatitis C virus. 62
35085584 2022
469
The Impact of Current Opioid Agonist Therapy on Hepatitis C Virus Treatment Initiation Among People Who Use Drugs From the Direct-acting Antiviral (DAA) Era: A Population-Based Study. 62
34125883 2022
470
Comparing Hepatitis C Virus Screening in Clinics Versus the Emergency Department. 62
35679493 2022
471
Monitoring of iron, lipid and liver profiles in Egyptian hepatitis C virus patients on sofosbuvir therapy. 62
35077948 2022
472
Hepatitis C Virus Nonstructural 5A Protein Interacts with Telomere Length Regulation Protein: Implications for Telomere Shortening in Patients Infected with HCV. 62
34949741 2022
473
Hepatitis C virus infection screening reduces mortality and is cost-effective independently of the intervention test. 62
35285662 2022
474
"Every One of Us Is a Strand in That Basket": Weaving Together Stories of Indigenous Wellness and Resilience From the Perspective of Those With Lived and Living Experience With HIV/Hepatitis C Virus. 62
34806860 2022
475
Statewide Assessment of the Hepatitis C Virus Care Cascade for Incarcerated Persons in Vermont. 62
35264027 2022
476
HEPATITIS C VIRUS SCREENING AND LINKAGE TO CARE IN MENTAL HEALTH UNITS: AN OPPORTUNITY FOR HCV ELIMINATION. 62
35312998 2022
477
Liver Disease Screening and Hepatitis C Virus Elimination in Taiwan Rural Indigenous Townships: Village-By-Village Screening and Linking to Outreach Hepatology Care. 62
35328957 2022
478
The Impact of Hepatitis C Virus, Metabolic Disturbance, and Unhealthy Behavior on Chronic Kidney Disease: A Secondary Cross-Sectional Analysis. 62
35329244 2022
479
Evaluation of hepatitis C virus antibody assay using dried blood spot samples. 62
35260691 2022
480
Correction to: Hepatitis C virus core protein activates Wnt/β-catenin signaling through multiple regulation of upstream molecules in the SMMC-7721 cell line. 62
34738154 2022
481
Identifying Different Mutation Sites Leading to Resistance to the Direct-Acting Antiviral (DAA) Sofosbuvir in Hepatitis C Virus Patients from Egypt. 62
35456731 2022
482
Induction of broadly neutralizing antibodies using a secreted form of the hepatitis C virus E1E2 heterodimer as a vaccine candidate. 62
35263223 2022
483
Evolutionary characteristics and immune mutation of hepatitis C virus genotype 1b among intravenous drug users in mainland, China. 62
35075775 2022
484
Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs. 62
34986001 2022
485
Using population-level incidence of hepatitis C virus and immigration status for data-driven screening policies: a case study in Israel. 62
33348364 2022
486
The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences. 62
34690281 2022
487
The Hepatitis C Clinical Exchange Network: A Local Health Department Partnership With Acute Care Hospitals to Promote Screening and Treatment of Hepatitis C Virus Infection. 62
34347654 2022
488
Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections. 62
35431505 2022
489
Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs. 62
34543417 2022
490
Hepatitis C virus infection could be a risk factor for adult-onset vitiligo in Egyptian patients: A cross-sectional study. 62
35348287 2022
491
Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019 - CORRIGENDUM. 62
35241187 2022
492
The potential value of plasma Circ-ITCH in hepatocellular carcinoma patients with current hepatitis C virus infection. 62
35288234 2022
493
Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. 62
34676692 2022
494
Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection. 62
35024454 2022
495
Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. 62
34954493 2022
496
Real-world outcomes of rapid regional hepatitis C virus treatment scale-up among people who inject drugs in Tayside, Scotland. 62
34877667 2022
497
Assessment of coronary inflammation in antiretroviral treated people with HIV infection and active HIV/hepatitis C virus co-infection. 62
34750294 2022
498
Sensitive detection of hepatitis C virus using a catalytic hairpin assembly coupled with a lateral flow immunoassay test strip. 62
34890941 2022
499
Suboptimal Uptake, Retention, and Adherence of Daily Oral Prexposure Prophylaxis Among People With Opioid Use Disorder Receiving Hepatitis C Virus Treatment. 62
35187191 2022
500
Modelling T-cell immunity against hepatitis C virus with liver organoids in a microfluidic coculture system. 62
35232252 2022
501
Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections. 62
35089390 2022
502
In silico design and analysis of NS4B inhibitors against hepatitis C virus. 62
33118481 2022
503
In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models. 62
35314909 2022
504
Prevalence of HIV, hepatitis B virus, and hepatitis C virus among incarcerated people in Iran: a systematic review and meta-analysis. 62
35032918 2022
505
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. 62
34812502 2022
506
MicroRNA let-7b inhibits hepatitis C virus and induces apoptosis in human hepatoma cells. 62
34807376 2022
507
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. 62
34967920 2022
508
Trends in the Prevalence of Hepatitis C Virus Infection based on the Insurance Status in the United States from 2013 to 2018. 62
34817925 2022
509
Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection. 62
34618379 2022
510
Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation. 62
33926816 2022
511
MicroRNA 122 Affects both the Initiation and the Maintenance of Hepatitis C Virus Infections. 62
34908444 2022
512
Hepatitis C virus and intracellular antiviral response. 62
34973476 2022
513
Complete genome sequencing and evolutionary analysis of hepatitis C virus subtype 6a, including strains from Guangdong Province, China. 62
35050401 2022
514
Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation. 62
34613666 2022
515
Hepatitis C Virus NS3/4A Inhibition and Host Immunomodulation by Tannins from Terminalia chebula: A Structural Perspective. 62
35164341 2022
516
Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care. 62
34767680 2022
517
Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment. 62
34773272 2022
518
The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study. 62
35012711 2022
519
An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. 62
34655573 2022
520
Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors. 62
34815586 2022
521
The low-resolution structural models of hepatitis C virus RNA subdomain 5BSL3.2 and its distal complex with domain 3'X point to conserved regulatory mechanisms within the Flaviviridae family. 62
35137150 2022
522
Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection. 62
35131346 2022
523
Statins in Hepatitis B or C Patients Is Associated With Reduced Hepatocellular Carcinoma Risk: A Systematic Review and Meta-Analysis. 62
35115293 2022
524
Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. 62
35031857 2022
525
Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation. 62
35227234 2022
526
Cardiovascular Implications of Immune Disorders in Women. 62
35175848 2022
527
Turning the Tide on Hepatitis C Virus-Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand. 62
34624175 2022
528
The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma. 62
35208582 2022
529
[Development approaches for vaccines against hepatitis C virus infections]. 62
35015104 2022
530
Hepatitis B and Hepatitis C Virus Infection Promote Liver Fibrogenesis through a TGF-β1-Induced OCT4/Nanog Pathway. 62
35022275 2022
531
Awareness and Epidemiology of Chronic Hepatitis C Virus Infections in Florida. 62
34914078 2022
532
Enhanced fitness of hepatitis C virus increases resistance to direct-acting antivirals. 62
35133954 2022
533
Inhibitory Effects of Bacterial Silk-like Biopolymer on Herpes Simplex Virus Type 1, Adenovirus Type 7 and Hepatitis C Virus Infection. 62
35225980 2022
534
Neutralizing Antibodies Against Hepatitis C Virus and Their Role in Vaccine Immunity. 62
34863787 2022
535
A Novel Imidazolinone Derivative with 5-Arylidene and 2-Substituted Mercapto Group as Potent Anti-Hepatitis C Virus Compound. 62
34927353 2022
536
Hepatitis C Virus Elimination in Methadone Treated Patients: Implementation of Hepatology Clinic in a Methadone Treatment Program. 62
35165226 2022
537
Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. 62
35059853 2022
538
Hepatitis C Virus Reflex Testing Protocol in an Emergency Department. 62
35302440 2022
539
An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis. 62
34184794 2022
540
Behind the Decrease of Liver Stiffness After Successful Hepatitis C Virus Eradication with Direct-Acting Antiviral Agents. 62
35238783 2022
541
Hepatitis C Virus Treatment and Solid Organ Transplantation. 62
35505819 2022
542
Grazoprevir/Elbasvir Treatment in Liver or Kidney Transplant Recipients with Genotype 1b Hepatitis C Virus Infection. 62
34902265 2022
543
High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor. 62
35214707 2022
544
Comprehensive Comparative Analysis of Standard Validated, Genetic, and Novel Biomarkers to Enhance Prognostic Risk-Stratification in Patients With Hepatitis C Virus Cirrhosis. 62
35142723 2022
545
HIV and Hepatitis C Virus Testing and Treatment Services in Specialty Treatment Facilities That Offer Medication for Opioid Use Disorder in the US. 62
35191936 2022
546
Uncovering Resistance to Hepatitis C Virus Infection: Scientific Contributions and Unanswered Questions in the Irish Anti-D Cohort. 62
35335630 2022
547
Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate. 62
35317156 2022
548
Learning from a rare phenomenon - spontaneous clearance of chronic hepatitis C virus post-liver transplant: A case report. 62
35317181 2022
549
Male-specific Association between Iron and Lipid Metabolism Changes and Erythroferrone after Hepatitis C Virus Eradication. 62
34433710 2022
550
Antivirals against HCV infection: the story thus far. 62
35298416 2022
551
Reduced Levels of NAD in Skeletal Muscle and Increased Physiologic Frailty Are Associated With Viral Coinfection in Asymptomatic Middle-Aged Adults. 62
35015741 2022
552
Reactive oxygen species as potential antiviral targets. 62
33949029 2022
553
Chronic Alcohol Exposure Among People Living with HIV Is Associated with Innate Immune Activation and Alterations in Monocyte Phenotype and Plasma Cytokine Profile. 62
35371104 2022
554
Autophagy-Related Activation of Hepatic Stellate Cells Reduces Cellular miR-29a by Promoting Its Vesicular Secretion. 62
35219894 2022
555
Analysis of Glaucoma Associated Genes in Response to Inflammation, an Examination of a Public Data Set Derived from Peripheral Blood from Patients with Hepatitis C. 62
35770250 2022
556
Antiviral Toll-like Receptor Signaling in Non-Parenchymal Liver Cells Is Restricted to TLR3. 62
35215812 2022
557
Emergence of Hepatitis C Virus Genotype 2c Infection Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Tokyo, Japan. 62
34074999 2022
558
Illness perception about hepatitis C virus infection: a cross-sectional study from Khyber Pakhtunkhwa Pakistan. 62
35062889 2022
559
[Investigation of Hepatitis C Virus (HCV) Genotypes by "Reverse Hybridisation Strip Assay" and DNA Sequence Analysis Methods]. 62
35088961 2022
560
Integrated analysis of differentially expressed genes, differentially methylated genes, and natural compounds in hepatitis C virus-induced cirrhosis. 62
35086375 2022
561
Detection of hepatitis C virus (HCV) RNA in the peripheral blood mononuclear cells of HCV-infected patients following sustained virologic response. 62
35066710 2022
562
Efficacy and safety of elbasvir/grazoprevir treatment for Chinese patients with hepatitis C virus genotype 1b: a retrospective study. 62
35836873 2022
563
Synthesis and structure-activity relationship study of new biaryl amide derivatives and their inhibitory effects against hepatitis C virus. 62
34883293 2022
564
Regulatory Role of Phospholipids in Hepatitis C Virus Replication and Protein Function. 62
35056049 2022
565
Evaluation of cure rate in patients with hepatitis C virus completing shortened courses of treatment. 62
34454865 2022
566
Clinical practice guidelines for the management of children with mother-to-child transmitted hepatitis C virus infection. 62
35224815 2022
567
Epidemiology of hepatitis B virus and/or hepatitis C virus infections among people living with human immunodeficiency virus in Africa: A systematic review and meta-analysis. 62
35639675 2022
568
Role of fluid-phase complement system regulation in the development of hepatitis C virus-associated glomerulonephritis. 62
36227893 2022
569
Percutaneous thermal ablation combined with transcatheter arterial chemoembolization for hepatitis C virus-related hepatocellular carcinoma: Efficacy and survival. 62
36212462 2022
570
Seroprevalence of Hepatitis B Virus, Hepatitis C Virus, Syphilis and Associated Factors Among Female Sex Workers in Gondar Town, Northwest Ethiopia. 62
36254334 2022
571
Long-term persistence of hepatocarcinogenic potential of a non-hypervascular hypointense nodule on EOB-MRI after the eradication of hepatitis C virus. 62
34472681 2022
572
Diastereoselective Synthesis of 2'-Dihalopyrimidine Ribonucleoside Inhibitors of Hepatitis C Virus Replication. 62
35036807 2022
573
Unexpectedly High Prevalence of Hepatitis C Virus Infection, Southern Laos. 62
34932463 2022
574
Assessment of Tennessee's county-level vulnerability to hepatitis C virus and HIV outbreaks using socioeconomic, healthcare, and substance use indicators. 62
35925969 2022
575
Knowledge of Hepatitis C virus vertical transmission and subsequent pregnancy outcome in virus-positive female blood donors. 62
35180448 2022
576
IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection. 62
35923969 2022
577
Transient elastography score is elevated during rheumatoid factor-positive chronic hepatitis C virus infection and rheumatoid factor decline is highly variable over the course of direct-acting antiviral therapy. 62
35482664 2022
578
Value of Bile Acids in Diagnosing Hepatitis C Virus-Induced Liver Cirrhosis and Hepatocellular Carcinoma. 62
35996509 2022
579
Hepatitis C virus risk among young people who inject drugs. 62
35968435 2022
580
The Impact of Antiviral Therapy for Hepatitis C Virus on the Survival of Patients after Hepatocellular Carcinoma Treatment. 62
36104175 2022
581
Association Between Prescription Opioid Therapy for Noncancer Pain and Hepatitis C Virus Seroconversion. 62
35019983 2022
582
Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey. 62
35061841 2022
583
Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance. 62
34864126 2022
584
Hepatitis C virus transmission cluster among injection drug users in Pakistan. 62
35839216 2022
585
Association of hepatitis C virus infection status and genotype with kidney disease risk: A population-based cross-sectional study. 62
35802581 2022
586
Natural Killer Group 2D Receptor and B1a Cells Crosstalk in Post-Hepatitis C Virus Infection Hepatocellular Carcinoma and Cirrhosis. 62
35879974 2022
587
Interventions to Improve Uptake of Direct-Acting Antivirals for Hepatitis C Virus in Priority Populations: A Systematic Review. 62
35812487 2022
588
Targeting Emerging RNA Viruses by Engineered Human Superantibody to Hepatitis C Virus RNA-Dependent RNA Polymerase. 62
35935185 2022
589
Role of hepatitis c virus in hepatocellular carcinoma and neurological disorders: an overview. 62
35965577 2022
590
Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis. 62
36197422 2022
591
Prevalence of Hepatitis C Virus Infection, Genotypes and Subtypes in Migrants from Pakistan in Barcelona, Spain. 62
36003985 2022
592
Sociodemographic characteristics associated with hepatitis C virus infection in Vietnamese Americans: A cross-sectional analysis of community screening data. 62
36166444 2022
593
Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture. 62
35992670 2022
594
Successful treatment of chronic hepatitis C virus infection with crushed elbasvir/grazoprevir administered through a nasogastric tube in a patient with hypoxic encephalopathy. 62
34558811 2022
595
Design of a novel multi-epitope vaccine candidate against hepatitis C virus using structural and nonstructural proteins: An immunoinformatics approach. 62
36040967 2022
596
A qualitative investigation of organizational challenges and facilitators to screening individuals experiencing homelessness for hepatitis C virus (HCV) in Houston, Texas. 62
35994438 2022
597
Probing a Stochastic Epidemic Hepatitis C Virus Model with a Chronically Infected Treated Population. 62
35911571 2022
598
Prevalence of Chronic Infection by Hepatitis C Virus in Asymptomatic Population With Risk Factors in Cartagena, Colombia. 62
35860730 2022
599
Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection. 62
35560032 2022
600
Recombinant Full-Length Hepatitis C Virus E1E2 Dimer Elicits Pangenotypic Neutralizing Antibodies. 62
35837406 2022
601
Epidemiology of Hepatitis C virus infection among incarcerated populations in North Dakota. 62
35349606 2022
602
Hepatitis C Virus Infection Cycle-Specific MicroRNA Profiling Reveals Stage-Specific miR-4423-3p Targets RIG-I to Facilitate Infection. 62
35402303 2022
603
Hepatectomy outcomes in patients with hepatitis C virus-related hepatocellular carcinoma with or without cirrhosis. 62
35071114 2022
604
Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study). 62
34983773 2022
605
A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective. 62
34736311 2022
606
Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy? 62
35502409 2022
607
Hepatitis C Virus Prevalence, Medical Status Awareness and Treatment Engagement among Homeless People Who use Drugs: Results of a Street Outreach Study. 62
35651594 2022
608
Lymphoepithelioma‑Like Cholangiocarcinoma with Hepatitis C Virus Infection Treated by Microwave Ablation: A Literature Review and Case Report. 62
35813580 2022
609
Targeting non-structural proteins of Hepatitis C virus for predicting repurposed drugs using QSAR and machine learning approaches. 62
35832613 2022
610
Antiviral Activity of Chitosan Nanoparticles Encapsulating Curcumin Against Hepatitis C Virus Genotype 4a in Human Hepatoma Cell Lines [Retraction]. 62
35818402 2022
611
Delayed recognition of breathing system contamination with blood containing hepatitis C virus following failure of a heat and moisture exchange filter. 62
35784384 2022
612
Poly(rC)-Binding Protein 1 Limits Hepatitis C Virus Virion Assembly and Secretion. 62
35215884 2022
613
Nurse practitioners as primary care site champions for the screening and treatment of hepatitis C virus. 62
35066534 2022
614
Formulation Design and Cell Cytotoxicity of Curcumin-Loaded Liposomal Solid Gels for Anti-Hepatitis C Virus. 62
35295681 2022
615
Hepatitis C virus and kidney transplantation: Recent trends and paradigm shifts. 62
35063799 2022
616
Prevalence and risk factors of hepatitis C virus infection in the rural northeastern United States. 62
34752949 2022
617
Identification of NS5B Resistance-Associated Mutations in Hepatitis C Virus Circulating in Treatment Naïve Vietnamese Patients. 62
35411152 2022
618
MxB Disrupts Hepatitis C Virus NS5A-CypA Complex: Insights From a Combined Theoretical and Experimental Approach. 62
35369502 2022
619
Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus. 62
35020772 2022
620
[Drug selection for simultaneous treatment of tuberculosis combined with hepatitis C virus infection]. 62
35152682 2022
621
Current management of children with hepatitis C virus mother-to-child transmission. 62
35175674 2022
622
Comparing Routine HIV and Hepatitis C Virus Screening to Estimate the Effect of Required Consent on HIV Screening Rates Among Hospitalized Patients. 62
33673778 2022
623
High recombination rate of hepatitis C virus revealed by a green fluorescent protein reconstitution cell system. 62
35223082 2022
624
Transplantation of Organs from Hepatitis C Virus-Positive Donors under Direct-Acting Antiviral Regimens. 62
35160222 2022
625
Analysis of serum and gene expression profile of cytokines (IL-6, TNF-α and TGF-β1) in chronic hepatitis C virus infection. 62
35469194 2022
626
HIV, hepatitis B virus, and hepatitis C virus co-infection among HIV positives in antiretroviral treatment program in selected hospitals in Addis Ababa: A retrospective cross-sectional study. 62
35452472 2022
627
Epidemiology, risk factors, and pathogenesis associated with a superbug: A comprehensive literature review on hepatitis C virus infection. 62
35795865 2022
628
Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus. 62
34332129 2022
629
Entry Inhibitors of Hepatitis C Virus. 62
35412143 2022
630
Occupational exposure to hepatitis C virus infection and associated factors among healthcare workers in Fattouma Bourguiba University Hospital, Tunisia. 62
36099280 2022
631
The use of technology-based adherence monitoring in the treatment of hepatitis C virus. 62
35591885 2022
632
Exploring how hospitalization can alter hepatitis c virus treatment prioritization and trajectories in people who use drugs: A qualitative analysis. 62
34161198 2022
633
Cyclic Phthalate Esters as Liver X Receptor Antagonists with Anti-hepatitis C Virus and Anti-severe Acute Respiratory Syndrome Coronavirus 2 Properties. 62
36184450 2022
634
Hepatitis C virus: A critical approach to who really needs treatment. 62
35126838 2022
635
Risk of Non-Hodgkin Lymphoma among Patients with Hepatitis B Virus and Hepatitis C Virus in Taiwan: A Nationwide Cohort Study. 62
35158850 2022
636
Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents. 62
36059971 2022
637
Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report. 62
36016569 2022
638
GLUT1 and ASCT2 Protein Expression in Papillary Thyroid Carcinoma Patients and Relation to Hepatitis C Virus: A Propensity-Score Matched Analysis. 62
35308569 2022
639
Seroprevalence of Epstein-Barr virus, hepatitis B virus, hepatitis C virus, and human immunodeficiency virus among patients with non-Hodgkin's lymphoma at the Yaounde General Hospital, Cameroon. 62
35949454 2022
640
Mother-to-child transmission of human immunodeficiency virus, hepatitis B virus and hepatitis C virus among pregnant women with single, dual or triplex infections of human immunodeficiency virus, hepatitis B virus and hepatitis C virus in Nigeria: A systematic review and meta-analysis. 62
35509955 2022
641
Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management. 62
36247180 2022
642
Hepatotoxicity during legacy cancer chemotherapy in patients infected with hepatitis C virus: A retrospective cohort study. 62
35990784 2022
643
Lack of Causal Relationships Between Chronic Hepatitis C Virus Infection and Alzheimer's Disease. 62
35356425 2022
644
Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication. 62
35087141 2022
645
A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response. 62
35071784 2022
646
Elevated Levels of IL-33, IL-17 and IL-25 Indicate the Progression from Chronicity to Hepatocellular Carcinoma in Hepatitis C Virus Patients. 62
35056005 2022
647
Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment. 62
34661320 2022
648
Mortality among Alaska Native Adults with Confirmed Hepatitis C Virus Infection Compared with the General Population in Alaska, 1995-2016. 62
35178364 2022
649
A 2-Step Strategy Combining FIB-4 With Transient Elastography and Ultrasound Predicted Liver Cancer After HCV Cure. 62
34817975 2022
650
Risk of hepatocellular carcinoma after hepatitis C virus cure. 62
35125821 2022
651
Impact of sustained virologic response in regression of portal hypertension in Egyptian patients with hepatitis C virus-associated cirrhosis and portal hypertension. 62
35433052 2022
652
Cohort study: Apparent redundancy of fibrosis assessment in young persons with HCV; development of realistic approaches to break the paradigm. 62
34606981 2022
653
Association Between Chronic Hepatitis C Virus Infection and Esophageal Cancer: A Systematic Review and Meta-analysis. 62
33780211 2022
654
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment. 62
33408122 2022
655
The influence of hepatitis C virus eradication on hepatocarcinogenesis in patients with hemophilia. 62
34571264 2022
656
The evolutionary dynamics and epidemiological history of hepatitis C virus genotype 6, including unique strains from the Li community of Hainan Island, China. 62
35600095 2022
657
Periodontal Disease and Risk of Dementia in Medicare Patients with Hepatitis C Virus. 62
34924375 2022
658
Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. 62
34582610 2022
659
Crosstalk Between Pyroptosis and Apoptosis in Hepatitis C Virus-induced Cell Death. 62
35237259 2022
660
Hepatitis C virus core protein uses triacylglycerols to fold onto the endoplasmic reticulum membrane. 62
34729868 2022
661
Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infection. 62
34411400 2022
662
CD8+ T-Cell Exhaustion Phenotype in Chronic Hepatitis C Virus Infection Is Associated With Epitope Sequence Variation. 62
35386708 2022
663
Guanosine inhibits hepatitis C virus replication and increases indel frequencies, associated with altered intracellular nucleotide pools. 62
35085375 2022
664
Rapid Visual Detection of Hepatitis C Virus Using Reverse Transcription Recombinase-Aided Amplification-Lateral Flow Dipstick. 62
35252031 2022
665
Association of the 3' untranslated region polymorphisms of HLA-G with susceptibility to chronic hepatitis C virus infection in the Chinese population. 62
34556350 2022
666
Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. 62
35110949 2022
667
Domain 2 of Hepatitis C Virus Protein NS5A Activates Glucokinase and Induces Lipogenesis in Hepatocytes. 62
35055105 2022
668
Hepatitis C Virus Infection in Eastern Libya: Efforts Needed to Improve HCV Testing and Linkage to Care in the Resource-Limited Setting. 62
35202210 2022
669
Prevalence and genotype distribution of hepatitis C virus within hemodialysis units in Thailand: role of HCV core antigen in the assessment of viremia. 62
35065604 2022
670
A Two-Level, Intramutant Spectrum Haplotype Profile of Hepatitis C Virus Revealed by Self-Organized Maps. 62
34756074 2021
671
Medicaid Expansion Association With End-Stage Liver Disease Mortality Depends on Leniency of Medicaid Hepatitis C Virus Coverage. 62
34118120 2021
672
An automated fast-flow/delayed paper-based platform for the simultaneous electrochemical detection of hepatitis B virus and hepatitis C virus core antigen. 62
34416431 2021
673
Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience. 62
34531135 2021
674
Disparities in Awareness of Hepatitis C Virus Among US Adults: An Analysis of the 2019 Health Information National Trends Survey. 62
34030156 2021
675
Variable Normalization of Naïve CD4+ Lymphopenia and Markers of Monocyte and T Cell Activation over the Course of Direct-Acting Anti-Viral Treatment of Chronic Hepatitis C Virus Infection. 62
35062255 2021
676
Prevalence of hepatitis C virus infection in non-dialysis CKD patients: a multicentre study in renal clinics. 62
34051092 2021
677
Phylogenetic analysis of human pegivirus from anti-hepatitis C virus IgG- positive patients. 62
34601095 2021
678
Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication. 62
33852513 2021
679
Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis. 62
34592051 2021
680
Hepatitis C virus DNA vaccines: a systematic review. 62
34903252 2021
681
Occult Infection with Hepatitis C Virus: Looking for Clear-Cut Boundaries and Methodological Consensus. 62
34945170 2021
682
Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. 62
34949310 2021
683
Hepatitis C virus in hemophilia: Health-related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study. 62
34870068 2021
684
Thiophen urea derivatives as a new class of hepatitis C virus entry inhibitors. 62
33455472 2021
685
Toll-like receptors and hepatitis C virus infection. 62
34419367 2021
686
Changes in the gut microbiota after hepatitis C virus eradication. 62
34876650 2021
687
Effective Treatment of Chronic Hepatitis C Virus Infection With Ledipasvir/Sofosbuvir in 2 Teenagers With HIV Coinfection: A Brief Report. 62
34232923 2021
688
Convergent use of phosphatidic acid for hepatitis C virus and SARS-CoV-2 replication organelle formation. 62
34907161 2021
689
Hepatitis C Virus Direct-Acting Antiviral Treatment Adherence Patterns and Sustained Viral Response Among People Who Inject Drugs Treated in Opioid Agonist Therapy Programs. 62
33876230 2021
690
Hepatitis C virus eradication on glycemic control and insulin resistance. 62
34909956 2021
691
Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir. 62
32804853 2021
692
Aminotransferase-to-platelet ratio index and Fibrosis-4 index score predict hepatic fibrosis evaluated by transient hepatic elastography in hepatitis C virus-infected hemodialysis patients. 62
33405422 2021
693
A Prospective Observational Study of 42 Patients with COVID-19 infection and a History of Hepatitis C Virus Infection and Thyroid Disease with Follow-Up Thyroid Function and Autoantibody Testing. 62
34969944 2021
694
Single nucleotide polymorphisms in PNPLA3, ADAR-1 and IFIH1 are associated with advanced liver fibrosis in patients co-infected with HIV-1//hepatitis C virus. 62
34482352 2021
695
Hepatitis C Virus-Induced Exosomal MicroRNAs and Toll-Like Receptor 7 Polymorphism Regulate B-Cell Activating Factor. 62
34724826 2021
696
Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals. 62
34583968 2021
697
Real-world monitoring progress towards the elimination of hepatitis C virus in Australia using sentinel surveillance of primary care clinics; an ecological study of hepatitis C virus antibody tests from 2009 to 2019. 62
35249577 2021
698
Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient-centered program from Italy. 62
34697911 2021
699
Outbreak of hepatitis B and hepatitis C virus infections associated with a cardiology clinic, West Virginia, 2012-2014. 62
33641684 2021
700
Baveno criteria perform better than expanded Baveno and Rete Sicilia Selezione Terapia-Hepatitis C virus criteria for predicting varices needing treatment. 62
33991311 2021
701
Association between hepatitis C virus infection and subsequent chronic inflammatory skin disease. 62
34460962 2021
702
Hepatitis C virus core protein inhibits hepatitis B virus replication by downregulating HBx levels via Siah-1-mediated proteasomal degradation during coinfection. 62
34882535 2021
703
Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report. 62
34924025 2021
704
Coinfection of Helicobacter pylori and Hepatitis C Virus in the Development of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. 62
35059071 2021
705
Severe Psoriasis Successfully Treated with Brodalumab after Eradication of Hepatitis C Virus with Glecaprevir and Pibrentasvir: A Case Report. 62
34858017 2021
706
Hepatitis C Virus is Treatable but We Need to Be Sure of a Cure. 62
34954924 2021
707
Assessment of outcome for sample of Iraqi patients with chronic hepatitis C virus infection treated by Ledipasvir/sofosbuvir drug. 62
35130230 2021
708
Neuropsychological effects of direct-acting antiviral treatment for Hepatitis C virus subjects: A systematic review. 62
34320255 2021
709
Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. 62
34704194 2021
710
Chemokine receptor CXCR6 gene polymorphism and treatment response of chronic hepatitis C virus in Egyptian patients. 62
35402715 2021
711
Hepatitis C virus viral load distribution in the era of extended access to direct acting antivirals treatment: a real-life single center study. 62
35048665 2021
712
Improved patient survival in hepatitis C virus-related hepatocellular carcinoma: Do direct-acting antivirals play a role? 62
34654059 2021
713
Center-level Utilization of Hepatitis C Virus-positive Donors for Orthotopic Heart Transplantation. 62
33988340 2021
714
Safety and efficacy of directly-acting antiviral therapy for chronic hepatitis C virus in elderly people. 62
34964012 2021
715
The treatment choices and outcome of hepatocellular carcinoma in hemophilic patients with human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfection due to contaminated blood products in Japan. 62
35070421 2021
716
Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). 62
34926713 2021
717
Spontaneous Clearance of Drug-Resistant Chronic Hepatitis C Virus Infection. 62
34662444 2021
718
Statement of retraction: [thiophen urea derivatives as a new class of hepatitis C virus entry inhibitors]. 62
34167408 2021
719
Hepatoprotective effects of metformin in hepatitis C virus-infected adolescents with beta thalassaemia major. 62
34965654 2021
720
Hepatitis C virus-specific markers in pediatric patients with chronic hepatitis C. 62
34859647 2021
721
Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia. 62
34560266 2021
722
DEPRESSION, ANXIETY AND QUALITY OF LIFE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION IN VOJVODINA. 62
35734493 2021
723
GOLT1B Activation in Hepatitis C Virus-Infected Hepatocytes Links ER Trafficking and Viral Replication. 62
35055994 2021
724
Antiviral treatment and prognosis in patients undergoing maintenance hemodialysis due to hepatitis C virus. 62
35232901 2021
725
New markers of oxidative stress in lichen planus and the influence of hepatitis C virus infection - a pilot study. 62
33951354 2021
726
Risks of hepatitis C virus reactivation in a real-life population of oncology patients treated in an academic center. 62
33131449 2021
727
Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment. 62
34308801 2021
728
An intelligent method based on feed-forward artificial neural network and least square support vector machine for the simultaneous spectrophotometric estimation of anti hepatitis C virus drugs in pharmaceutical formulation and biological fluid. 62
34332240 2021
729
Determinants of Hepatitis C Virus Prevalence in People With Serious Mental Illness: A Systematic Review and Meta-Analysis. 62
34905666 2021
730
The association of hepatitis C virus infection and thyroid disease: A systematic review and meta-analysis. 62
34825832 2021
731
Hepatitis C Virus Is Associated With Increased Mortality Among Incarcerated Hospitalized Persons in Massachusetts. 62
34934776 2021
732
Hepatitis C Virus Core Protein Down-Regulates Expression of Src-Homology 2 Domain Containing Protein Tyrosine Phosphatase by Modulating Promoter DNA Methylation. 62
34960785 2021
733
Temporal trends and impact of willingness to accept organs from donors with hepatitis C virus. 62
34726801 2021
734
Anti-hepatitis C virus and synergistic potential of Syzgium cumine a bioassay guided screening in liver-infected hepatocytes. 62
34951685 2021
735
Noninvasive Assessment of Fibrosis Regression after Direct-acting Antiviral Treatment in Hepatitis C Virus Patients. 62
34954919 2021
736
All-cause hepatocellular carcinoma survival in the era of direct-acting antiviral therapy. 62
34520088 2021
737
A bibliometric analysis of infectious diseases in patients with liver transplantation in the last decade. 62
34988155 2021
738
Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study. 62
34097994 2021
739
Hepatitis C Treatment Among Commercially or Medicaid-Insured Individuals, 2014-2018. 62
34362617 2021
740
Establishing an Epidemiologic Profile of Hepatitis C Virus Infection at the Los Angeles County Jail. 62
33602004 2021
741
Acute hepatitis C virus infection and direct-acting antiviral drugs: Perfect combination to eliminate the epidemic? 62
34293985 2021
742
Hepatitis C virus treatment with direct-acting antivirals induces rapid changes in the hepatic proteome. 62
34379872 2021
743
Factors Associated with Screening Baby Boomers for Hepatitis C Virus Infection Among Primary Care Providers: a Retrospective Analysis. 62
33443698 2021
744
Crushing and Splitting Direct-Acting Antivirals for Hepatitis C Virus Treatment: A Case Series and Literature Review. 62
34805439 2021
745
National trends in testing for hepatitis C virus in licensed opioid treatment programs: Differences by facility ownership and state medicaid expansion status. 62
34571287 2021
746
Sandwich nanohybrid of chitosan-polyvinyl alcohol for water treatment and Sofosbuvir drug delivery for anti-hepatitis C virus (HCV). 62
34480910 2021
747
Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals. 62
34904036 2021
748
Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system. 62
34607193 2021
749
The utility of two-dimensional real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C virus infection. 62
32804841 2021
750
Don't Wait: The Benefits of Early Diagnosis in Perinatal Hepatitis C Virus Transmission. 62
32640029 2021
751
[The historic perspective from discovery of hepatitis C virus to curative therapy and vaccine dreams]. 62
34796866 2021
752
Postoperative direct-acting antiviral treatment after liver resection in patients with hepatitis C virus-related hepatocellular carcinoma. 62
34476874 2021
753
Seronegative Chronic Hepatitis C Virus Infection: A Teachable Moment. 62
34515736 2021
754
Performances of NeuMoDx™, a random-access system for hepatitis B virus DNA and hepatitis C virus RNA quantification. 62
33677082 2021
755
Protocol for Optimizing the Use of Kidneys From Donors With Seropositivity for Hepatitis C Virus in Seronegative Recipients. 62
34657711 2021
756
Next-generation sequencing studies on the E1-HVR1 region of hepatitis C virus (HCV) from non-high-risk HCV patients living in Punjab and Khyber Pakhtunkhwa, Pakistan. 62
34448937 2021
757
Spectroscopic study of self-assembly of anti-hepatitis C virus sofosbuvir drug with bio-polymeric nanoparticles for improving the drug release effect. 62
34087770 2021
758
The management of infants, children, and youth at risk for hepatitis C virus infection. 62
34777665 2021
759
Epidemiologic profile of hepatitis C virus infection and genotype distribution in Burkina Faso: a systematic review with meta-analysis. 62
34724902 2021
760
National Epidemiological Study about Hepatitis C Virus Infection among Dialysis Patients. 62
35946285 2021
761
Declining Numbers of Hepatitis C Virus-Associated Liver Transplantations in Germany. 62
35129433 2021
762
Reciprocal induction of hepatitis C virus replication and stimulation of hepatic profibrogenic cytokine release and cellular viability by YKL-40. 62
34988158 2021
763
Impact of Co-occurring Drug Use, Hazardous Alcohol Use, and Mental Health Disorders on Drug Use Patterns in People With HIV and Hepatitis C Virus Infection. 62
35559126 2021
764
An opt-out approach to hepatitis C virus testing in English prisons: the literature underpinning the policy. 62
34761976 2021
765
Genotype-specific versus pangenotypic regimens in patients infected with hepatitis C virus genotype 1b in real-world settings. 62
34565137 2021
766
Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia. 62
33759276 2021
767
Increasing multiorgan heart transplantation with hepatitis C virus donors in the current-era. 62
34176726 2021
768
Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea. 62
34845874 2021
769
Effect of Hepatitis C Virus Infection on Heart Transplants in the Current Era. 62
33496557 2021
770
Mixed cryoglobulinaemia and hepatitis C virus: a paradigm of a virus-related autoimmune and lymphoproliferative disorder. 62
34842134 2021
771
A short hepatitis C virus NS5A peptide expression by AAV vector modulates human T cell activation and reduces vector immunogenicity. 62
34759330 2021
772
Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis. 62
34402547 2021
773
Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment. 62
34396494 2021
774
Brief report: Prevalence of hepatitis C virus infections in U.S. Air Force basic military trainees who donated blood, 2017-2020. 62
35044734 2021
775
APRI and FIB-4 performance to assess liver fibrosis against predefined Fibroscan values in chronic hepatitis C virus infection. 62
35136771 2021
776
Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018. 62
33400777 2021
777
Lack of hepatitis C virus reinfection in lifetime of Japanese general population with previous hepatitis C virus (HCV) infection successfully treated with anti-HCV therapy. 62
34419353 2021
778
Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence. 62
34312954 2021
779
Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. 62
33544129 2021
780
Circulating microRNA 9-3p and serum endocan as potential biomarkers for hepatitis C virus-related hepatocellular carcinoma. 62
34904043 2021
781
Hepatitis C Virus-Related Central and Peripheral Nervous System Disorders. 62
34942871 2021
782
A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy. 62
34835054 2021
783
Nucleic Acid Testing for Diagnosis of Perinatally Acquired Hepatitis C Virus Infection in Early Infancy. 62
32640018 2021
784
Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance. 62
34730511 2021
785
miR-155 regulates pro- and anti-inflammatory cytokine expression in human monocytes during chronic hepatitis C virus infection. 62
34926662 2021
786
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. 62
32887983 2021
787
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed. 62
34024853 2021
788
Depressive and Anxious Symptoms in Hepatitis C Virus Infected Patients Receiving DAA-Based Therapy. 62
34943472 2021
789
Hepatitis C virus care cascade in persons experiencing homelessness in the United States in the era of direct-acting antiviral agents: A scoping review. 62
34314081 2021
790
The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence. 62
33784424 2021
791
Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response. 62
34049354 2021
792
Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study. 62
34342081 2021
793
Modulation of Production of Th1/Th2 Cytokines in Peripheral Blood Mononuclear Cells and Neutrophils by Hepatitis C Virus Infection in Chronically Infected Patients. 62
34832674 2021
794
Comparison of antiplatelet antibody profiles between hepatitis C virus-associated immune thrombocytopenia and primary immune thrombocytopenia. 62
32967492 2021
795
Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience. 62
33930587 2021
796
Chronic Hepatitis B Virus in Patients with Chronic Hepatitis C Virus. 62
34593155 2021
797
Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus-related cirrhosis. 62
34487412 2021
798
Monitoring reversion of hepatitis C virus-induced cellular alterations by direct-acting antivirals using cryo soft X-ray tomography and infrared microscopy. 62
34726165 2021
799
Paper microfluidic implementation of loop mediated isothermal amplification for early diagnosis of hepatitis C virus. 62
34848705 2021
800
Hepatitis C virus genotype 4: A poorly characterized endemic genotype. 62
34185316 2021
801
Characterization of a Novel Hepatitis C Virus Genotype 1 Subtype from a Patient Failing 4 Weeks of Glecaprevir-Pibrentasvir Treatment. 62
34647796 2021
802
Hepatitis C virus E2 envelope glycoprotein produced in Nicotiana benthamiana triggers humoral response with virus-neutralizing activity in vaccinated mice. 62
34002936 2021
803
Association of Hepatitis C Virus Replication with the Catecholamine Biosynthetic Pathway. 62
34834946 2021
804
Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada. 62
34518099 2021
805
Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1. 62
34403905 2021
806
Enhanced liver fibrosis score as a predictive marker for hepatocellular carcinoma development after hepatitis C virus eradication. 62
34476099 2021
807
Hepatitis C virus-associated indolent B-cell lymphomas: A review on the role of the new direct antiviral agents therapy. 62
34477233 2021
808
Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working-age adults in Madrid (Spain). 62
34224188 2021
809
The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R). 62
34339561 2021
810
A Comprehensive Coordinator Supported Hepatitis C Virus Testing and Linkage to Treatment Program at Kaiser Permanente Mid-Atlantic States. 62
34834947 2021
811
Cellular OCIAD2 protein is a proviral factor for hepatitis C virus replication. 62
34371038 2021
812
Sensitive Determination of SARS-COV-2 and the Anti-hepatitis C Virus Agent Velpatasvir Enabled by Novel Metal-Organic Frameworks. 62
34661033 2021
813
PIAS1 Regulates Hepatitis C Virus-Induced Lipid Droplet Accumulation by Controlling Septin 9 and Microtubule Filament Assembly. 62
34684276 2021
814
The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection. 62
34703365 2021
815
Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison. 62
34412938 2021
816
Prevalence of occult hepatitis C virus infection in beta-thalassemia major patients in Ahvaz, Iran. 62
34275067 2021
817
The 2020 Nobel Prize in medicine for the discovery of hepatitis C virus: An epic saga of the fight against a troublesome virus. 62
34245922 2021
818
Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data. 62
33651446 2021
819
Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis. 62
34310812 2021
820
Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan. 62
33940114 2021
821
Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort. 62
34426040 2021
822
Fluorescent paper-based DNA sensor using pyrrolidinyl peptide nucleic acids for hepatitis C virus detection. 62
34090155 2021
823
HIV and Hepatitis C Virus Screening in the Emergency Department and Linkage to Care During COVID-19: Challenges and Solutions. 62
34267055 2021
824
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). 62
33963615 2021
825
Structural insights into hepatitis C virus receptor binding and entry. 62
34526719 2021
826
"Stigma is where the harm comes from": Exploring expectations and lived experiences of hepatitis C virus post-treatment trajectories among people who inject drugs. 62
33902968 2021
827
Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders. 62
34620204 2021
828
Discrepant Diagnostic Results of Nested Polymerase Chain Reaction-based Genotyping in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection. 62
33896867 2021
829
Drug use stigma and its association with active hepatitis C virus infection and injection drug use behaviors among community-based people who inject drugs in India. 62
34247900 2021
830
Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long? 62
34790004 2021
831
Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study. 62
34166565 2021
832
Patients with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for hepatitis C virus. 62
34101631 2021
833
StackHCV: a web-based integrative machine-learning framework for large-scale identification of hepatitis C virus NS5B inhibitors. 62
34622387 2021
834
The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis. 62
34051040 2021
835
The Compound SBI-0090799 Inhibits Zika Virus Infection by Blocking De Novo Formation of the Membranous Replication Compartment. 62
34468177 2021
836
Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. 62
34255961 2021
837
Autoantibodies and Rheumatologic Manifestations in Hepatitis C Virus Infection. 62
34827064 2021
838
Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients. 62
32930720 2021
839
HIV Prevention Trials Network 078: High Prevalence of Hepatitis C Virus Antibodies Among Urban US Men Who Have Sex With Men, Independent of Human Immunodeficiency Virus Status. 62
33346798 2021
840
Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection. 62
33598686 2021
841
Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan. 62
34712032 2021
842
Last Mile to Microelimination of Hepatitis C Virus Infection Among People Living With Human Immunodeficiency Virus. 62
33005954 2021
843
Distinct clinical features and prognostic factors of hepatitis C virus-associated non-Hodgkin's lymphoma: a systematic review and meta-analysis. 62
34627251 2021
844
Prevalence and risk factors for hepatitis c virus co-infection among human immunodeficiency virus-infected patients and effect of hepatitis c virus infection on acquired immunodeficiency syndrome cases at baseline. 62
34893569 2021
845
Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018. 62
34623891 2021
846
Uncommon hepatitis C virus among migrant sex workers in Chiangmai, Thailand. 62
34015529 2021
847
Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders. 62
34210584 2021
848
Study of Quasispecies Complexity and Liver Damage Progression after Liver Transplantation in Hepatitis C Virus Infected Patients. 62
34828337 2021
849
Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants. 62
34212476 2021
850
Community-Based Assessment and Treatment of Hepatitis C Virus-Related Liver Disease, Injecting Drug and Alcohol Use Amongst People Who Are Homeless: A Systematic Review and Meta-Analysis. 62
34210551 2021
851
The CCR5 and CXCR3 Pathways in Hepatitis C Virus Liver Transplanted Recipients Treated by a Direct Antiviral Agent Regimen: Informative Kinetics Profiles. 62
34252334 2021
852
Direct Relationship between Interleukin-10 Gene Polymorphism and Hepatocellular Carcinoma Complicated by Direct Acting Antiviral Treatment of Hepatitis C Virus. 62
34710996 2021
853
Ribavirin to the Rescue: Natural Killer-Cell Function After Hepatitis C Virus Treatment in Liver Transplant Recipients. 62
33587428 2021
854
Frequency and genotype distribution of hepatitis C virus infection in patients with diabetes type 2 in Ahvaz, Iran. 62
34900168 2021
855
Post-treatment serum Wisteria floribunda agglutinin-positive mac-2-binding protein level is a useful predictor of hepatocellular carcinoma development after hepatitis C virus eradication. 62
34622009 2021
856
Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. 62
34671027 2021
857
Impact of Chronic Hepatitis C virus co-infection on outcomes of infective endocarditis in people who inject drugs. 62
34339949 2021
858
Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection. 62
34452807 2021
859
Hepatitis C virus in people with serious mental illness: an analysis of the care cascade at a tertiary health service with a pilot 'identify and treat' strategy. 62
34719839 2021
860
In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet? 62
34786164 2021
861
Inclusion of hepatitis C virus testing in National Health Screening to accelerate HCV elimination in South Korea. 62
34782871 2021
862
Implementing opt-out hepatitis C virus (HCV) screening in Canadian provincial prisons: A model-based cost-effectiveness analysis. 62
34176704 2021
863
The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interluekin-8 Expression. 62
34680563 2021
864
Prevalence of positivity to antibodies to hepatitis C virus among volunteer blood donors in China: a meta-analysis. 62
34571442 2021
865
A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus. 62
34714420 2021
866
Maternal Hepatitis B or Hepatitis C Virus Carrier Status is Not a Risk Factor for Long-Term Oncologic Morbidity of the Offspring: A Population-Based Cohort Study. 62
33784229 2021
867
Seroprevalence of Hepatitis C Virus among Prisoners in Lakan Prison, North of Iran, Is There Still a Concern? 62
34816699 2021
868
Utility of hepatitis C virus core antigen testing for diagnosis and treatment monitoring in HCV infection: A study from India. 62
34294505 2021
869
B-RAF PROTEIN IMMUNOEXPRESSION IN HEPATOCELLULAR CARCINOMA DUE TO HEPATITIS C VIRUS RELATED CIRRHOSIS. 62
34909843 2021
870
Genotypic distribution of hepatitis C virus in Uttarakhand. 62
34210508 2021
871
Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico. 62
33620750 2021
872
Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis. 62
34665815 2021
873
Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort. 62
33966917 2021
874
Seroprevalence of the hepatitis C virus in healthcare personnel of the IMSS. 62
34393076 2021
875
Evaluation of factors affecting patients' refusal of HCV treatment in a cohort of Egyptian patients. 62
34651189 2021
876
Comparison of samples found positive by anti-HCV screening test with line immunoassay and determination of threshold value. 62
35018979 2021
877
Sofosbuvir/velpatasvir for the treatment of hepatitis C in pediatric patients. 62
34338120 2021
878
Association of Individual and Community Factors With Hepatitis C Infections Among Pregnant People and Newborns. 62
35977167 2021
879
Expert stakeholder perspectives on the acceptability of treatment-as-prevention in prison: a qualitative substudy of the 'Surveillance and Treatment of Prisoners with Hepatitis C' project (SToP-C). 62
33751739 2021
880
Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication. 62
34105867 2021
881
Prevalence and risk factors of chronic kidney disease in an HIV positive Mexican cohort. 62
34556049 2021
882
Non-primate hepacivirus transmission and prevalence: Novel findings of virus circulation in horses and dogs in Morocco. 62
34175479 2021
883
Health Behavior Survey Among People Who Use Opioids: Protocol for Implementing Technology-Based Rapid Response Surveillance in Community Settings. 62
34505834 2021
884
Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic. 62
34088556 2021
885
Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in pregnancy-updated guidelines: Replaces Consult Number 43, November 2017. 62
34116035 2021
886
Patient Centeredness in Hepatitis C Direct-Acting Antiviral Treatment Delivery to People Who Inject Drugs: A Scoping Review. 62
33372245 2021
887
Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China. 62
34479413 2021
888
Prospective cohort study of children exposed to hepatitis C virus through a pregnancy screening program. 62
34273517 2021
889
Hepatitis C virus infection and anaesthesia practice: A narrative review. 62
34378412 2021
890
Long-term benefits of viral clearance on extrahepatic manifestations of hepatitis C virus infection: the light at the end of the tunnel? 62
33978393 2021
891
Validity of Self-Reported Hepatitis C Virus Status Among Criminal Justice-Involved Persons Living With HIV. 62
34407381 2021
892
A Novel Small Molecule Inhibits Hepatitis C Virus Propagation in Cell Culture. 62
34319169 2021
893
NS5A-ISGylation via Lysine 26 Has a Critical Role for Efficient Propagation of Hepatitis C Virus Genotype 2a. 62
34795154 2021
894
Baseline Hepatitis C Virus NS5A Resistance-Associated Polymorphisms in Patients With and Without Human Immunodeficiency Virus Coinfection in Mexico. 62
33794105 2021
895
Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. 62
34630875 2021
896
The Influence of Hepatitis C Virus Infection on ORAL Health-Related Quality of Life in Patients with Oral Lichen Planus. 62
34501971 2021
897
Factors Associated with Seroconversion of Hepatitis C Virus in End Stage Renal Disease Patients. 62
34500518 2021
898
[Residual risk of liver disease after hepatitis C virus eradication]. 62
34468096 2021
899
Hepatitis C virus induces oxidation and degradation of apolipoprotein B to enhance lipid accumulation and promote viral production. 62
34492079 2021
900
Hepatitis C virus in India: Challenges and Successes. 62
34691402 2021
901
Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy. 62
34171407 2021
902
Updated Evidence on the Epidemiology of Hepatitis C Virus in Hemodialysis. 62
34578181 2021
903
Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infection. 62
34508913 2021
904
Hepatitis C virus (HCV) incidence among men who have sex with men (MSM) living with HIV: results from the French Hospital Database on HIV (ANRS CO4-FHDH) cohort study, 2014 to 2017. 62
34558403 2021
905
The outcome of re-treatment of relapsed hepatitis C virus infection in a resource-limited setting. 62
34631983 2021
906
Hepatitis C virus subtyping in Uttarakhand, India: a comparative study. 62
34631982 2021
907
Hepatitis C virus testing in a clinical HIV cohort in Ontario, Canada, 2000 to 2015. 62
34568583 2021
908
Detection of hepatitis C virus among HIV patients in Port Harcourt, Rivers State. 62
35222562 2021
909
Progress in hepatitis C virus management in chronic kidney disease. 62
34054074 2021
910
Direct antiviral agents for chronic hepatitis C virus infection improve health-related quality of life significantly in the long term. 62
34712826 2021
911
Screening, confirmation, and treatment rates of hepatitis C virus infection in a tertiary academic medical center in South Korea. 62
33788314 2021
912
Revisiting Prognosis After Liver Transplant in Patients Positive for Hepatitis C Virus: Focus on Hepatitis C Recurrence-Unrelated Complications. 62
34545778 2021
913
An intervention to increase hepatitis C virus diagnosis and treatment uptake among people in custody in Iran. 62
33991887 2021
914
Genetic variants associated with serum alanine aminotransferase levels among patients with hepatitis C virus infection: A genome-wide association study. 62
34003538 2021
915
Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis. 62
34185932 2021
916
Enhancing Linkage to Hepatitis C Virus Treatment Following Pregnancy in Women Identified During Perinatal Care. 62
34510828 2021
917
Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: A large single center analysis. 62
33515801 2021
918
Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals. 62
34286851 2021
919
Impact of direct acting antivirals on hepatitis C virus-related cryoglobulinemic syndrome. 62
33793154 2021
920
Hepatitis C virus-related vasculitis. 62
33268038 2021
921
Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors. 62
34489392 2021
922
Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells. 62
34252495 2021
923
Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years-Results of the POLAC Project. 62
34575286 2021
924
Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs. 62
34501448 2021
925
Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial. 62
33491236 2021
926
Quantifying transmission dynamics of acute hepatitis C virus infections in a heterogeneous population using sequence data. 62
34520487 2021
927
Bioorthogonal dissection of the replicase assembly of hepatitis C virus. 62
33798447 2021
928
A Systematic Review and Meta-Analysis on the Epidemiology of Hepatitis B and Hepatitis C Virus among Beta-Thalassemia Major Patients in Pakistan. 62
34602793 2021
929
Hepatitis C virus in sub-Saharan Africa: a long road to elimination. 62
34391525 2021
930
The distribution of hepatitis C virus infection in Shanghai, China: a time-spatial study. 62
34536999 2021
931
Hepatitis C Virus Infection in Pregnancy and Children: Its Implications and Treatment Considerations with Directly Acting Antivirals: A Review. 62
35199739 2021
932
LncRNA KCNQ1OT1 promoted hepatitis C virus-induced pyroptosis of β-cell through mediating the miR-223-3p/NLRP3 axis. 62
34733939 2021
933
Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients. 62
34186262 2021
934
Nursing practice is associated with high risk for hepatitis C virus infection. 62
33984487 2021
935
Engaging the Community in Designing a Hepatitis C Virus Treatment Program for Adults Experiencing Homelessness. 62
34189974 2021
936
Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. 62
33894103 2021
937
Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation. 62
34518443 2021
938
Trends in hepatitis C virus-associated mortality rates in Japan, 1998-2017. 62
33837565 2021
939
New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years. 62
34447228 2021
940
Hepatitis C Virus Infection: What Are We Currently Doing in Latin America About WHO's Proposals for 2030? 62
34584671 2021
941
Seroprevalence and Spatial Distribution of Hepatitis C Virus in Bahia, Brazil. 62
34424863 2021
942
Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use. 62
35977199 2021
943
Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection. 62
33612683 2021
944
Spectrum of Kidney Diseases in Patients With Hepatitis C Virus Infection. 62
33623996 2021
945
Outcomes of hepatitis C virus nucleic acid testing positive donors in aviremic recipients with delayed direct-acting antiviral initiation. 62
34132438 2021
946
Screening and prevention of hepatitis C virus reactivation during chemotherapy. 62
34497443 2021
947
A Genome-Wide Association Study on Liver Stiffness Changes during Hepatitis C Virus Infection Cure. 62
34441435 2021
948
Lung transplant recipient attitudes and beliefs on accepting an organ that is positive for hepatitis C virus. 62
34228382 2021
949
Optimisation and validation of a new method for antibody dependent cellular phagocytosis in hepatitis C virus infection. 62
34147479 2021
950
Noninvasive Markers for Monitoring Fibrosis Regression After Hepatitis C Virus Cure: What Do They Promise? 62
32503039 2021
951
Cytokine (IL-10, IL-6, TNF-α and TGF-β1) Gene Polymorphisms in Chronic Hepatitis C Virus Infection among Malay Male Drug Abusers. 62
34572300 2021
952
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C. 62
33497016 2021
953
Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City. 62
32016914 2021
954
Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. 62
33896097 2021
955
Molecular mechanisms underlying hepatitis C virus infection-related diabetes. 62
34090869 2021
956
Prevalence of Hepatitis C Virus Infection Identified From Nontargeted Screening Among Adult Visitors in an Academic Appalachian Regional Emergency Department. 62
34381848 2021
957
Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up. 62
34452460 2021
958
Hepatitis C Virus Evades Interferon Signaling by Suppressing Long Noncoding RNA Linc-Pint Involving C/EBP-β. 62
34160260 2021
959
The association between hepatitis C virus infection and renal function. 62
34074934 2021
960
HIV, hepatitis C virus and risk of new-onset left ventricular dysfunction in women. 62
33859109 2021
961
Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R). 62
34003549 2021
962
Neurological and psychiatric effects of hepatitis C virus infection. 62
34447230 2021
963
Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants. 62
34405680 2021
964
The Roles of Fibrosis Index Based on Four Factors and Aspartate Transaminase-to-Platelet Ratio Index Scoring Systems as an Alternative to Transient Elastography Liver Stiffness in Liver Fibrosis Staging in Human Immunodeficiency Virus and Hepatitis C Virus Co-Infected Patients. 62
34527089 2021
965
Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression? 62
32504083 2021
966
Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. 62
34046970 2021
967
Evaluation of Risk Factors for Hepatitis C Virus Infection Among Philadelphia's Shelter-Bound, Homeless Population: Data from a Student-Run Hepatitis C Virus Screening Initiative. 62
33252303 2021
968
Hepatitis C Virus RNA Transcript Associates with Prognosis in Non-human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma. 62
33592124 2021
969
Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro. 62
34097489 2021
970
Gastric antral vascular ectasia in hepatitis C virus related liver cirrhosis: Fetching for predictors. 62
34386601 2021
971
Immune Thrombocytopenic Purpura Complicated by Hepatitis C Virus-related Membranoproliferative Glomerulonephritis after Rituximab Therapy. 62
33583904 2021
972
Mortality is not increased in SARS-CoV-2 infected persons with hepatitis C virus infection. 62
33534931 2021
973
Diagnosis and monitoring of hepatitis C virus infection using the cobas® HCV test for use on the cobas® 4800 system. 62
34111663 2021
974
Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. 62
34152088 2021
975
Validation of a Genotype-Independent Hepatitis C Virus Near-Whole Genome Sequencing Assay. 62
34578305 2021
976
Role of Ras-related Nuclear Protein/Polypyrimidine Tract Binding Protein in Facilitating the Replication of Hepatitis C Virus. 62
34447674 2021
977
Differences in inpatient and outpatient hepatitis C virus prevalence and linkage to care rates in a safety net hospital hepatitis C screening program. 62
33724551 2021
978
Expansion of Unique Hepatitis C Virus-Specific Public CD8+ T Cell Clonotypes during Acute Infection and Reinfection. 62
34341170 2021
979
Gender-Specific Frequency Distribution of Hepatitis C Virus Genotypes in Punjab province, Pakistan: A Clinically Significant Descriptive Cross-Sectional Study. 62
34589367 2021
980
Dried blood spot sampling for hepatitis C virus infection: A new tool to simplify testing algorithms. 62
34126544 2021
981
Best practice recommendations for the use of hepatitis C viremic donor organs for hepatitis C virus naïve recipients. 62
34086371 2021
982
Identification of natural compounds extracted from crude drugs as novel inhibitors of hepatitis C virus. 62
34130179 2021
983
Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: Report of a Japanese nationwide survey. 62
34041804 2021
984
Comparative study between two 2D-Shear Waves Elastography techniques for the non-invasive assessment of liver fibrosis in patients with chronic hepatitis C virus (HCV) infection. 62
33657193 2021
985
Second direct-acting antiviral therapy for hepatitis C virus infection after umbilical cord blood transplantation: A case report. 62
33589371 2021
986
Planning the hepatitis C virus elimination in Cyprus: A modeling study. 62
34497446 2021
987
Differentiated Cells in Prolonged Hypoxia Produce Highly Infectious Native-Like Hepatitis C Virus Particles. 62
33665810 2021
988
Changing Epidemiology of Hepatitis B Virus and Hepatitis C Virus Coinfection in a Human Immunodeficiency Virus-Positive Population in China: Results From the Third and Fourth Nationwide Molecular Epidemiologic Surveys. 62
34398954 2021
989
Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection. 62
34540464 2021
990
The Putative Role of Natural Killer Cells in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma. 62
34452571 2021
991
Hepatitis C Virus in Pregnancy: A Systematic Review of the Literature. 62
32323289 2021
992
Avoiding Beta Blockers in Patients of Hepatitis C Virus-Related Compensated Cirrhosis With Clinically Significant Portal Hypertension After Cure With Antivirals: Are We There Yet? 62
33840732 2021
993
Reactivation of hepatitis C virus with severe hepatitis flare during steroid administration for interstitial pneumonia. 62
33983567 2021
994
Multiscale model of hepatitis C virus dynamics in plasma and liver following combination therapy. 62
34296543 2021
995
Ultrasensitive electrochemical detection of hepatitis C virus core antigen using terminal deoxynucleotidyl transferase amplification coupled with DNA nanowires. 62
34347172 2021
996
County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017. 62
33609308 2021
997
Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers. 62
34134875 2021
998
Learning From Novel Approaches to Paying for Hepatitis C Virus Medications in State Medicaid Programs. 62
36218721 2021
999
Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease. 62
35369667 2021
1000
Paraoxonase 1 gene (PON1) variants concerning hepatitis C virus (HCV) spontaneous clearance in hemodialysis individuals: a case-control study. 62
34445971 2021
1001
In Vitro Antiviral Activity of Tyrosinase from Mushroom Agaricus bisporus against Hepatitis C Virus. 62
34451856 2021
1002
Comparative evaluation of Elecsys, Atellica, and Alinity assays for measuring the anti-Hepatitis C virus (HCV) antibody. 62
34273861 2021
1003
Changes in the Distribution Pattern of Hepatitis C Virus Genotypes Among Chronic Hepatitis Patients: a Cross-Sectional Study. 62
34383415 2021
1004
[Treatment of hepatitis C virus infection with new direct-acting antivirals agents in pediatrics. Case report]. 62
34309319 2021
1005
Hepatitis C virus infection and cardiac dysfunction in women. 62
34270491 2021
1006
Viral hepatitis C cascade of care: A population-level comparison of immigrant and long-term residents. 62
33655665 2021
1007
Non-Invasive Indirect Markers of Liver Fibrosis after Interferon-Free Treatment for Hepatitis C. 62
34501398 2021
1008
Natural History of Incidental Enhancing Nodules on Cone-Beam Computed Tomography during Transarterial Therapy of Hepatocellular Carcinoma. 62
33901694 2021
1009
Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry. 62
33966349 2021
1010
Impact of coronavirus disease 2019 on prevention and elimination strategies for hepatitis B and hepatitis C. 62
34367499 2021
1011
[Prevalence of viral hepatitis type C in blood donors in Peru 2016 - 2017]. 62
34978553 2021
1012
An enhanced methodology for predicting protein-protein interactions between human and hepatitis C virus via ensemble learning algorithms. 62
34251992 2021
1013
Screening for Hepatitis C Virus. 62
34313704 2021
1014
Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies. 62
34372569 2021
1015
Hepatitis C Virus Infection and the New Therapeutical Approach. 62
35003766 2021
1016
De novo hepatocellular carcinoma in cirrhotic hepatitis C virus: Are directly acting antivirals beneficial? 62
32900667 2021
1017
Determination of SK7324, a new class of hepatitis C virus inhibitor, in rat plasma by UPLC-MS/MS and its application to the pharmacokinetic study of SK7324. 62
34256890 2021
1018
Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals. 62
32807510 2021
1019
A conserved epitope III on hepatitis C virus E2 protein has alternate conformations facilitating cell binding or virus neutralization. 62
34260404 2021
1020
Hepatitis C virus infection in HIV-infected men in Singapore, 2006-2018: incidence and associated factors. 62
34148565 2021
1021
In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus. 62
34280245 2021
1022
Acute pulmonary embolism in a patient with hepatitis C virus infection and hepatocellular carcinoma: a case report. 62
34331603 2021
1023
Coinfection of Hepatitis B and Hepatitis C Virus in Patients With Human Immunodeficiency Virus. 62
34466302 2021
1024
Quantitative and qualitative lipid improvement with chronic hepatitis C virus eradication using direct-acting antivirals. 62
33982310 2021
1025
Expression profiling of miRNA-196a biomarker in naïve hepatitis C virus-infected and Sofosbuvir plus Daclatasvir-treated patients. 62
33660021 2021
1026
Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes. Commentary to Sasso and colleagues. 62
34154889 2021
1027
High prevalence and genotype distribution of hepatitis C virus in people living with HIV in Kathmandu, Nepal. 62
33729860 2021
1028
Occurrence and clinical characteristics of occult hepatitis C virus infection in hemodialysis units at Ismailia, Egypt. 62
33731578 2021
1029
"He's under oath": Privacy and Confidentiality Views Among People Who Inject Drugs Enrolled in a Study of Social Networks and Human Immunodeficiency Virus/Hepatitis C Virus Risk. 62
33769904 2021
1030
Portal vein thrombosis in hepatitis C virus-related cirrhotic patients: Prevalence and clinical characteristics in an Egyptian cohort. 62
33663297 2021
1031
The Inflammatory Relationship Between Hepatitis C Virus With Coronary and Carotid Atherosclerosis. 62
32618587 2021
1032
Circulating micro-RNAs as biomarkers of liver fibrosis progression in hepatitis C virus/HIV-1-co-infected patients: a 'miR'-velous opportunity of early diagnosis? 62
34185715 2021
1033
[A real-world study of sofosbuvir-based drug treatment for hepatitis C virus genotype 6 infection in Hainan region of China]. 62
34371539 2021
1034
A study based on four immunoassays: Hepatitis C virus antibody against different antigens may have unequal contributions to detection. 62
34217305 2021
1035
Economic Evaluation of Implementing a Rapid Point-of-Care Screening Test for the Identification of Hepatitis C Virus under National Viral Hepatitis Control Programme in Tamil Nadu, South India. 62
34703152 2021
1036
Absence of interferon-λ 4 enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection. 62
34034600 2021
1037
Inhibitory activity of limonoids from Khaya grandifoliola C.DC (Meliaceae) against hepatitis C virus infection in vitro. 62
34290967 2021
1038
Early use of PCSK9 inhibitor therapy after heart transplantation from a hepatitis C virus positive donor. 62
34120877 2021
1039
Serum Golgi protein 73 as a sensitive biomarker for early detection of hepatocellular carcinoma among Egyptian patients with hepatitis C virus-related cirrhosis. 62
34305287 2021
1040
Hepatitis E Infection in a Longitudinal Cohort of Hepatitis C Virus and HCV/HIV Coinfected Persons. 62
33794657 2021
1041
Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings". 62
33892009 2021
1042
The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders. 62
34185563 2021
1043
DNA Methylation and Immune Cell Markers Demonstrate Evidence of Accelerated Aging in Patients with Chronic Hepatitis B Virus or Hepatitis C Virus, with or without Human Immunodeficienct Virus Co-infection. 62
32915202 2021
1044
Unusual Hepatitis C Virus Seroconversion in a Patient with Aplastic Anemia. 62
33164070 2021
1045
Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study. 62
34584004 2021
1046
Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis. 62
34584007 2021
1047
Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development. 62
33934558 2021
1048
Validated High-performance Liquid Chromatography Method for the Determination of JW5624, A New Class Of Hepatitis C Virus Inhibitor, in Rat Plasma and its Application in the Pharmacokinetic Study of JW5624. 62
33535254 2021
1049
Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study. 62
32856240 2021
1050
Diabetes is not associated with an increased risk of hepatocellular carcinoma in patients with alcoholic or hepatitis C virus cirrhosis. 62
33244982 2021
1051
Evaluation of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus seroprevalence in patients with diffuse large B cell lymphoma and Hodgkin's lymphoma. 62
34528547 2021
1052
Circulating microRNA signatures that predict liver fibrosis progression in patients with HIV-1/hepatitis C virus coinfections. 62
33813557 2021
1053
Treatment of hepatitis C virus infection. 62
33272891 2021
1054
Metabolic Impact of Diabetes Mellitus Type 2 in Hepatitis C Virus Infected Patients. 62
35003773 2021
1055
Interactive Impacts from Hepatitis C Virus Infection and Mixed Cryoglobulinemia on Complement Levels. 62
32737636 2021
1056
Follow-Up of Patients Who Achieved Sustained Virologic Response after Interferon-Free Treatment against Hepatitis C Virus: Focus on Older Patients. 62
34440967 2021
1057
Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings. 62
33652031 2021
1058
Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA. 62
32763480 2021
1059
An electrochemical biosensor for direct detection of hepatitis C virus. 62
33848501 2021
1060
Inhibition of Long Noncoding RNA Linc-Pint by Hepatitis C Virus in Infected Hepatocytes Enhances Lipogenesis. 62
33236406 2021
1061
Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience? 62
33171526 2021
1062
Cellular factors involved in the hepatitis C virus life cycle. 62
34366623 2021
1063
Sociodemographic features associated with Hepatitis C Virus (HCV) in pregnant females: A tertiary care centre study from Malwa region of Punjab (North India). 62
34568154 2021
1064
Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. 62
34307975 2021
1065
Hepatitis C Virus Subtypes Novel 6g-Related Subtype and 6w Could Be Indigenous in Southern Taiwan with Characteristic Geographic Distribution. 62
34372521 2021
1066
Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women. 62
33710024 2021
1067
The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients. 62
33601868 2021
1068
Serosurvey of anti-treponema pallidum (syphilis), anti-hepatitis C virus and anti-HIV antibodies in homeless persons of São Paulo city, southeastern Brazil. 62
34389284 2021
1069
Distribution of hepatitis C virus genotypes in Punjab region, Pakistan, based on a study of 4177 specimens. 62
33741510 2021
1070
Presence of interferon-λ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. 62
34078234 2021
1071
Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis. 62
33059055 2021
1072
Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy. 62
34238231 2021
1073
Evaluation of Hepatitis C Virus Core Antigen Assay in a Resource-Limited Setting in Pakistan. 62
34441289 2021
1074
High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. 62
34337093 2021
1075
Mesenchymal Stem Cells Can Both Enhance and Inhibit the Cellular Response to DNA Immunization by Genes of Nonstructural Proteins of the Hepatitis C Virus. 62
34360889 2021
1076
Glycometabolism regulates hepatitis C virus release. 62
34297778 2021
1077